WO2024102603A1 - Conjugaison pontée par glycane bisécant pour la production de conjugués de glycoprotéines - Google Patents
Conjugaison pontée par glycane bisécant pour la production de conjugués de glycoprotéines Download PDFInfo
- Publication number
- WO2024102603A1 WO2024102603A1 PCT/US2023/078425 US2023078425W WO2024102603A1 WO 2024102603 A1 WO2024102603 A1 WO 2024102603A1 US 2023078425 W US2023078425 W US 2023078425W WO 2024102603 A1 WO2024102603 A1 WO 2024102603A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- azide
- mole
- residue
- glcnac
- fa2b
- Prior art date
Links
- 108090000288 Glycoproteins Proteins 0.000 title claims abstract description 188
- 102000003886 Glycoproteins Human genes 0.000 title claims abstract description 188
- 230000021615 conjugation Effects 0.000 title abstract description 90
- 239000000611 antibody drug conjugate Substances 0.000 claims abstract description 136
- 229940049595 antibody-drug conjugate Drugs 0.000 claims abstract description 136
- 231100000599 cytotoxic agent Toxicity 0.000 claims abstract description 29
- 150000001413 amino acids Chemical class 0.000 claims abstract description 23
- 239000000203 mixture Substances 0.000 claims description 490
- 150000001540 azides Chemical class 0.000 claims description 309
- 150000003852 triazoles Chemical class 0.000 claims description 230
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical group CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 claims description 202
- 150000001345 alkine derivatives Chemical group 0.000 claims description 161
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims description 75
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims description 75
- 108090000623 proteins and genes Proteins 0.000 claims description 64
- 235000000346 sugar Nutrition 0.000 claims description 63
- JFTFXBKNMRRHJC-KEWYIRBNSA-N N-[(3R,4R,5S,6R)-2-azido-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical group CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1(O)N=[N+]=[N-] JFTFXBKNMRRHJC-KEWYIRBNSA-N 0.000 claims description 60
- 239000003814 drug Substances 0.000 claims description 56
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 54
- 235000018102 proteins Nutrition 0.000 claims description 53
- 102000004169 proteins and genes Human genes 0.000 claims description 53
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 claims description 45
- 230000004988 N-glycosylation Effects 0.000 claims description 44
- -1 trimcinolone Chemical compound 0.000 claims description 42
- 235000001014 amino acid Nutrition 0.000 claims description 38
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 38
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 38
- 125000002355 alkine group Chemical group 0.000 claims description 37
- 125000005629 sialic acid group Chemical group 0.000 claims description 35
- 229940124597 therapeutic agent Drugs 0.000 claims description 33
- 150000007523 nucleic acids Chemical class 0.000 claims description 32
- 102000039446 nucleic acids Human genes 0.000 claims description 31
- 108020004707 nucleic acids Proteins 0.000 claims description 31
- ZPWOOKQUDFIEIX-UHFFFAOYSA-N cyclooctyne Chemical compound C1CCCC#CCC1 ZPWOOKQUDFIEIX-UHFFFAOYSA-N 0.000 claims description 29
- 229940127089 cytotoxic agent Drugs 0.000 claims description 27
- 239000002254 cytotoxic agent Substances 0.000 claims description 27
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 26
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 24
- 229950006780 n-acetylglucosamine Drugs 0.000 claims description 23
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 23
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 21
- 229940024606 amino acid Drugs 0.000 claims description 21
- 229940127121 immunoconjugate Drugs 0.000 claims description 21
- 229910052799 carbon Inorganic materials 0.000 claims description 20
- 229940039227 diagnostic agent Drugs 0.000 claims description 18
- 239000000032 diagnostic agent Substances 0.000 claims description 18
- 125000003277 amino group Chemical group 0.000 claims description 17
- 239000012634 fragment Substances 0.000 claims description 15
- 229940123237 Taxane Drugs 0.000 claims description 14
- 229940122803 Vinca alkaloid Drugs 0.000 claims description 14
- 229940045799 anthracyclines and related substance Drugs 0.000 claims description 14
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 14
- 108010006654 Bleomycin Proteins 0.000 claims description 13
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical class N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 13
- 150000004814 combretastatins Chemical class 0.000 claims description 13
- 229930188854 dolastatin Natural products 0.000 claims description 13
- 229960004618 prednisone Drugs 0.000 claims description 13
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 13
- 231100000729 Amatoxin Toxicity 0.000 claims description 12
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims description 12
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 12
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 claims description 12
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims description 12
- 229960004495 beclometasone Drugs 0.000 claims description 12
- 229960002537 betamethasone Drugs 0.000 claims description 12
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims description 12
- 229960004436 budesonide Drugs 0.000 claims description 12
- 229960003290 cortisone acetate Drugs 0.000 claims description 12
- 229960003957 dexamethasone Drugs 0.000 claims description 12
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 12
- 239000000539 dimer Substances 0.000 claims description 12
- 229960005501 duocarmycin Drugs 0.000 claims description 12
- 229930184221 duocarmycin Natural products 0.000 claims description 12
- 229930013356 epothilone Natural products 0.000 claims description 12
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 claims description 12
- 229960002714 fluticasone Drugs 0.000 claims description 12
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims description 12
- 229940124750 glucocorticoid receptor agonist Drugs 0.000 claims description 12
- 229960000890 hydrocortisone Drugs 0.000 claims description 12
- 229960004584 methylprednisolone Drugs 0.000 claims description 12
- 229960001664 mometasone Drugs 0.000 claims description 12
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 claims description 12
- 229960005205 prednisolone Drugs 0.000 claims description 12
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 12
- YUOCYTRGANSSRY-UHFFFAOYSA-N pyrrolo[2,3-i][1,2]benzodiazepine Chemical class C1=CN=NC2=C3C=CN=C3C=CC2=C1 YUOCYTRGANSSRY-UHFFFAOYSA-N 0.000 claims description 12
- 229930184737 tubulysin Natural products 0.000 claims description 12
- JFUAWXPBHXKZGA-IBGZPJMESA-N 4-fluoro-2-[(4r)-5,5,5-trifluoro-4-hydroxy-2-methyl-4-(1h-pyrrolo[2,3-c]pyridin-2-ylmethyl)pentan-2-yl]phenol Chemical group C([C@@](O)(CC=1NC2=CN=CC=C2C=1)C(F)(F)F)C(C)(C)C1=CC(F)=CC=C1O JFUAWXPBHXKZGA-IBGZPJMESA-N 0.000 claims description 11
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims description 11
- 125000006239 protecting group Chemical group 0.000 claims description 11
- 239000012651 immune agonist Substances 0.000 claims description 10
- 229940044680 immune agonist Drugs 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 7
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 6
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 5
- 239000004473 Threonine Substances 0.000 claims description 5
- QRZUPJILJVGUFF-UHFFFAOYSA-N 2,8-dibenzylcyclooctan-1-one Chemical group C1CCCCC(CC=2C=CC=CC=2)C(=O)C1CC1=CC=CC=C1 QRZUPJILJVGUFF-UHFFFAOYSA-N 0.000 claims 2
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 claims 2
- 125000001425 triazolyl group Chemical group 0.000 claims 2
- 241000282414 Homo sapiens Species 0.000 abstract description 115
- 239000012636 effector Substances 0.000 abstract description 26
- 238000000034 method Methods 0.000 abstract description 24
- 238000003786 synthesis reaction Methods 0.000 abstract description 18
- 229920001542 oligosaccharide Polymers 0.000 abstract description 9
- 150000002482 oligosaccharides Chemical class 0.000 abstract description 8
- 101710112752 Cytotoxin Proteins 0.000 abstract description 3
- 239000002619 cytotoxin Substances 0.000 abstract description 3
- 230000005847 immunogenicity Effects 0.000 abstract description 3
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 104
- 210000004027 cell Anatomy 0.000 description 84
- 230000027455 binding Effects 0.000 description 55
- 238000006243 chemical reaction Methods 0.000 description 44
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 40
- 150000004676 glycans Chemical class 0.000 description 37
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 description 36
- 108010093470 monomethyl auristatin E Proteins 0.000 description 36
- 238000004458 analytical method Methods 0.000 description 33
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 31
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 31
- 125000003275 alpha amino acid group Chemical group 0.000 description 30
- 239000000562 conjugate Substances 0.000 description 27
- ZUHQCDZJPTXVCU-UHFFFAOYSA-N C1#CCCC2=CC=CC=C2C2=CC=CC=C21 Chemical group C1#CCCC2=CC=CC=C2C2=CC=CC=C21 ZUHQCDZJPTXVCU-UHFFFAOYSA-N 0.000 description 24
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 24
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 24
- 230000015572 biosynthetic process Effects 0.000 description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 24
- 230000000694 effects Effects 0.000 description 24
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 23
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 22
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 22
- 229930182830 galactose Natural products 0.000 description 22
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 21
- 102000004190 Enzymes Human genes 0.000 description 20
- 108090000790 Enzymes Proteins 0.000 description 20
- 239000000872 buffer Substances 0.000 description 20
- 230000001268 conjugating effect Effects 0.000 description 19
- 238000004811 liquid chromatography Methods 0.000 description 19
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 19
- 238000006467 substitution reaction Methods 0.000 description 19
- 108060003306 Galactosyltransferase Proteins 0.000 description 18
- 102000030902 Galactosyltransferase Human genes 0.000 description 18
- 239000000758 substrate Substances 0.000 description 18
- 238000012546 transfer Methods 0.000 description 18
- 206010028980 Neoplasm Diseases 0.000 description 17
- 229940079593 drug Drugs 0.000 description 17
- 241000894007 species Species 0.000 description 17
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 16
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 16
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 16
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 16
- QLTSDROPCWIKKY-PMCTYKHCSA-N beta-D-glucosaminyl-(1->4)-beta-D-glucosamine Chemical group O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O)[C@@H](CO)O1 QLTSDROPCWIKKY-PMCTYKHCSA-N 0.000 description 16
- 239000000523 sample Substances 0.000 description 16
- TXCIAUNLDRJGJZ-BILDWYJOSA-N CMP-N-acetyl-beta-neuraminic acid Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@]1(C(O)=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(N=C(N)C=C2)=O)O1 TXCIAUNLDRJGJZ-BILDWYJOSA-N 0.000 description 15
- 108010093031 Galactosidases Proteins 0.000 description 15
- 102000002464 Galactosidases Human genes 0.000 description 15
- 238000003556 assay Methods 0.000 description 15
- 230000003993 interaction Effects 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 229960000575 trastuzumab Drugs 0.000 description 15
- TXCIAUNLDRJGJZ-UHFFFAOYSA-N CMP-N-acetyl neuraminic acid Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(N=C(N)C=C2)=O)O1 TXCIAUNLDRJGJZ-UHFFFAOYSA-N 0.000 description 14
- 108060003951 Immunoglobulin Proteins 0.000 description 14
- 108010006232 Neuraminidase Proteins 0.000 description 14
- 102000005348 Neuraminidase Human genes 0.000 description 14
- 239000000427 antigen Substances 0.000 description 14
- 201000010099 disease Diseases 0.000 description 14
- 102000018358 immunoglobulin Human genes 0.000 description 14
- 210000002966 serum Anatomy 0.000 description 14
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 13
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 13
- 238000012575 bio-layer interferometry Methods 0.000 description 13
- 229960000106 biosimilars Drugs 0.000 description 13
- 238000011161 development Methods 0.000 description 13
- 230000018109 developmental process Effects 0.000 description 13
- 108091007433 antigens Proteins 0.000 description 12
- 102000036639 antigens Human genes 0.000 description 12
- 201000011510 cancer Diseases 0.000 description 12
- 238000011534 incubation Methods 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 108700023372 Glycosyltransferases Proteins 0.000 description 11
- LFTYTUAZOPRMMI-CFRASDGPSA-N UDP-N-acetyl-alpha-D-glucosamine Chemical compound O1[C@H](CO)[C@@H](O)[C@H](O)[C@@H](NC(=O)C)[C@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 LFTYTUAZOPRMMI-CFRASDGPSA-N 0.000 description 11
- 230000013595 glycosylation Effects 0.000 description 11
- 238000006206 glycosylation reaction Methods 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 10
- 239000004472 Lysine Substances 0.000 description 10
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 10
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 10
- 208000035475 disorder Diseases 0.000 description 10
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 108010019236 Fucosyltransferases Proteins 0.000 description 9
- 102000006471 Fucosyltransferases Human genes 0.000 description 9
- LQEBEXMHBLQMDB-JGQUBWHWSA-N GDP-beta-L-fucose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C3=C(C(NC(N)=N3)=O)N=C2)O1 LQEBEXMHBLQMDB-JGQUBWHWSA-N 0.000 description 9
- HSCJRCZFDFQWRP-UHFFFAOYSA-N Uridindiphosphoglukose Natural products OC1C(O)C(O)C(CO)OC1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-UHFFFAOYSA-N 0.000 description 9
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 239000012071 phase Substances 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 238000007634 remodeling Methods 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 238000001542 size-exclusion chromatography Methods 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 239000003643 water by type Substances 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- HSCJRCZFDFQWRP-ABVWGUQPSA-N UDP-alpha-D-galactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-ABVWGUQPSA-N 0.000 description 8
- 230000001093 anti-cancer Effects 0.000 description 8
- 239000002246 antineoplastic agent Substances 0.000 description 8
- 150000001720 carbohydrates Chemical class 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 210000004962 mammalian cell Anatomy 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- LQEBEXMHBLQMDB-UHFFFAOYSA-N GDP-L-fucose Natural products OC1C(O)C(O)C(C)OC1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C3=C(C(N=C(N)N3)=O)N=C2)O1 LQEBEXMHBLQMDB-UHFFFAOYSA-N 0.000 description 7
- 108010073807 IgG Receptors Proteins 0.000 description 7
- 102000009490 IgG Receptors Human genes 0.000 description 7
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 7
- LFTYTUAZOPRMMI-UHFFFAOYSA-N UNPD164450 Natural products O1C(CO)C(O)C(O)C(NC(=O)C)C1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(NC(=O)C=C2)=O)O1 LFTYTUAZOPRMMI-UHFFFAOYSA-N 0.000 description 7
- 108010061314 alpha-L-Fucosidase Proteins 0.000 description 7
- 102000012086 alpha-L-Fucosidase Human genes 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 108010064886 beta-D-galactoside alpha 2-6-sialyltransferase Proteins 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 239000002738 chelating agent Substances 0.000 description 7
- 238000002372 labelling Methods 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 150000003384 small molecules Chemical class 0.000 description 7
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 6
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 6
- 101000588395 Bacillus subtilis (strain 168) Beta-hexosaminidase Proteins 0.000 description 6
- 101001052060 Homo sapiens Beta-1,4-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase Proteins 0.000 description 6
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- WYUKJASPBYYQRJ-VSJOFRJTSA-N beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-[beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-GlcpNAc-(1->4)-beta-D-GlcpNAc Chemical compound O[C@@H]1[C@@H](NC(=O)C)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)NC(C)=O)[C@H](O)[C@@H](CO[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)NC(C)=O)O2)O)[C@@H](CO)O1 WYUKJASPBYYQRJ-VSJOFRJTSA-N 0.000 description 6
- 235000014633 carbohydrates Nutrition 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 6
- 235000018417 cysteine Nutrition 0.000 description 6
- 108020001507 fusion proteins Proteins 0.000 description 6
- 102000037865 fusion proteins Human genes 0.000 description 6
- 102000045442 glycosyltransferase activity proteins Human genes 0.000 description 6
- 108700014210 glycosyltransferase activity proteins Proteins 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 229940043131 pyroglutamate Drugs 0.000 description 6
- 230000007017 scission Effects 0.000 description 6
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 108090000712 Cathepsin B Proteins 0.000 description 5
- 102000004225 Cathepsin B Human genes 0.000 description 5
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 5
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 5
- 102000051366 Glycosyltransferases Human genes 0.000 description 5
- 239000007821 HATU Substances 0.000 description 5
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 5
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 5
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 5
- 108090000141 Sialyltransferases Proteins 0.000 description 5
- 102000003838 Sialyltransferases Human genes 0.000 description 5
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 5
- 230000002776 aggregation Effects 0.000 description 5
- 238000004220 aggregation Methods 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 5
- 239000000824 cytostatic agent Substances 0.000 description 5
- 230000002255 enzymatic effect Effects 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 230000000977 initiatory effect Effects 0.000 description 5
- 238000004949 mass spectrometry Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 5
- 239000004474 valine Substances 0.000 description 5
- 102100024775 Beta-1,4-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase Human genes 0.000 description 4
- 108010016626 Dipeptides Proteins 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 241000206602 Eukaryota Species 0.000 description 4
- 241000233866 Fungi Species 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 241000235058 Komagataella pastoris Species 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 4
- 241000235648 Pichia Species 0.000 description 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 4
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 4
- 229940125644 antibody drug Drugs 0.000 description 4
- 108010057005 beta-galactoside alpha-2,3-sialyltransferase Proteins 0.000 description 4
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 4
- 229910052796 boron Inorganic materials 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 229960002173 citrulline Drugs 0.000 description 4
- 238000004891 communication Methods 0.000 description 4
- 230000001085 cytostatic effect Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 238000004807 desolvation Methods 0.000 description 4
- 238000010494 dissociation reaction Methods 0.000 description 4
- 230000005593 dissociations Effects 0.000 description 4
- 235000019439 ethyl acetate Nutrition 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 230000002998 immunogenetic effect Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000009450 sialylation Effects 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- 150000008163 sugars Chemical class 0.000 description 4
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 3
- REHZLGLNCVZSAX-IANFNVNHSA-N 1-[(3R,4R,5S,6R)-3-amino-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-2-azidoethanone Chemical compound N(=[N+]=[N-])CC(=O)C1(O)[C@H](N)[C@@H](O)[C@H](O)[C@H](O1)CO REHZLGLNCVZSAX-IANFNVNHSA-N 0.000 description 3
- AMHZIUVRYRVYBA-UHFFFAOYSA-N 2-(2-amino-4,5-dihydroimidazol-1-yl)acetic acid Chemical compound NC1=NCCN1CC(O)=O AMHZIUVRYRVYBA-UHFFFAOYSA-N 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 102100021266 Alpha-(1,6)-fucosyltransferase Human genes 0.000 description 3
- 241000699802 Cricetulus griseus Species 0.000 description 3
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 3
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 3
- 108010027343 Glycoprotein 6-alpha-L-fucosyltransferase Proteins 0.000 description 3
- 101000819490 Homo sapiens Alpha-(1,6)-fucosyltransferase Proteins 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- SQVRNKJHWKZAKO-LUWBGTNYSA-N N-acetylneuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)CC(O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-LUWBGTNYSA-N 0.000 description 3
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 3
- 102100038551 Peptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidase Human genes 0.000 description 3
- 102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 3
- 108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- 241000193996 Streptococcus pyogenes Species 0.000 description 3
- 102000004243 Tubulin Human genes 0.000 description 3
- 108090000704 Tubulin Proteins 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 3
- 108010087667 beta-1,4-mannosyl-glycoprotein beta-1,4-N-acetylglucosaminyltransferase Proteins 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
- 235000013477 citrulline Nutrition 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 3
- 239000000386 donor Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 102000051957 human ERBB2 Human genes 0.000 description 3
- 238000002013 hydrophilic interaction chromatography Methods 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000009434 installation Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 108040002068 peptide-N4-(N-acetyl-beta-glucosaminyl)asparagine amidase activity proteins Proteins 0.000 description 3
- 230000035479 physiological effects, processes and functions Effects 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 239000002534 radiation-sensitizing agent Substances 0.000 description 3
- 230000000637 radiosensitizating effect Effects 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 230000003595 spectral effect Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- PVYJZLYGTZKPJE-UHFFFAOYSA-N streptonigrin Chemical compound C=1C=C2C(=O)C(OC)=C(N)C(=O)C2=NC=1C(C=1N)=NC(C(O)=O)=C(C)C=1C1=CC=C(OC)C(OC)=C1O PVYJZLYGTZKPJE-UHFFFAOYSA-N 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 210000005253 yeast cell Anatomy 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- PXBFMLJZNCDSMP-UHFFFAOYSA-N 2-Aminobenzamide Chemical compound NC(=O)C1=CC=CC=C1N PXBFMLJZNCDSMP-UHFFFAOYSA-N 0.000 description 2
- AFNOHTDETQTADW-ZQLGFOCFSA-N 2-azido-n-[(3r,4r,5s,6r)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical group OC[C@H]1OC(O)[C@H](NC(=O)CN=[N+]=[N-])[C@@H](O)[C@@H]1O AFNOHTDETQTADW-ZQLGFOCFSA-N 0.000 description 2
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 description 2
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 241000228257 Aspergillus sp. Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 2
- LJJUBMUNOGZMDD-UDEUCFDSSA-N C1=CC=CC=C1[C@@H]([C@@H](C)NC(=O)[C@@H]([C@@H](OC)[C@H]1N(CCC1)C(=O)C[C@@H](OC)[C@@H](N(C(=O)[C@H](C(C)C)NC(=O)[C@@H](N(C)C(=O)OCC1=CC=C(NC(=O)[C@H](CCCNC(=O)N)NC(=O)[C@@H](NC(=O)CCOCCOCCOCCOCCNC(=O)CCC(=O)N2CC3=CC=CC=C3C#CC3=CC=CC=C23)C(C)C)C=C1)C(C)C)C)[C@@H](C)CC)C)O Chemical compound C1=CC=CC=C1[C@@H]([C@@H](C)NC(=O)[C@@H]([C@@H](OC)[C@H]1N(CCC1)C(=O)C[C@@H](OC)[C@@H](N(C(=O)[C@H](C(C)C)NC(=O)[C@@H](N(C)C(=O)OCC1=CC=C(NC(=O)[C@H](CCCNC(=O)N)NC(=O)[C@@H](NC(=O)CCOCCOCCOCCOCCNC(=O)CCC(=O)N2CC3=CC=CC=C3C#CC3=CC=CC=C23)C(C)C)C=C1)C(C)C)C)[C@@H](C)CC)C)O LJJUBMUNOGZMDD-UDEUCFDSSA-N 0.000 description 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
- 229920002271 DEAE-Sepharose Polymers 0.000 description 2
- 108010092160 Dactinomycin Proteins 0.000 description 2
- OFDNQWIFNXBECV-UHFFFAOYSA-N Dolastatin 10 Natural products CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)CC)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 OFDNQWIFNXBECV-UHFFFAOYSA-N 0.000 description 2
- 102100021771 Endoplasmic reticulum mannosyl-oligosaccharide 1,2-alpha-mannosidase Human genes 0.000 description 2
- 108010087819 Fc receptors Proteins 0.000 description 2
- 102000009109 Fc receptors Human genes 0.000 description 2
- 108091006020 Fc-tagged proteins Proteins 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010015899 Glycopeptides Proteins 0.000 description 2
- 102000002068 Glycopeptides Human genes 0.000 description 2
- 101001115709 Homo sapiens 2-acylglycerol O-acyltransferase 3 Proteins 0.000 description 2
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 2
- 101000936922 Homo sapiens Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 Proteins 0.000 description 2
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 2
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000170280 Kluyveromyces sp. Species 0.000 description 2
- 108010000817 Leuprolide Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 108010090665 Mannosyl-Glycoprotein Endo-beta-N-Acetylglucosaminidase Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- HRHKSTOGXBBQCB-UHFFFAOYSA-N Mitomycin E Natural products O=C1C(N)=C(C)C(=O)C2=C1C(COC(N)=O)C1(OC)C3N(C)C3CN12 HRHKSTOGXBBQCB-UHFFFAOYSA-N 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- TXZBZODXIKVHOK-KEWYIRBNSA-N N(=[N+]=[N-])N[C@H]1C(O)(O[C@@H]([C@H]([C@@H]1O)O)CO)C(C)=O Chemical compound N(=[N+]=[N-])N[C@H]1C(O)(O[C@@H]([C@H]([C@@H]1O)O)CO)C(C)=O TXZBZODXIKVHOK-KEWYIRBNSA-N 0.000 description 2
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 241001489174 Ogataea minuta Species 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 241000235061 Pichia sp. Species 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 241000508269 Psidium Species 0.000 description 2
- 241000235088 Saccharomyces sp. Species 0.000 description 2
- 102100027732 Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 Human genes 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 108010086873 UDP-N-acetylglucosamine transporter Proteins 0.000 description 2
- HSCJRCZFDFQWRP-JZMIEXBBSA-N UDP-alpha-D-glucose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-JZMIEXBBSA-N 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- GRHWEVYJIHXESA-HBHDJDHDSA-N beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-[beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc Chemical compound O[C@@H]1[C@@H](NC(=O)C)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@H]3[C@@H]([C@@H](O)[C@H](O[C@H]4[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O4)O)[C@@H](CO)O3)NC(C)=O)[C@H](O)[C@@H](CO[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@H]3[C@@H]([C@@H](O)[C@H](O[C@H]4[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O4)O)[C@@H](CO)O3)NC(C)=O)O2)O)[C@@H](CO)O1 GRHWEVYJIHXESA-HBHDJDHDSA-N 0.000 description 2
- 238000003236 bicinchoninic acid assay Methods 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 229960005243 carmustine Drugs 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000024203 complement activation Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 229960000684 cytarabine Drugs 0.000 description 2
- 229960000640 dactinomycin Drugs 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 2
- OFDNQWIFNXBECV-VFSYNPLYSA-N dolastatin 10 Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 OFDNQWIFNXBECV-VFSYNPLYSA-N 0.000 description 2
- 108010045524 dolastatin 10 Proteins 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 239000002532 enzyme inhibitor Substances 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 229940045109 genistein Drugs 0.000 description 2
- 235000006539 genistein Nutrition 0.000 description 2
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 2
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 239000003667 hormone antagonist Substances 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000005865 ionizing radiation Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 2
- 229960004338 leuprorelin Drugs 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 108010009689 mannosyl-oligosaccharide 1,2-alpha-mannosidase Proteins 0.000 description 2
- 108010083819 mannosyl-oligosaccharide 1,3 - 1,6-alpha-mannosidase Proteins 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- FBOZXECLQNJBKD-UHFFFAOYSA-N methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-UHFFFAOYSA-N 0.000 description 2
- HRHKSTOGXBBQCB-VFWICMBZSA-N methylmitomycin Chemical compound O=C1C(N)=C(C)C(=O)C2=C1[C@@H](COC(N)=O)[C@@]1(OC)[C@H]3N(C)[C@H]3CN12 HRHKSTOGXBBQCB-VFWICMBZSA-N 0.000 description 2
- 229960001156 mitoxantrone Drugs 0.000 description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- CERZMXAJYMMUDR-UHFFFAOYSA-N neuraminic acid Natural products NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO CERZMXAJYMMUDR-UHFFFAOYSA-N 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 229940127084 other anti-cancer agent Drugs 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 229950004406 porfiromycin Drugs 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 239000012562 protein A resin Substances 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000007974 sodium acetate buffer Substances 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- 229960001603 tamoxifen Drugs 0.000 description 2
- HWCKGOZZJDHMNC-UHFFFAOYSA-M tetraethylammonium bromide Chemical compound [Br-].CC[N+](CC)(CC)CC HWCKGOZZJDHMNC-UHFFFAOYSA-M 0.000 description 2
- 150000003536 tetrazoles Chemical class 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- SRVJKTDHMYAMHA-WUXMJOGZSA-N thioacetazone Chemical compound CC(=O)NC1=CC=C(\C=N\NC(N)=S)C=C1 SRVJKTDHMYAMHA-WUXMJOGZSA-N 0.000 description 2
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 229960004355 vindesine Drugs 0.000 description 2
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 2
- 235000005282 vitamin D3 Nutrition 0.000 description 2
- 239000011647 vitamin D3 Substances 0.000 description 2
- 229940021056 vitamin d3 Drugs 0.000 description 2
- NGGMYCMLYOUNGM-UHFFFAOYSA-N (-)-fumagillin Natural products O1C(CC=C(C)C)C1(C)C1C(OC)C(OC(=O)C=CC=CC=CC=CC(O)=O)CCC21CO2 NGGMYCMLYOUNGM-UHFFFAOYSA-N 0.000 description 1
- BWBDAEIIXBEFSS-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) n-[2-[2-(diethylamino)ethylcarbamoyl]quinolin-6-yl]carbamate Chemical compound C1=CC2=NC(C(=O)NCCN(CC)CC)=CC=C2C=C1NC(=O)ON1C(=O)CCC1=O BWBDAEIIXBEFSS-UHFFFAOYSA-N 0.000 description 1
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 description 1
- WOWDZACBATWTAU-FEFUEGSOSA-N (2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-n-[(3r,4s,5s)-1-[(2s)-2-[(1r,2r)-3-[[(1s,2r)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-n,3-dimethylbutanamide Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)C1=CC=CC=C1 WOWDZACBATWTAU-FEFUEGSOSA-N 0.000 description 1
- AGGWFDNPHKLBBV-YUMQZZPRSA-N (2s)-2-[[(2s)-2-amino-3-methylbutanoyl]amino]-5-(carbamoylamino)pentanoic acid Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=O AGGWFDNPHKLBBV-YUMQZZPRSA-N 0.000 description 1
- MCEHFIXEKNKSRW-LBPRGKRZSA-N (2s)-2-[[3,5-dichloro-4-[(2,4-diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]pentanedioic acid Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=C(Cl)C=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1Cl MCEHFIXEKNKSRW-LBPRGKRZSA-N 0.000 description 1
- XOSLDLHSPLPVME-FKLVWXFWSA-N (2s,8s,14s,17s,20s,25s,28r,29s)-2-[(2s)-butan-2-yl]-28-ethyl-17-[(4-methoxyphenyl)methyl]-7,13,16,20,22,22,25,29-octamethyl-8-(2-methylpropyl)-14-propan-2-yl-1-oxa-4,7,10,13,16,19,24,27-octazacyclotriacontane-3,6,9,12,15,18,21,23,26,30-decone Chemical compound CN1C(=O)[C@H](C(C)C)N(C)C(=O)CNC(=O)[C@H](CC(C)C)N(C)C(=O)CNC(=O)[C@H]([C@@H](C)CC)OC(=O)[C@@H](C)[C@@H](CC)NC(=O)[C@H](C)NC(=O)C(C)(C)C(=O)[C@H](C)NC(=O)[C@@H]1CC1=CC=C(OC)C=C1 XOSLDLHSPLPVME-FKLVWXFWSA-N 0.000 description 1
- BQQGAGGSEMLWRS-UHFFFAOYSA-N (4-aminophenyl)methyl carbamate Chemical compound NC(=O)OCC1=CC=C(N)C=C1 BQQGAGGSEMLWRS-UHFFFAOYSA-N 0.000 description 1
- UQVNRKBFAXNOGA-LWTNMJDUSA-N (E)-tomaymycin Chemical class CO[C@H]1NC2=CC(O)=C(OC)C=C2C(=O)N2C\C(=C\C)C[C@@H]12 UQVNRKBFAXNOGA-LWTNMJDUSA-N 0.000 description 1
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- MQLACMBJVPINKE-UHFFFAOYSA-N 10-[(3-hydroxy-4-methoxyphenyl)methylidene]anthracen-9-one Chemical compound C1=C(O)C(OC)=CC=C1C=C1C2=CC=CC=C2C(=O)C2=CC=CC=C21 MQLACMBJVPINKE-UHFFFAOYSA-N 0.000 description 1
- DBPWSSGDRRHUNT-CEGNMAFCSA-N 17α-hydroxyprogesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DBPWSSGDRRHUNT-CEGNMAFCSA-N 0.000 description 1
- RCWJMKCTHJPXJV-UHFFFAOYSA-N 2,5-bis(aziridin-1-yl)-1,4-benzoquinone Chemical compound O=C1C=C(N2CC2)C(=O)C=C1N1CC1 RCWJMKCTHJPXJV-UHFFFAOYSA-N 0.000 description 1
- VEAIXXJTUWDCBJ-UHFFFAOYSA-N 2-(diaziridin-1-yl)cyclohexa-2,5-diene-1,4-dione Chemical compound O=C1C=CC(=O)C(N2NC2)=C1 VEAIXXJTUWDCBJ-UHFFFAOYSA-N 0.000 description 1
- DWZFIFZYMHNRRV-UHFFFAOYSA-N 2-[(3,4-dihydroxy-5-methoxyphenyl)methylidene]propanedinitrile Chemical compound COC1=CC(C=C(C#N)C#N)=CC(O)=C1O DWZFIFZYMHNRRV-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- HXUVTXPOZRFMOY-NSHDSACASA-N 2-[[(2s)-2-[[2-[(2-aminoacetyl)amino]acetyl]amino]-3-phenylpropanoyl]amino]acetic acid Chemical compound NCC(=O)NCC(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=CC=C1 HXUVTXPOZRFMOY-NSHDSACASA-N 0.000 description 1
- FZDFGHZZPBUTGP-UHFFFAOYSA-N 2-[[2-[bis(carboxymethyl)amino]-3-(4-isothiocyanatophenyl)propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)C(C)CN(CC(O)=O)CC(N(CC(O)=O)CC(O)=O)CC1=CC=C(N=C=S)C=C1 FZDFGHZZPBUTGP-UHFFFAOYSA-N 0.000 description 1
- OBVVKJDJORDBCH-CZDIJEQGSA-N 2-aminoacetic acid (2S)-2-amino-3-phenylpropanoic acid Chemical compound NCC(O)=O.NCC(O)=O.NCC(O)=O.OC(=O)[C@@H](N)CC1=CC=CC=C1 OBVVKJDJORDBCH-CZDIJEQGSA-N 0.000 description 1
- DODQJNMQWMSYGS-QPLCGJKRSA-N 4-[(z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-phenylbut-1-en-2-yl]phenol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 DODQJNMQWMSYGS-QPLCGJKRSA-N 0.000 description 1
- SSMIFVHARFVINF-UHFFFAOYSA-N 4-amino-1,8-naphthalimide Chemical compound O=C1NC(=O)C2=CC=CC3=C2C1=CC=C3N SSMIFVHARFVINF-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- XHSQDZXAVJRBMX-DDHJBXDOSA-N 5,6-dichloro-1-β-d-ribofuranosylbenzimidazole Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=CC(Cl)=C(Cl)C=C2N=C1 XHSQDZXAVJRBMX-DDHJBXDOSA-N 0.000 description 1
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 1
- CERZMXAJYMMUDR-QBTAGHCHSA-N 5-amino-3,5-dideoxy-D-glycero-D-galacto-non-2-ulopyranosonic acid Chemical compound N[C@@H]1[C@@H](O)CC(O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO CERZMXAJYMMUDR-QBTAGHCHSA-N 0.000 description 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N Adenosine Natural products C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 1
- 108010000239 Aequorin Proteins 0.000 description 1
- OMNVYXHOSHNURL-WPRPVWTQSA-N Ala-Phe Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 OMNVYXHOSHNURL-WPRPVWTQSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 102400000068 Angiostatin Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102000005427 Asialoglycoprotein Receptor Human genes 0.000 description 1
- 241000351920 Aspergillus nidulans Species 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 240000006439 Aspergillus oryzae Species 0.000 description 1
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 1
- 241000151861 Barnettozyma salicaria Species 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- FVLVBPDQNARYJU-XAHDHGMMSA-N C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O Chemical compound C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O FVLVBPDQNARYJU-XAHDHGMMSA-N 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- SHHKQEUPHAENFK-UHFFFAOYSA-N Carboquone Chemical compound O=C1C(C)=C(N2CC2)C(=O)C(C(COC(N)=O)OC)=C1N1CC1 SHHKQEUPHAENFK-UHFFFAOYSA-N 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 238000003734 CellTiter-Glo Luminescent Cell Viability Assay Methods 0.000 description 1
- 241001674013 Chrysosporium lucknowense Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- HVXBOLULGPECHP-WAYWQWQTSA-N Combretastatin A4 Chemical compound C1=C(O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-WAYWQWQTSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108010061994 Coronavirus Spike Glycoprotein Proteins 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 239000012625 DNA intercalator Substances 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- LQKSHSFQQRCAFW-UHFFFAOYSA-N Dolastatin 15 Natural products COC1=CC(=O)N(C(=O)C(OC(=O)C2N(CCC2)C(=O)C2N(CCC2)C(=O)C(C(C)C)N(C)C(=O)C(NC(=O)C(C(C)C)N(C)C)C(C)C)C(C)C)C1CC1=CC=CC=C1 LQKSHSFQQRCAFW-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical class OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- MBYXEBXZARTUSS-QLWBXOBMSA-N Emetamine Natural products O(C)c1c(OC)cc2c(c(C[C@@H]3[C@H](CC)CN4[C@H](c5c(cc(OC)c(OC)c5)CC4)C3)ncc2)c1 MBYXEBXZARTUSS-QLWBXOBMSA-N 0.000 description 1
- 102400001047 Endostatin Human genes 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 229940125646 FDA-approved antibody drug Drugs 0.000 description 1
- 241000223218 Fusarium Species 0.000 description 1
- 241001149959 Fusarium sp. Species 0.000 description 1
- 241000567178 Fusarium venenatum Species 0.000 description 1
- 108700012941 GNRH1 Proteins 0.000 description 1
- JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108010056771 Glucosidases Proteins 0.000 description 1
- 102000004366 Glucosidases Human genes 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- 108010026389 Gramicidin Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000251188 Holocephali Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000929928 Homo sapiens Angiotensin-converting enzyme 2 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- 241001138401 Kluyveromyces lactis Species 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108010028275 Leukocyte Elastase Proteins 0.000 description 1
- 102000016799 Leukocyte elastase Human genes 0.000 description 1
- JXLYSJRDGCGARV-PJXZDTQASA-N Leurosidine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-PJXZDTQASA-N 0.000 description 1
- LPGWZGMPDKDHEP-HLTPFJCJSA-N Leurosine Chemical compound C([C@]1([C@@H]2O1)CC)N(CCC=1C3=CC=CC=C3NC=11)C[C@H]2C[C@]1(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC LPGWZGMPDKDHEP-HLTPFJCJSA-N 0.000 description 1
- LPGWZGMPDKDHEP-GKWAKPNHSA-N Leurosine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@]6(CC)O[C@@H]6[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C LPGWZGMPDKDHEP-GKWAKPNHSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 description 1
- 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 239000012515 MabSelect SuRe Substances 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 108010054377 Mannosidases Proteins 0.000 description 1
- 102000001696 Mannosidases Human genes 0.000 description 1
- 108010087568 Mannosyltransferases Proteins 0.000 description 1
- 102000006722 Mannosyltransferases Human genes 0.000 description 1
- 229930126263 Maytansine Natural products 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 101000922822 Mus musculus Acidic amino acid decarboxylase GADL1 Proteins 0.000 description 1
- 101000798225 Mus musculus Antizyme inhibitor 2 Proteins 0.000 description 1
- 101100504121 Mus musculus Ighg gene Proteins 0.000 description 1
- 108010046068 N-Acetyllactosamine Synthase Proteins 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical class ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 102100023315 N-acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase Human genes 0.000 description 1
- 108010056664 N-acetyllactosaminide beta-1,6-N-acetylglucosaminyltransferase Proteins 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- WTBIAPVQQBCLFP-UHFFFAOYSA-N N.N.N.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O Chemical compound N.N.N.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O WTBIAPVQQBCLFP-UHFFFAOYSA-N 0.000 description 1
- 239000005104 Neeliglow 4-amino-1,8-naphthalimide Substances 0.000 description 1
- 101710204212 Neocarzinostatin Proteins 0.000 description 1
- 241000221961 Neurospora crassa Species 0.000 description 1
- KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 description 1
- 241000320412 Ogataea angusta Species 0.000 description 1
- 241001452677 Ogataea methanolica Species 0.000 description 1
- 241000489470 Ogataea trehalophila Species 0.000 description 1
- 241000826199 Ogataea wickerhamii Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000530350 Phaffomyces opuntiae Species 0.000 description 1
- 241000529953 Phaffomyces thermotolerans Species 0.000 description 1
- 241000195887 Physcomitrella patens Species 0.000 description 1
- 241000235062 Pichia membranifaciens Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- NCYCYZXNIZJOKI-OVSJKPMPSA-N Retinaldehyde Chemical compound O=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 1
- OWPCHSCAPHNHAV-UHFFFAOYSA-N Rhizoxin Natural products C1C(O)C2(C)OC2C=CC(C)C(OC(=O)C2)CC2CC2OC2C(=O)OC1C(C)C(OC)C(C)=CC=CC(C)=CC1=COC(C)=N1 OWPCHSCAPHNHAV-UHFFFAOYSA-N 0.000 description 1
- AUVVAXYIELKVAI-UHFFFAOYSA-N SJ000285215 Natural products N1CCC2=CC(OC)=C(OC)C=C2C1CC1CC2C3=CC(OC)=C(OC)C=C3CCN2CC1CC AUVVAXYIELKVAI-UHFFFAOYSA-N 0.000 description 1
- 108010089417 Sex Hormone-Binding Globulin Proteins 0.000 description 1
- 102100030758 Sex hormone-binding globulin Human genes 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 101000895926 Streptomyces plicatus Endo-beta-N-acetylglucosaminidase H Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- HATRDXDCPOXQJX-UHFFFAOYSA-N Thapsigargin Natural products CCCCCCCC(=O)OC1C(OC(O)C(=C/C)C)C(=C2C3OC(=O)C(C)(O)C3(O)C(CC(C)(OC(=O)C)C12)OC(=O)CCC)C HATRDXDCPOXQJX-UHFFFAOYSA-N 0.000 description 1
- 241000499912 Trichoderma reesei Species 0.000 description 1
- RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 description 1
- FYAMXEPQQLNQDM-UHFFFAOYSA-N Tris(1-aziridinyl)phosphine oxide Chemical compound C1CN1P(N1CC1)(=O)N1CC1 FYAMXEPQQLNQDM-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- CYKLRRKFBPBYEI-NQQHDEILSA-N UDP-alpha-D-glucosamine Chemical compound O1[C@H](CO)[C@@H](O)[C@H](O)[C@@H](N)[C@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 CYKLRRKFBPBYEI-NQQHDEILSA-N 0.000 description 1
- GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 description 1
- HSRXSKHRSXRCFC-WDSKDSINSA-N Val-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(O)=O HSRXSKHRSXRCFC-WDSKDSINSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 241000370136 Wickerhamomyces pijperi Species 0.000 description 1
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 1
- ZMQRJWIYMXZORG-GZIFKOAOSA-N [(1e,3r,4r,6r,7z,9z,11e)-3,6,13-trihydroxy-3-methyl-1-[(2s)-6-oxo-2,3-dihydropyran-2-yl]trideca-1,7,9,11-tetraen-4-yl] dihydrogen phosphate Chemical compound OC/C=C/C=C\C=C/[C@H](O)C[C@@H](OP(O)(O)=O)[C@@](O)(C)\C=C\[C@@H]1CC=CC(=O)O1 ZMQRJWIYMXZORG-GZIFKOAOSA-N 0.000 description 1
- LQKSHSFQQRCAFW-CCVNJFHASA-N [(2s)-1-[(2s)-2-benzyl-3-methoxy-5-oxo-2h-pyrrol-1-yl]-3-methyl-1-oxobutan-2-yl] (2s)-1-[(2s)-1-[(2s)-2-[[(2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxyl Chemical compound C([C@@H]1N(C(=O)C=C1OC)C(=O)[C@@H](OC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](C(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C)C(C)C)C1=CC=CC=C1 LQKSHSFQQRCAFW-CCVNJFHASA-N 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- JXLYSJRDGCGARV-KSNABSRWSA-N ac1l29ym Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-KSNABSRWSA-N 0.000 description 1
- 239000000370 acceptor Substances 0.000 description 1
- ZMPZNCDIFIQVJZ-UHFFFAOYSA-N acetic acid;n'-[2-(cyclohexylamino)ethyl]ethane-1,2-diamine Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.NCCNCCNC1CCCCC1 ZMPZNCDIFIQVJZ-UHFFFAOYSA-N 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 108010011559 alanylphenylalanine Proteins 0.000 description 1
- 229960001445 alitretinoin Drugs 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 108010021726 alpha-1,3-mannosylglycoprotein beta-1,4-N-acetylglucosaminyltransferase Proteins 0.000 description 1
- ORDAZKGHSNRHTD-UHFFFAOYSA-N alpha-Toxicarol Natural products O1C(C)(C)C=CC2=C1C=CC1=C2OC2COC(C=C(C(=C3)OC)OC)=C3C2C1=O ORDAZKGHSNRHTD-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- RGHILYZRVFRRNK-UHFFFAOYSA-N anthracene-1,2-dione Chemical class C1=CC=C2C=C(C(C(=O)C=C3)=O)C3=CC2=C1 RGHILYZRVFRRNK-UHFFFAOYSA-N 0.000 description 1
- 230000003527 anti-angiogenesis Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940045696 antineoplastic drug podophyllotoxin derivative Drugs 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 1
- 229940117893 apigenin Drugs 0.000 description 1
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 1
- 235000008714 apigenin Nutrition 0.000 description 1
- 239000012223 aqueous fraction Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 108010006523 asialoglycoprotein receptor Proteins 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 238000010461 azide-alkyne cycloaddition reaction Methods 0.000 description 1
- 150000001541 aziridines Chemical class 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- KQNZDYYTLMIZCT-KQPMLPITSA-N brefeldin A Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KQPMLPITSA-N 0.000 description 1
- JUMGSHROWPPKFX-UHFFFAOYSA-N brefeldin-A Natural products CC1CCCC=CC2(C)CC(O)CC2(C)C(O)C=CC(=O)O1 JUMGSHROWPPKFX-UHFFFAOYSA-N 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 1
- 229930195731 calicheamicin Natural products 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- AEIMYPLMACPBOD-UHFFFAOYSA-N carbonocyanidic acid;nickel Chemical compound [Ni].OC(=O)C#N AEIMYPLMACPBOD-UHFFFAOYSA-N 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 229960002115 carboquone Drugs 0.000 description 1
- XREUEWVEMYWFFA-CSKJXFQVSA-N carminomycin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XREUEWVEMYWFFA-CSKJXFQVSA-N 0.000 description 1
- 229930188550 carminomycin Natural products 0.000 description 1
- XREUEWVEMYWFFA-UHFFFAOYSA-N carminomycin I Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XREUEWVEMYWFFA-UHFFFAOYSA-N 0.000 description 1
- 229950001725 carubicin Drugs 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- XRZYELWZLNAXGE-KPKJPENVSA-N chembl539947 Chemical compound CC(C)(C)C1=CC(\C=C(/C#N)C(N)=S)=CC(C(C)(C)C)=C1O XRZYELWZLNAXGE-KPKJPENVSA-N 0.000 description 1
- NDAYQJDHGXTBJL-MWWSRJDJSA-N chembl557217 Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 NDAYQJDHGXTBJL-MWWSRJDJSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- AQIXAKUUQRKLND-UHFFFAOYSA-N cimetidine Chemical compound N#C/N=C(/NC)NCCSCC=1N=CNC=1C AQIXAKUUQRKLND-UHFFFAOYSA-N 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 1
- 229960002286 clodronic acid Drugs 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229960005537 combretastatin A-4 Drugs 0.000 description 1
- HVXBOLULGPECHP-UHFFFAOYSA-N combretastatin A4 Natural products C1=C(O)C(OC)=CC=C1C=CC1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-UHFFFAOYSA-N 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 description 1
- GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 230000022811 deglycosylation Effects 0.000 description 1
- ORDAZKGHSNRHTD-UXHICEINSA-N deguelin Chemical compound O1C(C)(C)C=CC2=C1C=CC1=C2O[C@@H]2COC(C=C(C(=C3)OC)OC)=C3[C@@H]2C1=O ORDAZKGHSNRHTD-UXHICEINSA-N 0.000 description 1
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- WVYXNIXAMZOZFK-UHFFFAOYSA-N diaziquone Chemical compound O=C1C(NC(=O)OCC)=C(N2CC2)C(=O)C(NC(=O)OCC)=C1N1CC1 WVYXNIXAMZOZFK-UHFFFAOYSA-N 0.000 description 1
- 229950002389 diaziquone Drugs 0.000 description 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
- 229960000452 diethylstilbestrol Drugs 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 108010045526 dolastatin 11 Proteins 0.000 description 1
- 108010045552 dolastatin 15 Proteins 0.000 description 1
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical class COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000001437 electrospray ionisation time-of-flight quadrupole detection Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- AUVVAXYIELKVAI-CKBKHPSWSA-N emetine Chemical compound N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@@H]1CC AUVVAXYIELKVAI-CKBKHPSWSA-N 0.000 description 1
- 229960002694 emetine Drugs 0.000 description 1
- AUVVAXYIELKVAI-UWBTVBNJSA-N emetine Natural products N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@H]1CC AUVVAXYIELKVAI-UWBTVBNJSA-N 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960000752 etoposide phosphate Drugs 0.000 description 1
- LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 1
- 229960004421 formestane Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229950010404 fostriecin Drugs 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- NGGMYCMLYOUNGM-CSDLUJIJSA-N fumagillin Chemical compound C([C@H]([C@H]([C@@H]1[C@]2(C)[C@H](O2)CC=C(C)C)OC)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O)C[C@@]21CO2 NGGMYCMLYOUNGM-CSDLUJIJSA-N 0.000 description 1
- 229960000936 fumagillin Drugs 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 101150023212 fut8 gene Proteins 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 108010026195 glycanase Proteins 0.000 description 1
- 239000000937 glycosyl acceptor Substances 0.000 description 1
- 239000000348 glycosyl donor Substances 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- SGJNQVTUYXCBKH-HNQUOIGGSA-N hispidin Chemical compound O1C(=O)C=C(O)C=C1\C=C\C1=CC=C(O)C(O)=C1 SGJNQVTUYXCBKH-HNQUOIGGSA-N 0.000 description 1
- SGJNQVTUYXCBKH-UHFFFAOYSA-N hispidin Natural products O1C(=O)C=C(O)C=C1C=CC1=CC=C(O)C(O)=C1 SGJNQVTUYXCBKH-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- HYFHYPWGAURHIV-UHFFFAOYSA-N homoharringtonine Natural products C1=C2CCN3CCCC43C=C(OC)C(OC(=O)C(O)(CCCC(C)(C)O)CC(=O)OC)C4C2=CC2=C1OCO2 HYFHYPWGAURHIV-UHFFFAOYSA-N 0.000 description 1
- 102000048657 human ACE2 Human genes 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 229960002899 hydroxyprogesterone Drugs 0.000 description 1
- XOSLDLHSPLPVME-UHFFFAOYSA-N ibu-epidolastatin 11 Natural products CN1C(=O)C(C(C)C)N(C)C(=O)CNC(=O)C(CC(C)C)N(C)C(=O)CNC(=O)C(C(C)CC)OC(=O)C(C)C(CC)NC(=O)C(C)NC(=O)C(C)(C)C(=O)C(C)NC(=O)C1CC1=CC=C(OC)C=C1 XOSLDLHSPLPVME-UHFFFAOYSA-N 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- BQINXKOTJQCISL-GRCPKETISA-N keto-neuraminic acid Chemical compound OC(=O)C(=O)C[C@H](O)[C@@H](N)[C@@H](O)[C@H](O)[C@H](O)CO BQINXKOTJQCISL-GRCPKETISA-N 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- YACHGFWEQXFSBS-RJXCBBHPSA-N leptomycin Chemical class OC(=O)/C=C(C)/C[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)/C=C(\C)/C=C/C[C@@H](C)\C=C(/CC)\C=C\[C@@H]1OC(=O)C=C[C@@H]1C YACHGFWEQXFSBS-RJXCBBHPSA-N 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 235000002867 manganese chloride Nutrition 0.000 description 1
- 229940099607 manganese chloride Drugs 0.000 description 1
- 150000002704 mannoses Chemical class 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000012269 metabolic engineering Methods 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 1
- 229960003248 mifepristone Drugs 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 150000004712 monophosphates Chemical class 0.000 description 1
- 150000002772 monosaccharides Chemical group 0.000 description 1
- NCGWKCHAJOUDHQ-UHFFFAOYSA-N n,n-diethylethanamine;formic acid Chemical compound OC=O.OC=O.CCN(CC)CC NCGWKCHAJOUDHQ-UHFFFAOYSA-N 0.000 description 1
- IBONACLSSOLHFU-KEWYIRBNSA-N n-[(3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]acetamide Chemical compound CC(=O)NC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O IBONACLSSOLHFU-KEWYIRBNSA-N 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 229940086322 navelbine Drugs 0.000 description 1
- QZGIWPZCWHMVQL-UIYAJPBUSA-N neocarzinostatin chromophore Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 229940060155 neuac Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen(.) Chemical compound [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical class NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 description 1
- 229950006344 nocodazole Drugs 0.000 description 1
- 239000003865 nucleic acid synthesis inhibitor Substances 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- HYFHYPWGAURHIV-JFIAXGOJSA-N omacetaxine mepesuccinate Chemical compound C1=C2CCN3CCC[C@]43C=C(OC)[C@@H](OC(=O)[C@@](O)(CCCC(C)(C)O)CC(=O)OC)[C@H]4C2=CC2=C1OCO2 HYFHYPWGAURHIV-JFIAXGOJSA-N 0.000 description 1
- 229960002230 omacetaxine mepesuccinate Drugs 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- HAGVCKULCLQGRF-UHFFFAOYSA-N pifithrin Chemical compound [Br-].C1=CC(C)=CC=C1C(=O)CN1[C+](N)SC2=C1CCCC2 HAGVCKULCLQGRF-UHFFFAOYSA-N 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 229960001237 podophyllotoxin Drugs 0.000 description 1
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 description 1
- 239000003600 podophyllotoxin derivative Substances 0.000 description 1
- 229920000765 poly(2-oxazolines) Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000232 polyglycine polymer Polymers 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011363 radioimmunotherapy Methods 0.000 description 1
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
- 229960004622 raloxifene Drugs 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 235000020945 retinal Nutrition 0.000 description 1
- 150000003726 retinal derivatives Chemical class 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- OWPCHSCAPHNHAV-LMONGJCWSA-N rhizoxin Chemical compound C/C([C@H](OC)[C@@H](C)[C@@H]1C[C@H](O)[C@]2(C)O[C@@H]2/C=C/[C@@H](C)[C@]2([H])OC(=O)C[C@@](C2)(C[C@@H]2O[C@H]2C(=O)O1)[H])=C\C=C\C(\C)=C\C1=COC(C)=N1 OWPCHSCAPHNHAV-LMONGJCWSA-N 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 229960000885 rifabutin Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229960003440 semustine Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 101150074810 siaT gene Proteins 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 1
- 230000003335 steric effect Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960001674 tegafur Drugs 0.000 description 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 229960002372 tetracaine Drugs 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- IXFPJGBNCFXKPI-FSIHEZPISA-N thapsigargin Chemical compound CCCC(=O)O[C@H]1C[C@](C)(OC(C)=O)[C@H]2[C@H](OC(=O)CCCCCCC)[C@@H](OC(=O)C(\C)=C/C)C(C)=C2[C@@H]2OC(=O)[C@@](C)(O)[C@]21O IXFPJGBNCFXKPI-FSIHEZPISA-N 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 125000003441 thioacyl group Chemical group 0.000 description 1
- ORYDPOVDJJZGHQ-UHFFFAOYSA-N tirapazamine Chemical compound C1=CC=CC2=[N+]([O-])C(N)=N[N+]([O-])=C21 ORYDPOVDJJZGHQ-UHFFFAOYSA-N 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- PXSOHRWMIRDKMP-UHFFFAOYSA-N triaziquone Chemical compound O=C1C(N2CC2)=C(N2CC2)C(=O)C=C1N1CC1 PXSOHRWMIRDKMP-UHFFFAOYSA-N 0.000 description 1
- 229960004560 triaziquone Drugs 0.000 description 1
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 description 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
- 229960001641 troglitazone Drugs 0.000 description 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
- 239000003744 tubulin modulator Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- CILBMBUYJCWATM-PYGJLNRPSA-N vinorelbine ditartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-PYGJLNRPSA-N 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 229950009268 zinostatin Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Definitions
- ADCs Antibody-drug-conjugates
- ADCs are versatile molecules composed of a monoclonal antibody covalently connected to small molecules.
- the antibody endows high binding specificity to the target, an improved lifetime in vivo, and the ability to trigger effector-mediated immune responses to clear the pathogenic targets.
- the payload molecules provide cytotoxicity with mechanisms of action to kill or impair functions of the targets. In concert, these functionalities are imperative in creating effective therapeutics with improved safety and pharmacokinetic properties. Conjugation through the existing lysine residues (e.g., by amine-succinimidyl ester) is one of the most commonly used methods for ADC development (Alves, Antib. Ther.2, 33-39 (2019); Chari et al., Angew. Chemie Int.
- the antibody N-glycan presents another great opportunity for this purpose because (1) antibody glycosylation sites are highly conserved and (2) the difference between glycan and peptide chemistry (i.e., glycosidic bonds versus amide bonds) enables several bio- orthogonal reactions to modify glycan structures (Agnew et al., Anal. Bioanal. Chem.413, 4989- 5001 (2021); Li et al., Angew. Chem. Int. Ed.
- Immunoglobulin G1 (IgG1), the major antibody class for ADCs development, has conserved N-glycans at Asn297 in the Fc domain with over 25 glycoforms being identified (Puci ⁇ et al., Mol. Cell. Proteomics 10, doi:10.1074/mcp.M111.010090 (2011)).
- Endoglycosidases have been used to trim the glycan structures down to the conserved fucose-N-acetylglucosamine (GlcNAc) dipeptide to enable enzymatic or chemical installation of coupling handles, such as azide (Angew. Chem. Int. Ed.
- the present invention provides a conjugation strategy that enables efficient, gene editing-free conjugation with site-specificity for generating glycoprotein conjugates and ADCs in particular.
- the present invention comprises linking N-azido acetylglucosamine (azido-GlcNAc or GlcNAz) to the ⁇ 1,4 linked mannose of the trimannose core of one or more IgG N-glycans, each azido-GlcNAc conjugated to the asparagine residue of an N-glycosylation site having the consensus amino acid sequence Asparagine-X-serine/threonine, wherein X is any amino acid except for proline, using human N-acetylglucosaminyltransferase III (GnT-III or MGAT3), wherein the azido-GlcNAc may then serve as an attachment point for azide-alkyne click chemistry conjugation to alkyne-bearing
- conjugation through the bisecting position of the N-glycan preserves the opportunity to remodel the N-glycan antenna structures of the bisected N-glycan to be terminated with galactose and/or ⁇ 2,3 or ⁇ 2,6 sialic acid residues, which are known to mediate various effector functions of antibodies, creating possibilities to fine-tune the ADC immune responses.
- the conjugation strategy of the present invention enables the production of ADCs having a DAR of up to two when the only N-glycosylation sites on the antibody are located at the Asn at position 297 (according to Eu numbering) of the heavy chain constant domain but may be greater than two if there are additional naturally occurring N-glycosylation sites located in the V H and/or V L domains.
- ADCs with DARs of up to 4, 6, 8, 10, 12, 14, 16, 18, or 20 may be obtained (See for example, U.S. Patent No.11332544 for engineered non-native N-glycan sites in antibodies).
- the present invention provides a glycoprotein comprising protein conjugated to at least one bisected N-glycan in which the nonreducing end of the ⁇ 1,4 linked mannose residue of the trimannosyl core (M3) of the bisected N-glycan is linked to the reducing end of an azido-N- acetyl glucosamine (6-azido-GlcNAc or GlcNAz) residue in a ⁇ 1,4 linkage, wherein M3 is represented by the formula comprising Man ⁇ 1-3(Man ⁇ 1-6)Man ⁇ 1-4GlcNAc ⁇ 1–4GlcNAc ⁇ 1– Asn; wherein the 6-azido-GlcNAc and GlcNAz is represented by the formula comprising ; and, wherein the nonreducing end of at least one of the ⁇ 1,6-linked or ⁇ 1,3-linked mannose residues is linked to the reducing end of an N-acetyl glucosamine (GlcNAc) residue by a ⁇ 1,2 linkage
- the nonreducing end of the GlcNAc residue is linked to the reducing end of a galactose residue by a ⁇ 1,4 linkage. In a further embodiment, the nonreducing end of the galactose residue is linked to the reducing end of a sialic acid residue by an ⁇ 2,6 linkage. In a further embodiment, the nonreducing end of the galactose residue is linked to the reducing end of a sialic acid residue by an ⁇ 2,3 linkage.
- the nonreducing end of the ⁇ 1,6-linked mannose residue is linked to the reducing end of a first GlcNAc residue by a ⁇ 1,2 linkage and the nonreducing end of the ⁇ 1,3-linked mannose residue is linked to the reducing end of a second GlcNAc residue by a ⁇ 1,2 linkage.
- the nonreducing end of the first GlcNAc residue is linked to the reducing end of a galactose residue by a ⁇ 1,4 linkage;
- the nonreducing end of the second GlcNAc residue is linked to the reducing end of a galactose residue by a ⁇ 1,4 linkage; or
- the nonreducing end of the first GlcNAc residue is linked to the reducing end of a first galactose residue by a ⁇ 1,4 linkage and the nonreducing end of the second GlcNAc residue is linked to the reducing end of a second galactose residue by a ⁇ 1,4 linkage.
- nonreducing end of the galactose residue of (i) or (ii) or the nonreducing end of the first and second galactose residues of (iii) each linked to the reducing end of a sialic acid residue by an ⁇ 2,3 linkage.
- nonreducing end of the galactose residue of (i) or (ii) or the nonreducing end of the first and second galactose residues of (iii) each linked to the reducing end of a sialic acid residue by an ⁇ 2,6 linkage.
- the azido group of the azido-GlcNAc or GlcNAz is conjugated to a payload comprising an alkyne function group in a triazole linkage.
- the payload is a therapeutic agent, a diagnostic agent, radionuclide, or protecting group.
- the therapeutic agent is a cytotoxic agent, an anti- inflammatory agent, a peptide, an immune agonist, or a nucleic acid molecule or nucleic acid analog.
- the anti-inflammatory agent is a glucocorticoid receptor agonist.
- the anti-inflammatory agent is Cortisol, cortisone acetate, beclometasone, prednisone, prednisolone, methylprednisolone, betamethasone, trimcinolone, budesonide, dexamethasone, fluticasone, or mometasone.
- the cytotoxic agent is selected from the group consisting of taxanes, anthracyclines, camptothecins, epothilones, mytomycins, combretastatins, vinca alkaloids, maytansinoids, enediynes, duocarmycins, tubulysins, amatoxins, bleomycins, dolastatins and auristatins, pyrrolobenzodiazepine dimers, indolinobenzodiazepine dimers, and radioisotopes.
- the protein comprises the fragment crystallizable (Fc) domain of an antibody.
- the protein is an antibody having a heavy chain and a light chain.
- the present invention provides an antibody conjugated to at least one bisected N- glycan in which the nonreducing end of the ⁇ 1,4 linked mannose residue of the trimannosyl core (M3) of the bisected N-glycan is linked to the reducing end of an azido-N-acetyl glucosamine (6- azido-GlcNAc or GlcNAz) residue in a ⁇ 1,4 linkage, wherein M3 is represented by the formula comprising Man ⁇ 1-3(Man ⁇ 1-6)Man ⁇ 1-4GlcNAc ⁇ 1–4GlcNAc ⁇ 1–Asn; wherein the 6-azido- GlcNAc is represented by the formula comprising 6 -Azido-GlcNAc ; and GlcNAz is represented by the formula comprising ; wherein the nonreducing end of at least one of the ⁇ 1,6-linked or ⁇ 1,3-linked mannose residues is linked to the reducing end of an N-acetyl glucosamine (G
- the nonreducing end of the GlcNAc residue is linked to the reducing end of a galactose residue by a ⁇ 1,4 linkage. In a further embodiment, the nonreducing end of the galactose residue is linked to the reducing end of a sialic acid residue by an ⁇ 2,6 linkage. In a further embodiment, the nonreducing end of the galactose residue is linked to the reducing end of a sialic acid residue by an ⁇ 2,3 linkage.
- the nonreducing end of the ⁇ 1,6-linked mannose residue is linked to the reducing end of a first GlcNAc residue by a ⁇ 1,2 linkage and the nonreducing end of the ⁇ 1,3-linked mannose residue is linked to the reducing end of a second GlcNAc residue by a ⁇ 1,2 linkage.
- the nonreducing end of the first GlcNAc residue is linked to the reducing end of a galactose residue by a ⁇ 1,4 linkage;
- the nonreducing end of the second GlcNAc residue is linked to the reducing end of a galactose residue by a ⁇ 1,4 linkage; or
- the nonreducing end of the first GlcNAc residue is linked to the reducing end of a first galactose residue by a ⁇ 1,4 linkage and the nonreducing end of the second GlcNAc residue is linked to the reducing end of a second galactose residue by a ⁇ 1,4 linkage.
- nonreducing end of the galactose residue of (i) or (ii) or the nonreducing end of the first and second galactose residues of (iii) each linked to the reducing end of a sialic acid residue by an ⁇ 2,3 linkage.
- nonreducing end of the galactose residue of (i) or (ii) or the nonreducing end of the first and second galactose residues of (iii) each linked to the reducing end of a sialic acid residue by an ⁇ 2,6 linkage.
- the azido group of the 6-azido-GlcNAc or GlcNAz is conjugated to a payload comprising an alkyne function group in a triazole linkage.
- the payload is a therapeutic agent, a diagnostic agent, radionuclide, or protecting group.
- the therapeutic agent is a cytotoxic agent, an anti- inflammatory agent, a peptide, an immune agonist, or a nucleic acid molecule or nucleic acid analog.
- the anti-inflammatory agent is a glucocorticoid receptor agonist.
- the anti-inflammatory agent is Cortisol, cortisone acetate, beclometasone, prednisone, prednisolone, methylprednisolone, betamethasone, trimcinolone, budesonide, dexamethasone, fluticasone, or mometasone.
- the cytotoxic agent is selected from the group consisting of taxanes, anthracyclines, camptothecins, epothilones, mytomycins, combretastatins, vinca alkaloids, maytansinoids, enediynes, duocarmycins, tubulysins, amatoxins, bleomycins, dolastatins and auristatins, pyrrolobenzodiazepine dimers, indolinobenzodiazepine dimers, and radioisotopes.
- the bisected N-glycan is conjugated to an asparagine residue at position 297 of the constant domain, wherein the position is according to Eu numbering.
- the bisected N-glycan is conjugated to an asparagine residue of a N-glycosylation site comprising the amino acid sequence asparagine-X- serine/threonine wherein X is any amino acid except proline.
- the present invention further provides an antibody comprising the structure: A b-[B] n wherein Ab is an antibody; B is a bisected N-glycan wherein the bisecting sugar residue of the bisected N-glycan is a 6-azido-GlcNAc or GlcNAz residue having an azide functional group; and, n is an integer from 1-20.
- the bisected N-glycan B comprises a structure selected from the group consisting of A2B-azide; FA2B-azide; A2B[3]G1-azide; FA2[3]BG1-azide; A2B[6]G1-azide; FA2B[6]G1-azide; A2BG2-azide; FA2BG2-azide; A2B[3]G1S1(6)-azide; FA2B[3]G1S1(6)-azide; A2B[6]G1S1(6)-azide; FA2B[6]G1S1(6)-azide; A2BG2S2(6)-azide; FA2BG2S2(6)-azide; A2B[3]G1S1(3)-azide; FA2B[3]G1S1(3)-azide; A2B[6]G1S1(3)-azide; FA2B[6]G1S1(3)-azide
- the present invention further provides a composition comprising a plurality of antibodies and a pharmaceutically acceptable carrier, wherein each antibody independently comprises the structure: A b-[B] n wherein Ab is an antibody; B is a bisected N-glycan wherein the bisecting sugar residue of the bisected N-glycan is provided by a 6-azido-GlcNAc or GlcNAz residue having an azide functional group; and, n is an integer from 1-20.
- the bisected N-glycan B comprises a structure selected from the group consisting of A2B-azide; FA2B-azide; A2B[3]G1-azide; FA2[3]BG1-azide; A2B[6]G1-azide; FA2B[6]G1-azide; A2BG2-azide; FA2BG2-azide; A2B[3]G1S1(6)-azide; FA2B[3]G1S1(6)-azide; A2B[6]G1S1(6)-azide; FA2B[6]G1S1(6)-azide; A2BG2S2(6)-azide; FA2BG2S2(6)-azide; A2B[3]G1S1(3)-azide; FA2B[3]G1S1(3)-azide; A2B[6]G1S1(3)-azide; FA2B[6]G1S1(3)-azide
- the composition comprises predominantly one or two bisected N-glycan B structures.
- the predominant one or two bisected N-glycan B structures comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the total N-glycans of the composition.
- the present invention further provides an antibody conjugate comprising the structure: A b-[B-T-L-Pay] n wherein Ab is an antibody; B is a bisected N-glycan wherein the bisecting sugar residue of the bisected N-glycan is a 6-azido-GlcNAc or GlcNAz residue; L is a linker element comprising an alkyne functional group or a bond; Pay is a payload, which comprises an alkyne functional group when L is a bond; T is a triazole linkage formed between the linkage of the azide functional group and the alkyne functional group; and, n is an integer from 1-20.
- L is a self-immolative linker.
- L has the formula L 1 -L 2 , wherein each of L 1 and L 2 is independently a linker element or a bond.
- L comprises a distal end comprising an alkyne containing group linked to the azide of the 6-azido-GlcNAc or GlcNAz residue of the bisected N-glycan B in a triazole linkage T and a proximal end linked to Pay.
- the alkyne group is a strained cyclooctyne.
- the strained cyclooctyne is DBCO.
- the bisected N-glycan B comprises a structure selected from the group consisting of A2B-azide; FA2B-azide; A2B[3]G1-azide; FA2[3]BG1-azide; A2B[6]G1-azide; FA2B[6]G1-azide; A2BG2-azide; FA2BG2-azide; A2B[3]G1S1(6)-azide; FA2B[3]G1S1(6)-azide; A2B[6]G1S1(6)-azide; FA2B[6]G1S1(6)-azide; A2BG2S2(6)-azide; FA2BG2S2(6)-azide; A2B[3]G1S1(3)-azide; FA2B[3]G1S1(3)-azide; A2B[6]G1S1(3)-azide; FA2B[6]G1S1(3)-azide
- the bisecting sugar residue is azido-GlcNAc and the triazole linkage has the structure wherein the wavy line identifies the bond between the amine group of the GlcNAz residue and the C2 carbon of the glucose residue comprising the GlcNAz residue, and the double wavy lines identify bonds between the alkyne functional group of L or Pay when L is a bond; or, the bisecting sugar residue is 6-azido-GlcNAc and the triazole linkage has the structure wherein the wavy line identifies the bond between the C5 and C6 carbons of the glucose residue comprising the 6-azido-GlcNAc residue and the double wavy lines identify bonds between the alkyne functional group of L or Pay when L is a bond.
- the payload is a therapeutic agent, a diagnostic agent, radionuclide, or protecting group.
- the therapeutic agent is a cytotoxic agent, an anti- inflammatory agent, a peptide, or a nucleic acid molecule or nucleic acid analog.
- the anti-inflammatory agent is a glucocorticoid receptor agonist.
- the anti-inflammatory agent is Cortisol, cortisone acetate, beclometasone, prednisone, prednisolone, methylprednisolone, betamethasone, trimcinolone, budesonide, dexamethasone, fluticasone, or mometasone.
- the cytotoxic agent is selected from the group consisting of taxanes, anthracyclines, camptothecins, epothilones, mytomycins, combretastatins, vinca alkaloids, maytansinoids, enediynes, duocarmycins, tubulysins, amatoxins, bleomycins, dolastatins and auristatins, pyrrolobenzodiazepine dimers, indolinobenzodiazepine dimers, and radioisotopes.
- the present invention further provides a composition comprising a plurality of ADCs and a pharmaceutically acceptable carrier, wherein each ADC independently comprises the structure: A b-[B-T-L-Pay] n wherein Ab is an antibody; B is a bisected N-glycan wherein the bisecting sugar residue of the bisected N-glycan is a 6-azido-GlcNAc or GlcNAz residue having an azide functional group; L is a linker element comprising an alkyne functional group or a bond; Pay is a payload, which comprises an alkyne functional group when L is a bond; T is a triazole linkage formed between the linkage of the azide functional group and the alkyne functional group; and, n is an integer from 1-20.
- L is a self-immolative linker.
- L has the formula L 1 -L 2 , wherein each of L 1 and L 2 is independently a linker element or a bond.
- L comprises a distal end comprising an alkyne containing group linked to the azide of the 6-azido-GlcNAc or GlcNAz residue of bisected N- glycan B in triazole linkage T and a proximal end linked to Pay.
- the alkyne group is a strained cyclooctyne.
- the strained cyclooctyne is DBCO.
- the bisected N-glycan B comprises a structure selected from the group consisting of A2B-azide; FA2B-azide; A2B[3]G1-azide; FA2[3]BG1-azide; A2B[6]G1-azide; FA2B[6]G1-azide; A2BG2-azide; FA2BG2-azide; A2B[3]G1S1(6)-azide; FA2B[3]G1S1(6)-azide; A2B[6]G1S1(6)-azide; FA2B[6]G1S1(6)-azide; A2BG2S2(6)-azide; FA2BG2S2(6)-azide; A2B[3]G1S1(3)-azide; FA2B[3]G1S1(3)-azide; A2B[6]G1S1(3)-azide; 25584 FA2B[6]G1S1(3)-
- the composition comprises predominantly one or two bisected N-glycan B structures.
- the predominant one or two bisected N-glycan B structures comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the total N-glycans of the composition.
- the bisecting sugar residue is azido-GlcNAc and the triazole linkage has the structure wherein the wavy line identifies the bond between the amine group of the GlcNAz residue and the C2 carbon of the glucose residue comprising the GlcNAz residue and the double wavy lines identify bonds between the alkyne functional group of L or Pay when L is a bond; or, the bisecting sugar residue is 6-azido-GlcNAc and the triazole linkage has the structure wherein the wavy line identifies the bond between the C5 and C6 carbons of the glucose residue comprising the 6-azido-GlcNAc residue and the double wavy lines identify bonds between the alkyne functional group of L or Pay when L is a bond.
- the predominant N-glycans in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structure A2B-azide or FA2B-azide or both A2B-azide and FA2B-azide, wherein the azide is part of the triazole linkage T.
- the predominant N-glycans in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 25584 mole%, 98 mole%, 99 mole%, or 100 mole% of the structure A2B[3]G1-azide or FA2B[3]G1- azide or both A2B[3]G1-azide and FA2B[3]G1-azide, wherein the azide is part of the triazole linkage T.
- the predominant N-glycans in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structure A2B[6]G1-azide or FA2B[6]G1- azide or both A2B[6]G1-azide and FA2B[6]G1-azide, wherein the azide is part of the triazole linkage T.
- the predominant N-glycans in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structure A2BG2S2-azide or FA2BG2S2- azide or both A2BG2-azide and FA2BG2-azide, wherein the azide is part of the triazole linkage T.
- the composition, the predominant N-glycans in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structure A2B[3]G1S1(6 or 3)-azide or FA2B[3]G1S1(6 or 3)-azide or both A2B[3]G1S1(6 or 3)-azide and FA2B[3]G1S1(6 or 3)-azide, wherein the azide is part of the triazole linkage T.
- the predominant N-glycans in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structure A2B[6]G1S1(6 or 3)-azide or FA2B[6]G21S1(6 or 3)-azide or both A2B[6]G1S1(6 or 3)-azide and FA2B[6]G1S1(6 or 3)- azide, wherein the azide is part of the triazole linkage T.
- the predominant N-glycans in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structures A2BG2S2(6 or 3)-azide or FA2BG2S2(6 or 3)-azide or both A2BG2S2(6 or 3)-azide and FA2BG2S2(6 or 3)-azide, wherein the azide is part of the triazole linkage T.
- the payload is a therapeutic agent, a diagnostic agent, radionuclide, or protecting group.
- the therapeutic agent is a cytotoxic agent, an anti- inflammatory agent, a peptide, an immune agonist, or a nucleic acid molecule or nucleic acid analog.
- the anti-inflammatory agent is a glucocorticoid receptor agonist.
- the anti-inflammatory agent is Cortisol, cortisone acetate, beclometasone, prednisone, prednisolone, methylprednisolone, betamethasone, trimcinolone, budesonide, dexamethasone, fluticasone, or mometasone.
- the cytotoxic agent is selected from the group consisting of taxanes, anthracyclines, camptothecins, epothilones, mytomycins, combretastatins, vinca alkaloids, maytansinoids, enediynes, duocarmycins, tubulysins, amatoxins, bleomycins, dolastatins and auristatins, pyrrolobenzodiazepine dimers, indolinobenzodiazepine dimers, and radioisotopes.
- the present invention further provides for the use of an antibody conjugate comprising the structure: A b-[B-T-L-Pay] n wherein Ab is an antibody; B is a bisected N-glycan wherein the bisecting sugar residue of the bisected N-glycan is a 6-azido-GlcNAc or GlcNAz residue having an azide functional group; L is a linker element comprising an alkyne functional group or a bond; Pay is a payload, which comprises an alkyne functional group when L is a bond; T is a triazole linkage formed between the linkage of the azide functional group and the alkyne functional group; and, n is an integer from 1-20 for the manufacture of a medicament for treatment of a disease or disorder in a subject.
- the disease or disorder is cancer.
- L is a self-immolative linker.
- L has the formula L 1 -L 2 , wherein each of L 1 and L 2 is independently a linker element or a bond.
- L comprises a distal end comprising an alkyne containing group linked to the azide of the 6-azido-GlcNAc or GlcNAz residue of bisected N-glycan B in triazole linkage T and a proximal end linked to Pay.
- the alkyne group is a strained cyclooctyne.
- the strained cyclooctyne is DBCO.
- the bisected N-glycan B comprises a structure selected from the group consisting of A2B-azide; FA2B-azide; A2B[3]G1-azide; FA2[3]BG1-azide; A2B[6]G1-azide; FA2B[6]G1-azide; A2BG2-azide; FA2BG2-azide; A2B[3]G1S1(6)-azide; FA2B[3]G1S1(6)-azide; A2B[6]G1S1(6)-azide; FA2B[6]G1S1(6)-azide; A2BG2S2(6)-azide; FA2BG2S2(6)-azide; A2B[3]G1S1(3)-azide; FA2B[3]G1S1(3)-azide; A2B[3]G1S1(3)-
- the bisecting sugar residue is azido-GlcNAc and the triazole linkage has the structure wherein the wavy line identifies the bond between the amine group of the GlcNAz residue and the C2 carbon of the glucose residue comprising the GlcNAz residue and the double wavy lines identify bonds between the alkyne functional group of L or Pay when L is a bond; or, the bisecting sugar residue is 6-azido-GlcNAc and the triazole linkage has the structure wherein the wavy line identifies the bond between the C5 and C6 carbons of the glucose residue comprising the 6-azido-GlcNAc residue and the double wavy lines identify bonds between the alkyne functional group of L or Pay when L is a bond.
- the payload is a therapeutic agent, a diagnostic agent, radionuclide, or protecting group.
- the therapeutic agent is a cytotoxic agent, an anti- inflammatory agent, a peptide, an immune agonist, or a nucleic acid molecule or nucleic acid analog.
- the anti-inflammatory agent is a glucocorticoid receptor agonist.
- the anti-inflammatory agent is Cortisol, cortisone acetate, beclometasone, prednisone, prednisolone, methylprednisolone, betamethasone, trimcinolone, budesonide, dexamethasone, fluticasone, or mometasone.
- the cytotoxic agent is selected from the group consisting of taxanes, anthracyclines, camptothecins, epothilones, mytomycins, combretastatins, vinca alkaloids, maytansinoids, enediynes, duocarmycins, tubulysins, amatoxins, bleomycins, 25584 dolastatins and auristatins, pyrrolobenzodiazepine dimers, indolinobenzodiazepine dimers, and radioisotopes.
- the present invention further provides an antibody conjugate comprising the structure: A b-[B-T-L-Pay] n wherein Ab is an antibody; B is a bisected N-glycan wherein the bisecting sugar residue of the bisected N-glycan is a 6-azido-GlcNAc or GlcNAz residue having an azide functional group; L is a linker element comprising an alkyne functional group or a bond; Pay is a payload, which comprises an alkyne functional group when L is a bond; T is a triazole linkage formed between the linkage of the azide functional group and the alkyne functional group; and, n is an integer from 1-20 for treatment of a disease or disorder.
- the disease or disorder is cancer.
- L is a self-immolative linker.
- L has the formula L 1 -L 2 , wherein each of L 1 and L 2 is independently a linker element or a bond.
- L comprises a distal end comprising an alkyne containing group linked to the azide of the 6-azido-GlcNAc or GlcNAz residue of bisected N-glycan B in triazole linkage T and a proximal end linked to Pay.
- the alkyne group is a strained cyclooctyne.
- the strained cyclooctyne is DBCO.
- the bisected N-glycan B comprises a structure selected from the group consisting of A2B-azide; FA2B-azide; A2B[3]G1-azide; FA2[3]BG1-azide; A2B[6]G1-azide; FA2B[6]G1-azide; A2BG2-azide; FA2BG2-azide; A2B[3]G1S1(6)-azide; FA2B[3]G1S1(6)-azide; A2B[6]G1S1(6)-azide; FA2B[6]G1S1(6)-azide; A2BG2S2(6)-azide; FA2BG2S2(6)-azide; A2B[3]G1S1(3)-azide; FA2B[3]G1S1(3)-azide; A2B[3]G1S1(3)-
- the bisecting sugar residue is azido-GlcNAc and the triazole linkage has the structure 25584 wherein the wavy line identifies the bond between the amine group of the GlcNAz residue and the C2 carbon of the glucose residue comprising the GlcNAz residue and the double wavy lines identify bonds between the alkyne functional group of L or Pay when L is a bond; or, the bisecting sugar residue is 6-azido-GlcNAc and the triazole linkage has the structure wherein the wavy line identifies the bond between the C5 and C6 carbons of the glucose residue comprising the 6-azido-GlcNAc residue and the double wavy lines identify bonds between the alkyne functional group of L or Pay when L is a bond.
- the payload is a therapeutic agent, a diagnostic agent, radionuclide, or protecting group.
- the therapeutic agent is a cytotoxic agent, an anti- inflammatory agent, a peptide, an immune agonist, or a nucleic acid molecule or nucleic acid analog.
- the anti-inflammatory agent is a glucocorticoid receptor agonist.
- the anti-inflammatory agent is Cortisol, cortisone acetate, beclometasone, prednisone, prednisolone, methylprednisolone, betamethasone, trimcinolone, budesonide, dexamethasone, fluticasone, or mometasone.
- the cytotoxic agent is selected from the group consisting of taxanes, anthracyclines, camptothecins, epothilones, mytomycins, combretastatins, vinca alkaloids, maytansinoids, enediynes, duocarmycins, tubulysins, amatoxins, bleomycins, dolastatins and auristatins, pyrrolobenzodiazepine dimers, indolinobenzodiazepine dimers, and radioisotopes.
- the present invention further provides a method for treating a disease or disorder in a subject comprising: administering a therapeutically effective amount of an antibody conjugate comprising the structure: 25584 A b-[B-T-L-Pay] n wherein Ab is an antibody; B is a bisected N-glycan wherein the bisecting sugar residue of the bisected N-glycan is a 6-azido-GlcNAc or GlcNAz residue having an azide functional group; L is a linker element comprising an alkyne functional group or a bond; Pay is a payload, which comprises an alkyne functional group when L is a bond; T is a triazole linkage formed between the linkage of the azide functional group and the alkyne functional group; and, n is an integer from 1-20.
- the disease or disorder is cancer.
- L is a self-immolative linker.
- L has the formula L 1 -L 2 , wherein each of L 1 and L 2 is independently a linker element or a bond.
- L comprises a distal end comprising an alkyne containing group linked to the azide of the 6- azido-GlcNAc or GlcNAz residue of bisected N-glycan B in triazole linkage T and a proximal end linked to Pay.
- the alkyne group is a strained cyclooctyne.
- the strained cyclooctyne is DBCO.
- the bisected N-glycan B comprises a structure selected from the group consisting of A2B-azide; FA2B-azide; A2B[3]G1-azide; FA2[3]BG1-azide; A2B[6]G1-azide; FA2B[6]G1-azide; A2BG2-azide; FA2BG2-azide; A2B[3]G1S1(6)-azide; FA2B[3]G1S1(6)-azide; A2B[6]G1S1(6)-azide; FA2B[6]G1S1(6)-azide; A2BG2S2(6)-azide; FA2BG2S2(6)-azide; A2B[3]G1S1(3)-azide; FA2B[3]G1S1(3)-azide; A2B[3]G1S1(3)-
- the bisecting sugar residue is azido-GlcNAc and the triazole linkage has the structure 25584 wherein the wavy line identifies the bond between the amine group of the GlcNAz residue and the C2 carbon of the glucose residue comprising the GlcNAz residue and the double wavy lines identify bonds between the alkyne functional group of L or Pay when L is a bond; or, the bisecting sugar residue is 6-azido-GlcNAc and the triazole linkage has the structure wherein the wavy line identifies the bond between the C5 and C6 carbons of the glucose residue comprising the 6-azido-GlcNAc residue and the double wavy lines identify bonds between the alkyne functional group of L or Pay when L is a bond.
- the payload is a therapeutic agent, a diagnostic agent, radionuclide, or protecting group.
- the therapeutic agent is a cytotoxic agent, an anti- inflammatory agent, a peptide, an immune agonist, or a nucleic acid molecule or nucleic acid analog.
- the anti-inflammatory agent is a glucocorticoid receptor agonist.
- the anti-inflammatory agent is Cortisol, cortisone acetate, beclometasone, prednisone, prednisolone, methylprednisolone, betamethasone, trimcinolone, budesonide, dexamethasone, fluticasone, or mometasone.
- the cytotoxic agent is selected from the group consisting of taxanes, anthracyclines, camptothecins, epothilones, mytomycins, combretastatins, vinca alkaloids, maytansinoids, enediynes, duocarmycins, tubulysins, amatoxins, bleomycins, dolastatins and auristatins, pyrrolobenzodiazepine dimers, indolinobenzodiazepine dimers, and radioisotopes.
- the present invention further provides use of an antibody comprising the structure: A b-[B] n wherein Ab is an antibody; B is a bisected N-glycan wherein the bisecting sugar residue of the bisected N-glycan is a 6-azido-GlcNAc or GlcNAz residue having an azide functional group; and, n is an integer from 1-20 for the manufacture of a medicament for treatment of a disease or disorder.
- the disease or disorder is cancer.
- the bisected N-glycan B comprises a structure selected from the group consisting of A2B-azide; FA2B-azide; A2B[3]G1-azide; FA2[3]BG1-azide; 25584 A2B[6]G1-azide; FA2B[6]G1-azide; A2BG2-azide; FA2BG2-azide; A2B[3]G1S1(6)-azide; FA2B[3]G1S1(6)-azide; FA2B[6]G1S1(6)-azide; FA2B[6]G1S1(6)-azide; A2BG2S2(6)-azide; FA2BG2S2(6)-azide; A2B[3]G1S1(3)-azide; FA2B[3]G1S1(3)-azide; A2B[6]G1S1(3)-azide; FA2B[6]G1S1(3)-
- the present invention further provides an antibody comprising the structure: A b-[B] n wherein Ab is an antibody; B is a bisected N-glycan wherein the bisecting sugar residue of the bisected N-glycan is a 6-azido-GlcNAc or GlcNAz having an azide functional group; and, n is an integer from 1-20 for the manufacture of a medicament for treatment of a disease or disorder.
- the disease or disorder is cancer.
- the bisected N-glycan B comprises a structure selected from the group consisting of A2B-azide; FA2B-azide; A2B[3]G1-azide; FA2[3]BG1-azide; A2B[6]G1-azide; FA2B[6]G1-azide; A2BG2-azide; FA2BG2-azide; A2B[3]G1S1(6)-azide; FA2B[3]G1S1(6)-azide; A2B[6]G1S1(6)-azide; FA2B[6]G1S1(6)-azide; A2BG2S2(6)-azide; FA2BG2S2(6)-azide; A2B[3]G1S1(3)-azide; FA2B[3]G1S1(3)-azide; A2B[6]G1S1(3)-azide; FA2B[6]G1S1(3)-azide
- the present invention further provides an antibody comprising the structure: A b-[B] n wherein Ab is an antibody; B is a bisected N-glycan wherein the bisecting sugar residue is azido- GlcNAc or GlcNAz having an azide functional group; and, n is an integer from 1-20 for the manufacture of an antibody conjugate.
- the bisected N-glycan B comprises a structure selected from the group consisting of A2B-azide; FA2B-azide; A2B[3]G1-azide; FA2[3]BG1-azide; A2B[6]G1-azide; FA2B[6]G1-azide; A2BG2-azide; FA2BG2-azide; A2B[3]G1S1(6)-azide; FA2B[3]G1S1(6)-azide; A2B[6]G1S1(6)-azide; FA2B[6]G1S1(6)-azide; A2BG2S2(6)-azide; FA2BG2S2(6)-azide; A2B[3]G1S1(3)-azide; FA2B[3]G1S1(3)-azide; A2B[6]G1S1(3)-azide; FA2B[6]G1S1(3)-azide
- the present invention provides a method for making a composition of antibodies comprising the structure: A b-[B] n wherein Ab is an antibody; B is a bisected N-glycan wherein the bisecting sugar residue of the bisected N-glycan is a 6-azido-GlcNAc or GlcNAz residue having an azide functional group; and, n is an integer from 1-20, comprising the steps of: (a) providing an aqueous composition of N-glycosylated antibodies comprising a plurality of complex N-glycans; (b) reacting the N-glycosylated antibodies with a neuraminidase and a galactosidase to produce N-glycosylated antibodies comprising predominantly GlcNAc terminated N-glycans; (c) reacting the GlcNAc-terminated N-glycans with human N- acetylglucosaminyltransferase III (GnT-III or
- the antibodies from step (c) are isolated to provide a composition comprising the antibodies comprising structure Ab-[B] n .
- the antibodies comprising structure Ab-[B] n are reacted with one or more fucosidases to produce a composition comprising afucosylated antibodies comprising structure Ab-[B] n .
- the bisected N-glycan B comprises predominantly a structure selected from the group consisting of A2B-azide and FA2B-azide, wherein the azide refers to the azide of 6-azido-GlcNAc or GlcNAz.
- the antibodies in step (c) are reacted with a ⁇ 1-4 galactosyltransferase in the presence of UDP-galactose to produce galactose-terminated bisected N-glycans comprising predominantly a structure selected from the group consisting of A2B[3]G1-azide; FA2B[3]G1-azide; A2B[6]G1-azide; FA2B[6]G1-azide; A2BG2-azide; and, FA2BG2-azide, wherein the azide refers to the azide of 6-azido-GlcNAc or GlcNAz.
- the galactose-terminated bisected N-glycans are reacted with (i) ⁇ 2-6-sialyltransferase in the presence of CMP-sialic acid to produce sialic acid terminated N-glycans comprising predominantly a structure selected from the group consisting of 25584 A2B[3]G1S1(6)-azide; FA2B[3]G1S1(6)-azide; A2B[6]G1S1(6)-azide; FA2B[6]G1S1(6)-azide; A2BG2S2(6)-azide; and, FA2BG2S2(6)-azide or (ii) ⁇ 2-3-sialyltransferase in the presence of CMP-sialic acid to produce sialic acid terminated N-glycans comprising predominantly a structure selected from the group consisting of A2B[3]G1S1(3)-azide; FA2B
- the antibodies in step (b) are reacted with one or more N- acetyl-glucosaminidases to produce antibodies comprising paucimannose N-glycans, which are then reacted with GnT-I to produce antibodies comprising N-glycans comprising the structure A1[3] and FA1[3] and the resulting antibodies are reacted with GnT-III to produce bisected N- glycan B comprising a structure selected from the group consisting of A1B[3]-azide and FA1B[3]-azide, wherein the azide refers to the azide of 6-azido-GlcNAc or GlcNAz.
- the antibodies in step (c) are further reacted with a ⁇ 1- 4 galactosyltransferase in the presence of UDP-galactose to produce galactose-terminated bisected N-glycans comprising predominantly a structure selected from the group consisting of A1B[3]-azide; FA1B[3]-azide; A1B[3]G1-azide; and FA1B[3]G1-azide, wherein the azide refers to the azide of 6-azido-GlcNAc or GlcNAz.
- the galactose-terminated bisected N-glycans are reacted with (i) ⁇ 2-6-sialyltransferase in the presence of CMP-sialic acid to produce sialic acid terminated N-glycans comprising predominantly a structure selected from the group consisting of A1B[3]G1S1(6)-azide and FA1B[3]G1S1(6)-azide; or (ii) ⁇ 2-3-sialyltransferase in the presence of CMP-sialic acid to produce sialic acid terminated N-glycans comprising predominantly a structure selected from the group consisting of A1B[3]G1S1(6)-azide and FA1B[3]G1S1(6)- azide, wherein the azide refers to the azide of 6-azido-GlcNAc or GlcNAz.
- the present invention further provides a method for producing an antibody conjugate comprising: ( a) providing an antibody comprising the structure Ab-[B] n wherein Ab is an antibody; B is a bisected N-glycan wherein the bisecting sugar residue of the bisected N-glycan is a 6-azido-GlcNAc or GlcNAz residue having an azide functional group; and, n is an integer from 1-20; and (b) conjugating the alkyne functional group of L-Pay or Pay, when L is a bond, to the azide functional group to produce an antibody conjugate comprising the structure Ab-[B-T-L- Pay] n .
- the bisected N-glycan B comprises a structure selected from the group consisting of A2B-azide; FA2B-azide; A2B[3]G1-azide; FA2[3]BG1-azide; A2B[6]G1-azide; FA2B[6]G1-azide; A2BG2-azide; FA2BG2-azide; A2B[3]G1S1(6)-azide; FA2B[3]G1S1(6)-azide; A2B[6]G1S1(6)-azide; FA2B[6]G1S1(6)-azide; A2BG2S2(6)-azide; FA2BG2S2(6)-azide; A2B[3]G1S1(3)-azide; FA2B[3]G1S1(3)-azide; A2B[6]G1S1(3)-azide; FA2B[6]G1S1(3)-azide
- the present invention further provides an antibody comprising one or more N- glycans selected from the group consisting of A2B-azide; FA2B-azide; A2B[3]G1-azide; FA2[3]BG1-azide; A2B[6]G1-azide; FA2B[6]G1-azide; A2BG2-azide; FA2BG2-azide; A2B[3]G1S1(6)-azide; FA2B[3]G1S1(6)-azide; A2B[6]G1S1(6)-azide; FA2B[6]G1S1(6)-azide; A2BG2S2(6)-azide; FA2BG2S2(6)-azide; A2B[3]G1S1(3)-azide; FA2B[3]G1S1(3)-azide; A2B[6]G1S1(3)-azide; FA2B[6]G1S
- the present invention further provides an antibody comprising one or more N- glycans selected from the group consisting of A2B-azide; FA2B-azide; A2B[3]G1-azide; FA2[3]BG1-azide; A2B[6]G1-azide; FA2B[6]G1-azide; A2BG2-azide; FA2BG2-azide; A2B[3]G1S1(6)-azide; FA2B[3]G1S1(6)-azide; A2B[6]G1S1(6)-azide; FA2B[6]G1S1(6)-azide; A2BG2S2(6)-azide; FA2BG2S2(6)-azide; A2B[3]G1S1(3)-azide; FA2B[3]G1S1(3)-azide; A2B[6]G1S1(3)-azide; FA2B[6]G1S
- the present invention further provides an antibody comprising one or more N- glycans selected from the group consisting of A2B-azide; FA2B-azide; A2B[3]G1-azide; FA2[3]BG1-azide; A2B[6]G1-azide; FA2B[6]G1-azide; A2BG2-azide; FA2BG2-azide; A2B[3]G1S1(6)-azide; FA2B[3]G1S1(6)-azide; A2B[6]G1S1(6)-azide; FA2B[6]G1S1(6)-azide; A2BG2S2(6)-azide; FA2BG2S2(6)-azide; A2B[3]G1S1(3)-azide; FA2B[3]G1S1(3)-azide; A2B[6]G1S1(3)-azide; FA2B[6]G1S
- the present invention further provides an antibody-drug conjugate (ADC) comprising an antibody disclosed herein conjugated to a payload comprising an alkyne group.
- ADC antibody-drug conjugate
- the payload is a cytotoxic agent, an anti-inflammatory agent, a radionuclide, or diagnostic agent.
- BRIEF DESCRIPTION OF THE DRAWINGS Fig.1A shows a scheme for converting FA2 to FA2B using N- acetylglucosaminyltransferase III (GnT-III) in the presence of UDP-azido-GlcNAc (N 3 -UDP- ⁇ ).
- GnT-III N- acetylglucosaminyltransferase III
- N 3 -UDP- ⁇ UDP-azido-GlcNAc
- 1B shows installing azido-GlcNAc (N 3 -UDP- ⁇ ) to antibody N-glycans through the activity of N-acetylglucosaminyltransferase III (GnT-III). Shown is dose-dependent treatment of GnT-III on intact human serum IgGs with FA2 and FA2B glycoforms to introduce the bisecting azido-GlcNAc residue thereon.
- the bottom chromatogram shows the control experiment using UDP-GlcNAc as the saccharide donor, instead of UDP-azido-GlcNAc.
- Fig.1C shows a comparison of GnT-III activity between different UDP-GlcNAc derivative substrates.
- Fig.2 shows glycan profile analysis using liquid chromatography. Upper panel: glycan standards isolated from human serum. Oxford notation is used for glycan nomenclature. Bottom panel: native anti-HER2 mouse IgG2a glycan profile. Glycan mass was confirmed by a tandem mass spectrometer (data available on inquiry).
- Figs.3A-3D show payload conjugation through the N-glycan bisecting site.
- Fig.3A shows an exemplary scheme of the bisecting glycan conjugation strategy.
- the N-glycans of an IgG comprising fucose are harmonized to FA2.
- GnT-III is then used to install an azido-GlcNAc to the bisecting position of IgG N-glycans.
- a payload comprising a dibenzocyclooctyne (DBCO) group is conjugated to the azide group of the azido-GlcNAc.
- the resulting conjugate comprises the payload linked to the bisecting N-glycan in a triazole linkage.
- DBCO dibenzocyclooctyne
- the oval shape represents the payload.
- Fig.3B shows an exemplary payload comprising the cytotoxin MMAE linked to a DBCO group via PEG4 linker.
- Fig.3C shows deconvoluted mass of the mouse IgG substrate before and after monomethylauristatin E (MMAE) conjugation to the exemplary payload of Fig.3B.
- Data shows the heavy chains (HC) only for simplicity. No conjugation was observed on the light chains.
- the oval shape represents the payload.
- Fig.3D shows LC-MS analysis on isolated substrate N-glycans confirmed the formation of the FA2-azido glycoform after glycan remodeling.
- Fig.4A-4C shows a linker cleavage study using Cathepsin B and Endoglycosidase S (Endo S).
- Fig.4A shows that mass spectrometry analysis indicated that Cathepsin B cleaves the Valine-Citruline-p-aminobenzylalcohol (Val-Cit-PAB) linker (ii); while Endo S cleaves the ⁇ 1-4 GlcNAc-GlcNAc linkage (iii). In-line fragmentation of the MMAE/linker was observed (i) in the analysis.
- Fig.4B shows formulas of MMAE and linker with (Fig.4B-1, Fig.4B-2, and Fig. 4B-3) and without (Fig.4B-3, Fig.4B-4, and Fig.4B-5) the cleavable Val-Cit-PABC peptides conjugated to the FA2B-azide N-glycans of an antibody. Dashed lines indicated the cleavage sites observed in the MS analysis.
- Fig.4C shows quantitative analysis of ADC recovery from rat plasma after incubation for 3 days. Day 0: the samples were frozen immediately after the ADCs were added to plasma.
- Figs.5A-5B shows synthesis of human IgG-MMAE ADC using bisecting-glycan bridged conjugation to FA2B-azide.
- Fig.5A shows LC-MS analysis of isolated N-glycans from anti-HER2 human IgG1 (Trastuzumab biosimilar) and its glycoengineering into FA2B-azide and A2B-azide glycoforms.
- Fig.5B shows MMAE conjugation was confirmed by deconvoluted IgG mass. Data shows the heavy chains (HC) only for simplicity. No conjugation was observed on the light chains. The oval shape represents the payload.
- Figs.6A-6D show payload conjugation through bisecting glycans is biocompatible.
- Isotype hIgG1 refers to a generic human IgG isotype standard; hIgG1 refers to anti-HER2 human IgG1 (Trastuzumab biosimilar); and hIgG1-MMAE refers to Trastuzumab biosimilar conjugated to MMAE via the bisecting N-glycan FA2B-azide.
- Fig.6A shows a comparison of HER2 binding ability before and after MMAE conjugation to FA2B-azide using biolayer interferometry (BLI). Star marks: show that isotype hIgG1 has no detectable binding signal in the tested concentration range.
- Fig.6B shows flow cytometry assay confirmed the binding of hIgG1-MMAE to SKBR3 surface.
- A cells without secondary antibody staining
- B cells without hIgG1-MMAE treatment
- C cells treated with both hIgG1-MMAE and secondary antibody.
- the hIgG1-MMAE was used as the primary antibody to detect HER2 and an anti-human IgG antibody was used as the secondary antibody.
- Fig.6C shows hIgG1-MMAE internalization study using SKBR3 cells and Incucyte ® ADC internalization assay (Sartorius AG).
- Fig.6D shows a comparison of Fc ⁇ Rs binding ability before and after MMAE conjugation using BLI.
- Fig.6E shows cell viability studies demonstrate target-specific toxicity of the hIgG-MMAE compared to ADCs synthesized by using lysine conjugation or engineered cysteine conjugation (positive controls).
- ADCs made of isotype human IgG1 were used as the negative controls.
- FA2B-azide structure is shown.
- Fig.6F shows a comparison of HER2-expressing cell killing activity between hIgG-MMAE conjugated to FA2B-azide or FA2BG2-azide.
- Figs.7A-7C shows glycoengineering of ADCs and its impact on Fc ⁇ R interactions.
- Fig.7A shows a scheme of glycoengineering methods to control ADC glycoforms.
- Fig.7B-1 shows chromatographic analysis of engineered N-glycans.
- Fig.7B-2 Mass spectrometry analysis of the reduced human IgG1 Trastuzumab biosimilar with engineered N-glycoforms and the corresponding MMAE ADCs.
- HC stands for heavy chain.
- the oval shape represents the payload.
- Fig.7C shows Fc ⁇ R binding response assay using BLI reveals the regulatory effects of ADC glycoforms. The binding assay was triplicated. Curve width indicates the standard deviation at each time point.
- Fig.8 shows optimization of GnT-III reactions to install azido-GlcNAc on intact human serum IgG. Serum IgG with FA2 glycoform was used as the substrate.
- the figure presents each data point and the mean value.
- Fig.9 shows GnT-III substrate selectivity on serum IgG with different glycoforms. GnT-III only functions on N-glycans having a terminal GlcNAc residue.
- the transformation of N-glycan structures was carried out by successive enzymatic remodeling as reported in Hsu, Y.-P. et al. Successive remodeling of IgG glycans using a solid-phase enzymatic platform. Communications Biology 5, 328 (2022).
- Fig.10 shows synthesis of mouse IgG-MMAE ADC.
- Panel A shows a table summarizing the observed mass changes of mouse IgG heavy chain (HC) after glycan harmonization, azido-GlcNAc introduction, and MMAE conjugation reactions. Refer to Fig.3C for the mass spectra.
- Panel B shows that a change in hydrophilicity was observed after MMAE conjugation, as indicated by hydrophilic interaction chromatography.
- Panel C shows that size- exclusion chromatography did not show any significant change in protein size after MMAE conjugation, indicating no aggregation or degradation after the reaction.
- Fig.11 shows synthesis of human IgG-MMAE ADC.
- Panel A the table summarizes the observed mass changes of human IgG heavy chain (HC) after glycan harmonization, azido-GlcNAc introduction, and MMAE conjugation reactions.
- HC human IgG heavy chain
- Fig.5B for the mass spectra.
- Panel B shows a change in hydrophilicity was observed after MMAE conjugation, as indicated by hydrophilic interaction chromatography.
- Panel C shows that size- exclusion chromatography did not show any significant change in protein size after MMAE conjugation.
- Fig.12A shows a Western Blot analysis of human IgG1-MMAE ADC binding ability to human HER2.
- the ADC was used as the primary antibody to detect HER2, and an anti- human IgG antibody was used as the secondary antibody.
- Fig.12B shows cell images were collected from the Incucyte ® ADC internalization assay.
- FabFluoris a pH-sensitive probe that turns red color after internalization into cell lysosome.
- Fig.13 shows a comparison of HER2 and Fc ⁇ Rs binding ability before and after MMAE conjugation to the mouse IgG2a substrate using BLI. Star mark: no detectable binding signal in the tested concentration range.
- Fig.14 shows that melting temperature (Tm) and aggregation temperature (Tagg) assays showed no detectable destabilizing effect after the payload conjugation. Each data point and the mean value are presented.
- Fig.15A, Fig.15B, Fig.15C, Fig.15D and Fig.15E show various biantennary and bisected N-glycans structures drawn following the recommendations of the Symbol Nomenclature for Glycans (SNFG), National Institutes of Health (NIH), National Library of Medicine, National Center for Biotechnology Information, Bethesda, MD and may be accessed at www.ncbi.nlm.nih.gov/glycans/snfg.html. The names of the structures correspond to the Oxford Notation Names in Table 1.
- ⁇ 1-N linkage shown is the linkage between the reducing end of the chitobiose core (GlcNAc ⁇ 1-4GlcNAc) to the sidechain amino group of Asn that comprises the N-glycosylation site Asn-X-Thr/Ser wherein X is any amino acid except Pro.
- Fig.16A, Fig.16B, and Fig.16C show exemplary azido-GlcNAc bisected N- glycan structures of the present invention drawn following the recommendations of the SNFG.
- ⁇ 1-N linkage shown is the linkage between the reducing end of the chitobiose core to the sidechain amino group of Asn that comprises the N-glycosylation site Asn-X-Thr/Ser wherein X is any amino acid except Pro.
- Fig.17 and Fig.17-1 show a representative structure of N-glycans comprising an A2B-azide core linked to the Asn residue of Ab or an FA2B-azide core linked to the Asn residue of Ab.
- n is an integer from 1 to 20 and Ab is antibody.
- Fig.18 and Fig.18-1 show a representative structure of N-glycans comprising an A2B-triazole-L-payload core linked to the Asn residue of Ab or an FA2B-triazole-L-payload core linked to the Asn residue of Ab.
- n is an integer from 1 to 20
- Pay is payload
- L is a linker or a bond
- Ab is antibody.
- Fig.19 and Fig.19-1 show a representative structure of N-glycans comprising an A1B[3]-azide core linked to the Asn residue of Ab or FA1B[3]-azide core linked to the Asn residue of Ab.
- n is an integer from 1 to 20 and Ab is antibody.
- Fig.20 and Fig.20-1 show a representative structure of N-glycans comprising an A1B[3]-triazole-payload core linked to the Asn residue of Ab or an FA1B[3]-triazole-L-payload core linked to the Asn residue of Ab.
- n is an integer from 1 to 20
- Pay is payload
- L is linker or a bond
- Ab is antibody.
- N-glycan and “glycoform” are used interchangeably and refer to an N-linked oligosaccharide, for example, one that is attached by an asparagine-N- acetylglucosamine linkage to an asparagine residue of a polypeptide.
- N-linked glycoproteins 25584 contain an N-acetylglucosamine residue linked to the amide nitrogen of an asparagine residue in the protein.
- glycoproteins The predominant sugars found on glycoproteins are glucose (Glc), galactose (Gal), mannose (Man), fucose (Fuc), N-acetylgalactosamine (GalNAc), N-acetylglucosamine (GlcNAc) and sialic acid (Sia).
- Sialic acids are a class of ⁇ -keto acid sugars with a nine-carbon backbone. The most common member of this group is N-acetylneuraminic acid (Neu5Ac or NANA) found in animals and some prokaryotes.
- N -glycans have a common pentasaccharide core of Man 3 GlcNAc 2 comprising a mannose linked at its reducing end to the nonreducing end of a chitobiose core (GlcNAc ⁇ 1- 4GlcNAc) in a ⁇ 1,4 linkage and one mannose residue linked to the ⁇ 1,4 linked mannose in an ⁇ 1,3 linkage and the other mannose linked to the ⁇ 1,4-linked mannose in an ⁇ 1,6 linkage, represented by the structure showing the Man 3 GlcNAc 2 linked to an asparagine residue comprising an N-glycosylation site in a glycoprotein Man ⁇ 1-6 M an ⁇ 1-4 GlcNAc ⁇ 1-4 G lcNAc ⁇ 1 A sn Man ⁇ 1-3 .
- the GlcNAc residue at the reducing end may also be linked to a fucose residue in an ⁇ 1,6 linkage.
- N-glycan structures are presented with the nonreducing end to the left and the reducing end to the right or the nonreducing end at the top and the reducing end at the bottom.
- the reducing end of the N-glycan is the end that is attached to the Asn residue comprising the glycosylation site on the protein.
- N-glycans differ with respect to the number of branches (antennae) comprising peripheral sugars (e.g., GlcNAc, galactose, fucose and sialic acid) that are added to the Man 3 GlcNAc 2 (“Man 3 ”) core structure, which is also referred to as the “trimannose core”, the “pentasaccharide core”, the trimannosyl core”, or the “paucimannose core”.
- N-glycans are classified according to their branched constituents (e.g., high mannose, complex, or hybrid).
- a “high mannose” type N-glycan comprises five or more mannose residues.
- a “complex” type N-glycan typically has at least one GlcNAc residue attached in a ⁇ 1,2 linkage to the nonreducing end of the mannose residue at the nonreducing end of the 1,3 mannose arm and at least one GlcNAc residue attached in a ⁇ 1,2 linkage to the nonreducing end of the mannose residue at the nonreducing end of the 1,6 mannose arm of the trimannose core.
- Complex N-glycans may further include galactose (“Gal”) or N- acetylgalactosamine (“GalNAc”) residues that are optionally further linked to sialic acid (“Sia”) 25584 or Sia derivatives (e.g., “NANA” or “NeuAc”, where “Neu” refers to neuraminic acid and “Ac” refers to acetyl).
- Gal galactose
- GalNAc N- acetylgalactosamine
- Sia derivatives e.g., “NANA” or “NeuAc”, where “Neu” refers to neuraminic acid and “Ac” refers to acetyl.
- Complex N-glycans may also have intrachain substitutions comprising “bisecting” GlcNAc residue and core fucose (“Fuc”) residue.
- a “hybrid” N-glycan comprises at least one GlcNAc attached in a ⁇ 1,2 linkage to the nonreducing end of the mannose residue at the nonreducing end of the 1,3 mannose arm of the trimannose core and zero or more mannoses attached to the nonreducing end of the mannose on the nonreducing end of the 1,6 mannose arm of the trimannose core.
- the GlcNAc residue may then be attached to a galactose residue and the galactose residue may be attached to a sialic acid residues.
- N-glycans are also referred to as “glycoforms.”
- G-2 With respect to complex N-glycans, the terms "G-2”, “G-1”, “G0”, “G1”, “G2”, “A1”, and “A2” mean the following.
- G-2 refers to an N-glycan structure that can be characterized as Man 3 GlcNAc 2
- G-1 refers to an N-glycan structure that can be characterized as GlcNAcMan 3 GlcNAc 2
- G0 refers to an N-glycan structure that can be characterized as GlcNAc 2 Man 3 GlcNAc 2
- G1 refers to an N-glycan structure that can be characterized as GalGlcNAc 2 Man 3 GlcNAc 2
- G2 refers to an N-glycan structure that can be characterized as Gal 2 GlcNAc 2 Man 3 GlcNAc 2
- the term “A1” refers to an N- glycan structure that can be characterized as SiaGal 2 GlcNAc 2 Man 3 GlcNAc 2
- A2 refers to an N-glycan structure that can be characterized as Sia 2
- G-2", “G-1”, “G0”, “G1”, “G2”, “A1”, and “A2” refer to N-glycan species that lack fucose attached to the GlcNAc residue at the reducing end of the N-glycan.
- the term includes an “F”
- the "F” indicates that the N-glycan species contains a fucose residue on the GlcNAc residue at the reducing end of the N-glycan.
- G0F, G1F, G2F, A1F, and A2F all indicate that the N-glycan further includes a fucose residue attached to the GlcNAc residue at the reducing end of the N-glycan.
- N-glycans include biantennary N-glycans, bisected N-glycans, and multiantennary N-glycans.
- the N-glycan comprises a 1,6 mannose arm and a 1,3 mannose arm in which the 1,6 mannose arm and the 1,3 mannose arm each comprises one GlcNAc residue linked in a ⁇ 1,2 linkage to the mannose residue at the non- reducing end of the arm.
- Each GlcNAc residue may be independently further attached to a 25584 galactose residue and each galactose residue may be independently further attached to a sialic acid residue.
- biantennary N-glycans may include N-glycans having the short-hand formula GlcNAc 2 Man 3 GlcNAc 2 , Gal (1-2) GlcNAc 2 Man 3 GlcNAc 2 , or Sia (1-2) Gal (1- 2) GlcNAc 2 Man 3 GlcNAc 2 .
- the term "(1-2)" refers to 1 or 2 sugar residues.
- multiantennary N-glycan refers to a biantennary N-glycan that further comprises (i) a GlcNAc residue attached in a ⁇ 1,4 linkage to the nonreducing end of the mannose residue comprising the non-reducing end of the 1,6 arm or the 1,3 arm of the N-glycan or (ii) a GlcNAc residue is attached in a ⁇ 1,4 linkage to the nonreducing end of the mannose residue comprising the non-reducing end of the 1,6 arm and a GlcNAc residue is attached in a ⁇ 1,4 linkage to the nonreducing end of the mannose residue comprising the non-reducing end of the 1,3 arm of the N-glycan.
- Each GlcNAc residue may be independently further attached to a galactose residue and the galactose residue may be independently further attached to a sialic acid residue.
- multiantennary N-glycans can be characterized by the short-hand formulas GlcNAc (3-4) Man 3 GlcNAc 2 , Gal (1-4) GlcNAc (3- 4) Man 3 GlcNAc 2 , or Sia (1-4) Gal (1-4) GlcNAc (3-4) Man 3 GlcNAc 2 .
- the term "(1-4)" refers to 1, 2, 3, or 4 residues and the term “(3-4)” refers to 3 or 4 sugar residues.
- bisected N-glycan refers to N- glycans in which the reducing end of a GlcNAc residue is linked in a ⁇ 1,4 linkage to the nonreducing end of the central mannose residue at the nonreducing end of the trimannose core.
- a bisected N-glycan may be characterized by the formula GlcNAc 3 Man 3 GlcNAc 2 wherein each mannose residue is linked at its non-reducing end to a GlcNAc residue.
- a multiantennary N-glycan is characterized as GlcNAc 3 Man 3 GlcNAc 2
- the short-hand formula indicates that two GlcNAc residues are linked to the mannose residue at the non-reducing end of one of the two arms of the N-glycan and one GlcNAc residue is linked to the mannose residue at the non-reducing end of the other arm of the N-glycan.
- the GlcNAc residues at the end of the 1,3 and 1,6 arms of the bisected N-glycan may each be further linked to a galactose residue, which may be further linked to a sialic acid residue, the bisecting GlcNAc residue is not further extended.
- Table 1 provides a list of representative biantennary and bisected N-glycans, which includes the linkage to the Asn residue in the N-glycosylation site Asn-X-Ser/Thr, wherein X may be any amino acid other than proline.
- Fig.15A, Fig.15B, Fig.15C, and Fig.15D shows these various biantennary and bisected N-glycans structures drawn following the 25584 recommendations of the Symbol Nomenclature for Glycans (SNFG), National Institutes of Health (NIH), National Library of Medicine, National Center for Biotechnology Information, Bethesda, MD and may be access at www.ncbi.nlm.nih.gov/glycans/snfg.html.
- 25584 25584 25584 25584 25584 25584 25584 25584 Abbreviations used herein are of common usage in the art, see, e.g., abbreviations of sugars, above.
- N-azidoacetylglucosamine refers to an N-acetylglucosamine comprising an azide group linked to the terminal carbon of the acetyl group thereof or to the C6 carbon thereof.
- GlcNAz refers to an N-acetylglucosamine comprising an azide group linked to the terminal carbon of its acetyl group and may be represented by the following formula .
- GlcNAz residue refers to the GlcNAz linked to the ⁇ 1- 4-linked mannose residue of the trimannose core and may be represented by the following formula wherein the wavy line is a bond to the C4 carbon of the ⁇ 1-4-linked mannose residue of the tri- mannose core.
- the term further includes embodiments wherein the azide group is also linked to an alkyne of a payload or linker-payload.
- the term “6-azido-6-deoxy-N-acetyl-glucosamine” or “6-azido- GlcNAc” refers to a GlcNAc residue comprising an azido group linked to the C6 carbon and may be represented by the formula . 25584 As used herein, the term “6-azido-GlcNAc residue” refers to the GlcNAz linked to the ⁇ 1-4-linked mannose residue of the trimannose core and may be represented by the following formula wherein the wavy line is a bond to the C4 carbon of the ⁇ 1-4-linked mannose residue of the tri- mannose core.
- glycoprotein refers to any protein having one or more N-glycans attached thereto.
- the term refers both to proteins that are generally recognized in the art as a glycoprotein and to proteins which have been genetically engineered to contain one or more N-linked glycosylation sites.
- a “humanized glycoprotein” or a “human-like glycoprotein” refers alternatively to a protein having attached thereto complex or hybrid N-glycans.
- recombinant host cell (“expression host cell”, “expression host system”, “expression system” or simply “host cell”), as used herein, is intended to refer to a cell into which a recombinant vector has been introduced. It should be understood that such terms are intended to refer not only to the particular subject cell but to the progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term "host cell” as used herein.
- a recombinant host cell may be an isolated cell or cell line grown in culture or may be a cell which resides in a living tissue or organism. Preferred host cells are yeasts and fungi.
- mole percent of an N-glycan present in a preparation of a glycoprotein means the molar percent of a particular N-glycan present in the pool of N- linked oligosaccharides released when the protein preparation is treated with PNGase and then quantified by a method that is not affected by glycoform composition, (for instance, labeling a PNGase released glycan pool with a fluorescent tag such as 2-aminobenzamide and then separating by high performance liquid chromatography or capillary electrophoresis and then quantifying glycans by fluorescence intensity).
- 50 mole percent Gal ⁇ 1- 4GlcNAc ⁇ 1-2Man ⁇ 1-3(Man ⁇ 1-6)Man ⁇ 1-4GlcNAc ⁇ 1–4(Fuc ⁇ 1,6)GlcNAc means that 50 percent 25584 of the released glycans are Gal ⁇ 1-4GlcNAc ⁇ 1-2Man ⁇ 1-3(Man ⁇ 1-6)Man ⁇ 1-4GlcNAc ⁇ 1– 4(Fuc ⁇ 1,6)GlcNAc and the remaining 50 percent are comprised of other N-linked oligosaccharides.
- the mole percent of a particular glycan in a preparation of glycoprotein will be between 20% and 100%, preferably above 25%, 30%, 35%, 40% or 45%, more preferably above 50%, 55%, 60%, 65% or 70% and most preferably above 75%, 80% 85%, 90% or 95%.
- operably linked expression control sequences refers to a linkage in which the expression control sequence is contiguous with the gene of interest to control the gene of interest, as well as expression control sequences that act in trans or at a distance to control the gene of interest.
- expression control sequence or “regulatory sequences” are used interchangeably and as used herein refer to polynucleotide sequences which are necessary to affect the expression of coding sequences to which they are operably linked.
- Expression control sequences are sequences which control the transcription, post-transcriptional events and translation of nucleic acid sequences.
- Expression control sequences include appropriate transcription initiation, termination, promoter and enhancer sequences; efficient RNA processing signals such as splicing and polyadenylation signals; sequences that stabilize cytoplasmic mRNA; sequences that enhance translation efficiency (e.g., ribosome binding sites); sequences that enhance protein stability; and when desired, sequences that enhance protein secretion.
- control sequences differs depending upon the host organism; in prokaryotes, such control sequences generally include promoter, ribosomal binding site, and transcription termination sequence.
- control sequences is intended to include, at a minimum, all components whose presence is essential for expression, and can also include additional components whose presence is advantageous, for example, leader sequences and fusion partner sequences.
- transfect transfection
- transfecting refer to the introduction of a heterologous nucleic acid into eukaryote cells, both higher and lower eukaryote cells.
- the term “transformation” has been used to describe the introduction of a nucleic acid into a yeast or fungal cell; however, herein the term “transfection” is used to refer to the introduction of a nucleic acid into any eukaryote cell, including yeast and fungal cells.
- eukaryotic refers to a nucleated cell or organism, and includes insect cells, plant cells, mammalian cells, animal cells and lower eukaryotic cells. 25584
- the term “lower eukaryotic cells” includes yeast and filamentous fungi.
- Yeast and filamentous fungi include, but are not limited to Pichia pastoris, Pichia finlandica, Pichia trehalophila, Pichia koclamae, Pichia membranaefaciens, Pichia minuta (Ogataea minuta, Pichia lindneri), Pichia opuntiae, Pichia thermotolerans, Pichia salictaria, Pichia guercuum, Pichia pijperi, Pichia stiptis, Pichia methanolica, Pichia sp., Saccharomyces cerevisiae, Saccharomyces sp., Hansenula polymorpha, Kluyveromyces sp., Kluyveromyces lactis, Candida albicans, Aspergillus sp., Aspergillus nidulans, Aspergillus niger, Aspergillus oryzae, Trichoderma rees
- the term "antibody” or “immunoglobulin” as used herein refers to a glycoprotein comprising at least two heavy chains (HCs) and two light chains (LCs) inter- connected by disulfide bonds.
- Each HC is comprised of a heavy chain variable region or domain (V H ) and a heavy chain constant region or domain.
- Each light chain is comprised of an LC variable region or domain (V L ) and a LC constant domain.
- the heavy chain constant region is comprised of three domains, CH1, CH2 and CH3.
- the basic antibody structural unit for antibodies is a Y-shaped tetramer comprising two HC/LC pairs (2H).
- Each tetramer includes two identical pairs of polypeptide chains, each pair having one LC (about 25 kDa) and HC chain (about 50-70 kDa) (H+L).
- Each HC:LC pair comprises one V H : one V L pair.
- the one V H :one V L pair may be referred to by the term “Fab”.
- each antibody tetramer comprises two Fabs, one per each arm of the Y-shaped antibody.
- T he LC constant domain is comprised of one domain, CL.
- the human V H includes seven family members: V H 1, V H 2, V H 3, V H 4, V H 5, V H 6, and V H 7; and the human V L includes 16 family members: V ⁇ 1, V ⁇ 2, V ⁇ 3, V ⁇ 4, V ⁇ 5, V ⁇ 6, V ⁇ 1, V ⁇ 2, V ⁇ 3, V ⁇ 4, V ⁇ 5, V ⁇ 6, V ⁇ 7, V ⁇ 8, V ⁇ 9, and V ⁇ 10.
- Each of these family members can be further divided into particular subtypes.
- the V H and V L can be further subdivided into regions of hypervariability, termed complementarity determining region (CDR) areas, interspersed with regions that are more conserved, termed framework regions (FR).
- CDR complementarity determining region
- Each V H and V L is composed of three CDR regions and four FR regions, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.
- Numbering of the amino acids in a VH may be determined using the Kabat numbering scheme. See Béranger, et al., Ed. Ginetoux, Correspondence between the IMGT unique numbering for C-DOMAIN, the IMGT exon 25584 numbering, the Eu and Kabat numberings: Human IGHG, Created: 17/20172001, Version: 08/06/2016, which is accessible at www.imgt.org/IMGTScientificChart/Numbering/ Hu_IGHGnber.html).
- the constant regions of the antibodies may mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (C1q) of the classical complement system.
- the numbering of the amino acids in the heavy chain constant domain begins with number 118, which is in accordance with the Eu numbering scheme.
- the Eu numbering scheme is based upon the amino acid sequence of human IgG1 (Eu), which has a constant domain that begins at amino acid position 118 of the amino acid sequence of the IgG1 described in Edelman et al., Proc. Natl. Acad. Sci.
- variable regions of the heavy and light chains contain a binding domain comprising the CDRs that interacts with an antigen.
- the common numbering schemes include the following. • Kabat numbering scheme is based on sequence variability and is the most commonly used (See Kabat et al. Sequences of Proteins of Immunological Interest, 5th Ed.
- IMGT ImmunoGeneTics
- IMGT ImmunoGeneTics numbering scheme is a standardized numbering system for all the protein sequences of the immunoglobulin superfamily, including variable domains from antibody light and heavy chains as well as T cell receptor chains from different species and counts residues continuously from 1 to 128 based on the germ-line V 25584 sequence alignment (see Giudicelli et al., Nucleic Acids Res.25:206–11 (1997); Lefranc, Immunol Today 18:509(1997); Lefranc et al., Dev Comp Immunol.27:55–77 (2003)).
- the term “isolated” antibodies or antigen-binding fragments thereof are at least partially free of other biological molecules from the cells or cell cultures in which they are produced. Such biological molecules include nucleic acids, proteins, lipids, carbohydrates, or other material such as cellular debris and growth medium. An isolated antibody or antigen-binding fragment may further be at least partially free of expression system components such as biological molecules from a host cell or of the growth medium thereof. Generally, the term “isolated” is not intended to refer to a complete absence of such biological molecules or to an absence of water, buffers, or salts or to components of a pharmaceutical formulation that includes the antibodies or fragments.
- the term "monoclonal antibody” refers to a population of substantially homogeneous antibodies, i.e., the antibody molecules comprising the population are identical in amino acid sequence except for possible naturally occurring mutations that may be present in minor amounts.
- conventional (polyclonal) antibody preparations typically include a multitude of different antibodies having different amino acid sequences in their variable domains that are often specific for different epitopes.
- the modifier "monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies and is not to be construed as requiring production of the antibody by any particular method.
- the monoclonal antibodies to be used in accordance with the present 25584 invention may be made by the hybridoma method first described by Kohler et al., Nature 256: 495 (1975) or may be made by recombinant DNA methods (see, e.g., U.S. Pat. No.4,816,567).
- the "monoclonal antibodies” may also be isolated from phage antibody libraries using the techniques described in Clackson et al., Nature 352: 624-628 (1991), and Marks et al., J. Mol. Biol.222: 581-597 (1991), for example. See also Presta, J. Allergy Clin. Immunol.116: 731 (2005).
- Fc domain As used herein, the term "Fc domain”, “Fc region”, or “Fc” as used herein is the crystallizable fragment domain or region obtained from an antibody that comprises the CH2 and CH3 domains of an antibody, which defines the C-terminal region of an immunoglobulin heavy chain, including, for example, native sequence Fc regions, recombinant Fc regions, and variant Fc regions. Typically, amino acids in the Fc domain are numbered according to the Eu numbering convention (See Edelmann et al., Biochem.63: 78-85 (1969)).
- the human IgG heavy chain Fc region is often defined to stretch from an amino acid residue at position Cys226, or from Pro230, to the carboxyl-terminus thereof.
- the heavy and light chains of antibodies are typically expressed as a precursor protein comprising a leader or signal peptide sequence at the N-terminus, which is removed following translation to provide the mature heavy and light chains.
- the mature heavy chain and light chain N-terminal amino acid residues are usually independently a Gln or Glu residue. Either amino acid may spontaneously cyclize in vitro to form pyroglutamate, which may occur for substantially all antibodies in a composition.
- a composition of intact antibodies may comprise antibody populations in which all N-terminal residues are pyroglutamate, antibody populations in which all N-terminal residues are Glu or Gln, and antibody populations having a mixture of antibodies in which the N-terminal residue is Glu, Gln, or pyroglutamate.
- antibody or “immunoglobulin” or “VH” or “VL” or “HC” or “LC” include variants that comprise N-terminal pyroglutamate.
- the C-terminal lysine of the heavy chain may be removed, for example, during production or purification of the antibody, or by recombinantly engineering the nucleic acid encoding a heavy chain of the antibody to not include the codon for the K447 lysine.
- a composition of intact antibodies may comprise antibody populations with all K447 residues removed, antibody populations with no K447 residues removed, and antibody populations having a mixture of antibodies with and without the K447 residue.
- the heavy chain further has the G446 residue removed as well.
- the term “antibody” or “immunoglobulin” or “HC” or “LC” include variants that lack a C- terminal K447 residue or G446 K447 residues.
- the term “antibody” or “immunoglobulin” or “HC” or “LC” include a composition of intact antibodies that comprises antibody populations in which all N- terminal residues are pyroglutamate, antibody populations in which all N-terminal residues are Glu or Gln, and antibody populations having a mixture of antibodies in which the N-terminal residue is Glu, Gln, or pyroglutamate and may further comprise antibody populations with all K447 or G446 K447 residues removed, antibody populations with no K447 residues removed, and antibody populations having a mixture of antibodies with and without the K447 or G446 K447 residue.
- fragments within the scope of the terms “antibody” or “immunoglobulin” include those produced by digestion with various proteases, those produced by chemical cleavage and/or chemical dissociation and those produced recombinantly, so long as the fragment remains capable of specific binding to a target molecule.
- fragments include Fc, Fab, Fab’, Fv, F(ab’)2, and single chain Fv (scFv) fragments.
- fragments single chain Fv
- Immunoglobulins further include immunoglobulins or fragments that have been modified in sequence but remain capable of specific binding to a target molecule, including: interspecies chimeric and humanized antibodies; antibody fusions; heteromeric antibody complexes and antibody fusions, such as diabodies (bispecific antibodies), single-chain diabodies, and intrabodies (See, for example, Intracellular Antibodies: Research and Disease Applications, (Marasco, ed., Springer-Verlag New York, Inc., 1998).
- ADCC antibody-dependent cell-mediated cytotoxicity
- CDC complement-dependent cytotoxicity
- phagocytosis clearance of immunocomplexes
- B cells IgG serum half-life
- catalytic antibody refers to immunoglobulin molecules that are capable of catalyzing a biochemical reaction. Catalytic antibodies are well known in the art and have been described in U.S. Patent Application Nos.7,205,136; 4,888,281; 5,037,750 to Schochetman et al., U.S. Patent Application Nos.5,733,757; 5,985,626; and 6,368,839 to Barbas, III et al. (the disclosures of which are all incorporated herein by reference).
- ADCC antibody-dependent cell-mediated cytotoxicity
- CDC complement-dependent cytotoxicity
- phagocytosis clearance of immunocomplexes
- B cells IgG serum half-life
- the term “consisting essentially of” will be understood to imply the inclusion of a stated integer or group of integers; while excluding modifications or other integers which would materially affect or alter the stated integer.
- the term “consisting essentially of” a stated N-glycan will be understood to include the N-glycan whether or not that N-glycan is fucosylated at the N-acetylglucosamine (GlcNAc) which is directly linked to the asparagine residue of the glycoprotein.
- the term "predominant” or “predominantly” used with respect to the production of N-glycans refers to a structure which represents the major peak detected by ultrahigh pressure liquid chromatography with ultraviolet (UPLC-UV) absorbance measurement. Glycan masses may be confirmed with UPLC interfaced to electrospray quadrupole time-of- flight mass spectrometry (ESI-QTOF-MS). For example, if a composition consists of species A at 40 mole percent, species B at 35 mole percent and species C at 25 mole percent, the composition comprises predominantly species A, and species B would be the next most predominant species.
- UPLC-UV ultrahigh pressure liquid chromatography with ultraviolet
- Some host cells may produce compositions comprising neutral N-glycans and charged N-glycans such as mannosylphosphate.
- neutral N-glycan means that of the total plurality of neutral N-glycans in the composition, the predominant N-glycan is of a particular structure.
- the term “essentially free of” a particular sugar residue, such as fucose, or galactose and the like, is used to indicate that the glycoprotein composition is substantially devoid of N-glycans which contain such residues.
- 25584 essentially free means that the amount of N-glycan structures containing such sugar residues does not exceed 10%, and preferably is below 5%, more preferably below 1%, most preferably below 0.5%, wherein the percentages are by weight or by mole percent.
- substantially all of the N- glycan structures in a glycoprotein composition according to the present invention are free of, for example, fucose, or galactose, or both.
- a glycoprotein composition “lacks” or “is lacking” a particular sugar residue, such as fucose or galactose, when no detectable amount of such sugar residue is present on the N-glycan structures at any time.
- the glycoprotein compositions are produced by lower eukaryotic organisms, as defined above, including yeast (for example, Pichia sp.; Saccharomyces sp.; Kluyveromyces sp.; Aspergillus sp.), and will “lack fucose,” because the cells of these organisms do not have the enzymes needed to produce fucosylated N-glycan structures.
- yeast for example, Pichia sp.; Saccharomyces sp.; Kluyveromyces sp.; Aspergillus sp.
- the term “essentially free of fucose” encompasses the term “lacking fucose.”
- a composition may be “essentially free of fucose” even if the composition at one time contained fucosylated N-glycan structures or contains limited, but detectable amounts of fucosylated N-glycan structures as described above.
- the term “multiplicity” refers to a large number of the same or substantially same molecules, proteins, enzymes, species, etc.
- a multiplicity of glycoproteins refers to a population of glycoproteins in which the glycoproteins have the same amino acid sequence and the same N-glycan structure.
- a multiplicity of glycoproteins refers to a population of glycoproteins wherein the glycoproteins have substantially the same amino acid sequence and the N-glycans have substantially the same structure.
- the term “plurality” refers to a large number of a variety of species of molecules, proteins, enzymes, species, etc.
- a plurality of glycoproteins refers to (i) a population of glycoproteins in which the glycoproteins have substantially the same amino acid sequence and more than one N-glycan structure, e.g., N-glycans comprising a mixture of Sia (1-2) Gal (1-2) GlcNAc (1-2) Man 3 GlcNAc 2 , Gal (1-2) GlcNAc (1-2) Man 3 GlcNAc 2 , and GlcNAc (1-2) Man 3 GlcNAc 2 structures, or (ii) a population of glycoproteins in which the glycoproteins comprise more than one amino acid sequence and a single N-glycan structure or more than one N-glycan structure.
- N-glycans comprising a mixture of Sia (1-2) Gal (1-2) GlcNAc (1-2) Man 3 GlcNAc 2 , Gal (1-2) GlcNAc (1-2) Man 3 GlcNAc 2 , and GlcNAc (1-2) Man 3 Glc
- the term “sequentially” refers to forming or following in a logical order or sequence.
- a glycoprotein may be reacted with a neuraminidase, a galactosidase, and a GlcNAcase in that order to produce a paucimannose N-glycan.
- the term “remodel” or “remodeling” refers to changing the structure of an N-glycan having a particular glycoform to another glycoform, by removing and/or adding sugar residues to the N-glycan. The term further includes changing the structures of the N- glycans of a population of glycoproteins.
- glycosylation enzymes refers to exoglycosidases, endoglycosidases, and glycosyltransferases, and includes both native and naturally occurring enzymes and recombinant variants thereof that comprise at least the catalytic activity of the glycosylation enzyme.
- exoglycosidases are glycoside hydrolase enzymes (EC 3.2) that cleave the glycosidic linkage of a terminal monosaccharide in an oligosaccharide or polysaccharide.
- Exoglycosidases include neuraminidases, galactosidases, N- acetylglucosaminidases, and fucosidases.
- “endoglycosidases” are glycoside hydrolase enzymes (EC 3.2) that cleave the glycosidic linkage between the two N-acetylglucosamine (GlcNAc) residues of the chitobiose core, but which recognize and cleave different types of N-linked glycans.
- endoglycosidase H cleaves within the chitobiose core of high mannose and some hybrid oligosaccharides from N-linked glycoproteins
- endoglycosidase S is highly specific for removing N-linked glycans from the heavy chain of native IgG
- endoglycosidase D cleaves paucimannose N-linked glycans.
- glycosyltransferases are enzymes (EC 2.4) that catalyze the transfer of saccharide moieties from an activated nucleotide sugar (also known as the "glycosyl donor") to a nucleophilic glycosyl acceptor molecule, the nucleophile of which can be oxygen-, carbon-, nitrogen-, or sulfur-based.
- glycosyltransferases include but are not limited to N-acetylglucosaminyltransferase (GnT) I, which transfers GlcNAc from UDP-GlcNAc to the ⁇ 1,3-linked terminal mannose (Man) residue on paucimannose N-glycans; GnTII, which transfers GlcNAc from UDP-GlcNAc to the ⁇ 1,6-linked terminal mannose of GlcNAcMan 3 GlcNAc 2 N-glycans in a ⁇ 1,2 linkage; GnTIII, which transfers GlcNAc from UDP- GlcNAc to the ⁇ 1,4-linked central mannose of GlcNAcMan 3 GlcNAc 2 N-glycans in a ⁇ 1,4 linkage; ⁇ 1,4-galactosyltransferase (GalT), which transfers galactose (Gal) from UDP-galactose to the terminal Glc
- effector moiety comprises agents (e.g., proteins, nucleic acids, lipids, carbohydrates, glycopeptides, and fragments thereof) with biological or other functional activity.
- the effector moiety may be a therapeutic agent, a diagnostic agent, or a functional element such as a cleavable linker.
- a payload that is directly or indirectly conjugated to the antibody may comprise an effector moiety.
- ADC antibody-drug conjugates
- EDCs extracellular drug conjugates
- Fab- or Fc- fusions Fab- or Fc- fusions
- the present invention provides a new antibody conjugation strategy comprising modifying the N-glycans of the antibody to comprise bisected N-glycans wherein the bisecting sugar of the N-glycan is an azidoacetylglucosamine (6-azido-GlcNAc or GlcNAz) residue and conjugating payloads to the bisecting azidoacetylglucosamine residue.
- the azido group allows for azide-alkyne click chemistry conjugation of the antibody to payloads comprising an alkyne group suitable for conjugation.
- the strategy enables site-specific conjugation with high biocompatibility to the antibody and does not require genetic editing.
- the Examples herein show that this strategy can be applied to human IgG1 and mouse IgG2a and may be extrapolated to other IgG subclasses, for example, the IgG4 subclass.
- payload conjugation through the bisecting N-azidoacetylglucosamine residue preserves the opportunity to remodel the structure of the bi-antennary arms of the bisected N-glycan to have different glycoforms, for example, for the N-glycans to be GlcNAc terminated, galactose terminated, sialic acid terminated, fucosylated, afucosylated, or the like.
- the Examples herein show that several of these glycoforms result in ADCs with different binding affinities to Fc ⁇ Rs. These results show that the present invention enable the production of ADCs that can further be modified to have particular 25584 binding affinities for Fc ⁇ Rs by modifying the glycoforms of the bisected N-glycans conjugated to the payload.
- the Examples show that N-glycans can serve as a regulatory handle to optimize the immunogenicity and pharmacokinetics of antibody conjugates. Together, conjugation through the bisecting IgG N-glycan presents a versatile strategy for developing antibody conjugates with site-specificity. The highly conserved core structure of N-glycans enables this strategy to translate to glycoproteins other than antibodies for biotherapeutic development.
- the present invention provides a method for making glycoprotein conjugates in general and antibody-drug conjugates in particular.
- Bisected N-glycans Comprising a Bisecting N-azidoacetylglucosamine Residue
- Glycoproteins expressed in mammalian cell culture may comprise one or more N- glycans and in a composition of such glycoproteins, the glycoforms present may be heterogenous.
- each Asn at position 297 (Eu numbering) of the Fc domain of an antibody expressed in mammalian cell culture is conjugated to an N-glycan having a particular glycoform.
- Additional glycoforms may be present in antibodies comprising one or naturally occurring N-glycosylation sites in the VH and/or VL domains and further still in antibodies engineered to comprise one or more non-naturally occurring N-glycosylation sites.
- the particular glycoform varies from antibody to antibody, which results in a composition comprising a heterogenous mixture N-glycan glycoforms.
- the glycoproteins are purified from the cell culture and then treated in vitro with one or more neuraminidases and one or more galactosidases to produce a composition of glycoproteins in which the predominant N-glycan is the bi-antennary FA2 N-glycan represented by the formula GlcNAc ⁇ 1-2Man ⁇ 1-3(GlcNAc ⁇ 1-2Man ⁇ 1-6)Man ⁇ 1-4GlcNAc ⁇ 1–4(Fuc ⁇ 1- 6)GlcNAc ⁇ 1–Asn or the formula Fuc G lcNAc Man ⁇ 1-3 .
- the glycoproteins may be expressed in a yeast host cell that has been genetically modified to produce glycoproteins comprising mammalian or human-like N- glycans.
- yeast host cell such as Pichia pastoris and Saccharomyces cerevisiae do not produce complex N- 25584 glycans because they lack GnT-I, GnT-II, various mannosidases, galactosyltransferases, fucosyltransferases, and sialyltransferases.
- the yeast N-glycosylation pathway comprises initiating ⁇ 1,6-mannosyltransaferase and a number of other mannosyltransferases, which together result in the production of high mannose N-glycans, which are not found in mammalian cells.
- the N-glycosylation pathway in yeast may be modified by deleting the gene encoding the initiating ⁇ 1,6-mannosyltransaferase and introducing into the yeast cell those glycosyltransferases needed to produce N-glycans having a particular glycoforms.
- yeast such as Pichia pastoris and Saccharomyces cerevisiae comprising a deletion of the gene encoding the initiating ⁇ 1,6-mannosyltransaferase and the introduction of nucleic acid molecules encoding ⁇ 1,2-mannosidase, GnT-I, mannosidase II, and GnT-II, and optionally UDP-GlcNAc transporters results in a yeast host cell that is capable of producing glycoproteins comprising predominantly the A2 biantennary N-glycan. (See for example, U.S. Pat. No.7326681).
- glycoproteins comprising predominantly the FA2 biantennary N-glycan shown above results in a yeast host cell that is capable of producing glycoproteins comprising predominantly the FA2 biantennary N-glycan shown above.
- the glycoproteins comprising the FA2 biantennary N-glycans may be reacted in vitro with a GnT-III in the presence of UDP-azido-GlcNAc (UDP-GlcNAz or UDP-6-azido- GlcNAc) to produce a composition of N-glycosylated glycoproteins in which the predominant N- glycan is a bisected FA2B-azide N-glycan represented by the formula (i) GlcNAc ⁇ 1-2Man ⁇ 1- 3(GlcNAc ⁇ 1-2Man ⁇ 1-6)(Azido-GlcNAc ⁇ 1-4)Man ⁇ 1-4GlcNAc ⁇ 1–4(Fuc ⁇ 1-6)GlcNAc ⁇ 1–
- glycoproteins comprising predominantly FA2B-azide N-glycans may be used for conjugating to a payload as disclosed herein. However, in further embodiments, it may be desirable to conjugate payloads to glycoproteins comprising galactosylated N-glycans or sialylated N-glycans.
- glycoproteins comprising FA2B-azide N-glycans are reacted in vitro with a ⁇ 1-4 galactosyltransferase (GalT) in the presence of UDP-glucose to 25584 produce a composition of N-glycosylated glycoproteins in which the predominant N-glycan is a bisected FA2BG2-azide N-glycan represented by the formula Gal ⁇ 1-4GlcNAc ⁇ 1-2Man ⁇ 1- 3(Gal ⁇ 1-4GlcNAc ⁇ 1-2Man ⁇ 1-6)(GlcNAz ⁇ 1-4)Man ⁇ 1-4GlcNAc ⁇ 1–4(Fuc ⁇ 1-6)GlcNAc ⁇ 1–Asn or Gal ⁇ 1-4 G lcNAc ⁇ 1-2 Man Fuc ⁇ 1-6 ⁇ 1-6 Azido-GlcNAc ⁇ 1-4 Man ⁇ 1-4 GlcNAc ⁇ 1-4 ⁇ 1 GlcNAc Asn ; wherein Azido-GlcNAc
- the glycoproteins comprising predominantly FA2BG2-azide N-glycans may be used for conjugating to a payload as disclosed herein.
- the predominant N-glycans are a mixture of bisected FA2BG2-azide, bisected FA2B[3]G1-azide, and bisected FA2B[6]G1-azide N-glycans wherein the bisected FA2B[3]G1-azide N-glycan is represented by the formula Gal ⁇ 1-4GlcNAc ⁇ 1- 2Man ⁇ 1-3(GlcNAc ⁇ 1-2Man ⁇ 1-6)(GlcNAz ⁇ 1-4)Man ⁇ 1-4GlcNAc ⁇ 1–4(Fuc ⁇ 1-6)GlcNAc ⁇ 1–Asn or the formula G lcNAc ⁇ 1-2 Man ⁇ 1-6 Azido-GlcNAc ⁇ 1-4 Man Asn G al ; wherein Azido-GlcNAc is GlcNAz or 6-azido
- glycoproteins comprising these predominant glycoforms may be used for conjugating to a payload as disclosed herein.
- glycoproteins comprising FA2BG2-azide N-glycans are reacted with an ⁇ 2-6 sialyltransferase (SiaT) in the presence of CMP-sialic acid to produce a composition of N-glycosylated glycoproteins in which the predominant N-glycan is a bisected 25584 FA2BG2S2(6)-azide N-glycan represented by the formula Sia ⁇ 2-6Gal ⁇ 1-4GlcNAc ⁇ 1-2Man ⁇ 1- 3(Sia ⁇ 2-6Gal ⁇ 1-4GlcNAc ⁇ 1-2Man ⁇ 1-6)(GlcNAz ⁇ 1-4)Man ⁇ 1-4GlcNAc ⁇ 1–4(Fuc ⁇ 1- 6)GlcNAc ⁇ 1–Asn or the formula ⁇ Sia 2-6 Gal ⁇ 1-4 G lcNAc ⁇ 1-2 Man Fuc ⁇ 1-6
- the glycoproteins comprising predominantly FA2BG2S2(6)-azide N-glycans may be used for conjugating to a payload as disclosed herein.
- the predominant N-glycans are a mixture of bisected FA2BG2S2(6)-azide, bisected FA2BG2[3]S1(6)-azide, and bisected FA2BG2[6]S1(6)-azide N- glycans wherein the bisected FA2BG2[3]S1(6)-azide N-glycan is represented by the formula Sia ⁇ 2-6Gal ⁇ 1-4GlcNAc ⁇ 1-2Man ⁇ 1-3(Gal ⁇ 1-4GlcNAc ⁇ 1-2Man ⁇ 1-6)(GlcNAz ⁇ 1-4)Man ⁇ 1- 4GlcNAc ⁇ 1–4(Fuc ⁇ 1-6)GlcNAc ⁇ 1–Asn or the formula Gal ⁇ 1-4 G lcNAc ⁇ 1-2 Man ⁇ 1-6 Azido-GlcNAc ⁇ 1-4 Man
- glycoproteins comprising these predominant glycoforms may be used for conjugating to a payload as disclosed herein.
- glycoproteins comprising FA2BG2-azide N-glycans are reacted with an ⁇ 2-3 sialyltransferase (SiaT) in the presence of CMP-sialic acid to produce a composition of N-glycosylated glycoproteins in which the predominant N-glycan is a bisected FA2BG2S2(3)-azide N-glycan represented by the formula Sia ⁇ 2-3Gal ⁇ 1-4GlcNAc ⁇ 1-2Man ⁇ 1- 25584 3(Sia ⁇ 2-3Gal ⁇ 1-4GlcNAc ⁇ 1-2Man ⁇ 1-6)(GlcNAz ⁇ 1-4)Man ⁇ 1-4GlcNAc ⁇ 1–4(Fuc ⁇ 1- 6)GlcNAc ⁇ 1–Asn or the formula Sia ⁇ 2-3 Gal ⁇ 1-4 GlcNAc ⁇ 1-2 Man Fuc ⁇ 1-6 ⁇
- the glycoproteins comprising predominantly FA2BG2S2(3)-azide N-glycans may be used for conjugating to a payload as disclosed herein.
- the predominant N-glycans are a mixture of bisected FA2BG2S2(3)-azide, bisected FA2BG2[3]S1(3)-azide, and bisected FA2BG2[6]S1(3)-azide N- glycans wherein the bisected FA2BG2[3]S1(3)-azide N-glycan is represented by the formula Sia ⁇ 2-3Gal ⁇ 1-4GlcNAc ⁇ 1-2Man ⁇ 1-3(Gal ⁇ 1-4GlcNAc ⁇ 1-2Man ⁇ 1-6)(GlcNAz ⁇ 1-4)Man ⁇ 1- 4GlcNAc ⁇ 1–4(Fuc ⁇ 1-6)GlcNAc ⁇ 1–Asn or the formula Asn S ia ⁇ 2-3 Gal ⁇ 1-4 G lcNAc ⁇ 1-2 ⁇ Man 1-3 ; wherein Azid
- the glycoproteins comprising the above predominant glycoforms may be used for conjugating to a payload directly or indirectly comprising an alkyne group for forming a triazole linkage with the azido group of the bisecting GlcNAz as disclosed herein.
- the glycoprotein may be an antibody, a Fab, scFv, or a fusion protein comprising an Fc domain of an antibody fused or conjugated to a heterologous protein.
- the classic antibody ADCC response is mediated by natural killer (NK) cells following the binding of the Fc ⁇ RIIIa to the Fc region of antibody molecules. This binding triggers the NK cells to release cytokines and cytolytic agents that eventually kill the target cell.
- the ADCC activity is highly affected by the Fc N-glycan.
- the Fc N-glycans are heterogeneous biantennary complex type with a fucose residue attached to the core position. These N-glycans contain little to no sialic acid with zero galactose residues (A2), one galactose residue (A2[3 or 6]G1) or two galactose residues (A2G2).
- the glycoproteins may be expressed in a mammalian cell culture in which the mammalian cells thereof have been genetically engineered to produce glycoproteins comprising afucosylated N-glycans.
- deleting the FUT8 gene in Chinese hamster ovary (CHO) cells produces a mutant CHO cell that produces afucosylated glycoproteins (Yamane-Ohnuki et al., Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol Bioeng.87: 614–22 (2004) and Malphettes et al., Highly efficient deletion of FUT8 in CHO cell lines using zinc-finger nucleases yields cells that produce completely nonfucosylated antibodies. Biotechnol Bioeng.106: 774–83 (2010)).
- the glycoproteins are purified from the cell culture and then treated in vitro with one or more neuraminidases and one or more galactosidases to produce a composition of glycoproteins in which the predominant N-glycan is the bi-antennary afucosylated A2 N-glycan represented by the formula GlcNAc ⁇ 1-2Man ⁇ 1-3(GlcNAc ⁇ 1- 2Man ⁇ 1-6)Man ⁇ 1-4GlcNAc ⁇ 1–4GlcNAc ⁇ 1–Asn or the formula M an ⁇ 1-4 GlcNAc ⁇ 1-4 ⁇ 1 1-2 GlcNAc Asn G lcNAc ⁇ Man ⁇ 1-3 .
- the glycoproteins may be expressed in a yeast host cell that has been genetically modified to produce glycoproteins comprising mammalian or human-like N- glycans.
- the N-glycosylation pathway in yeast may be modified by deleting the gene encoding the initiating ⁇ 1,6-mannosyltransaferase and introducing into the yeast cell those glycosyltransferases needed to produce N-glycans having a particular glycoforms.
- yeast such as Pichia pastoris and Saccharomyces cerevisiae comprising a deletion of the gene encoding the initiating ⁇ 1,6-mannosyltransaferase and the introduction of nucleic acid molecules encoding ⁇ 1,2-mannosidase, GnT-I, mannosidase II, and GnT-II and optionally UDP-GlcNAc transporters results in a yeast host cell that is capable of producing glycoproteins comprising predominantly afucosylated A2 N-glycans comprising the structure above. (See for example, U.S. Pat. No.7326681).
- T he glycoproteins comprising the biantennary GlcNAc 2 Man 3 GlcNAc 2 N-glycans are reacted with a GnT-III in the presence of UDP-azide-GlcNAc to produce a composition of N- glycosylated glycoproteins in which the predominant N-glycan is a bisected A2B-azide N-glycan represented by the formula GlcNAc ⁇ 1-2Man ⁇ 1-3(GlcNAc ⁇ 1-2Man ⁇ 1-6)(GlcNAz ⁇ 1-4)Man ⁇ 1- 4GlcNAc ⁇ 1–4GlcNAc ⁇ 1–Asn or the formula G lcNAc ⁇ 1-2 Man ⁇ 1-6 Azido-GlcNAc ⁇ 1-4 Man Asn G lcNAc ⁇ 1-2 ⁇ Man 1-3 ; wherein Azido-GlcNAc is GlcNAz or 6-azido-GlcNAc.
- glycoproteins comprising predominantly A2B-azide N-glycans may be used for conjugating to a payload as disclosed herein. However, in further embodiments, it may be desirable to conjugate payloads to glycoproteins comprising galactosylated N-glycans of sialylated N-glycans.
- glycoproteins comprising A2B-azide N-glycans are reacted with a ⁇ 1-4 galactosyltransferase (GalT) in the presence of UDP-glucose to produce a composition of N-glycosylated glycoproteins in which the predominant N-glycan is a bisected A2BG2-azide N-glycan represented by the formula Gal ⁇ 1-4GlcNAc ⁇ 1-2Man ⁇ 1-3(Gal ⁇ 1- 4GlcNAc ⁇ 1-2Man ⁇ 1-6)(GlcNAz ⁇ 1-4)Man ⁇ 1-4GlcNAc ⁇ 1–4GlcNAc ⁇ 1–Asn or the formula wherein Azido-GlcNAc is GlcNAz or 6-azido-GlcNAc.
- GalT galactosyltransferase
- the glycoproteins comprising predominantly FA2BG2-azide N-glycans may be used for conjugating to a payload as disclosed herein.
- the predominant N-glycans are a mixture of bisected A2BG2-azide, bisected A2B[3]G1-azide, and bisected A2B[6]G1-azide N-glycans wherein the bisected A2B[3]G1-azide N-glycan is represented by the formula Gal ⁇ 1-4GlcNAc ⁇ 1-2Man ⁇ 1- 3(GlcNAc ⁇ 1-2Man ⁇ 1-6)(GlcNAz ⁇ 1-4)Man ⁇ 1-4GlcNAc ⁇ 1–4GlcNAc ⁇ 1–Asn or the formula Azido-GlcNAc ⁇ 1-4 Man ⁇ 1-4 GlcNAc ⁇ 1-4 G lcNAc ⁇ 1 Asn G al ; wherein Azido-GlcNAc is GlcNAz or 6-azid
- glycoproteins comprising these predominant glycoforms may be used for conjugating to a payload as disclosed herein.
- antibodies comprising A2BG2-azide N-glycans are reacted with an ⁇ 2-6 sialyltransferase (SiaT) in the presence of CMP-sialic acid to produce a composition of N-glycosylated glycoproteins in which the predominant N-glycan is a bisected A2BG2S2(6)-azide N-glycan represented by the formula Sia ⁇ 2-6Gal ⁇ 1-4GlcNAc ⁇ 1-2Man ⁇ 1- 3(Sia ⁇ 2-6Gal ⁇ 1-4GlcNAc ⁇ 1-2Man ⁇ 1-6)(GlcNAz ⁇ 1-4)Man ⁇ 1-4GlcNAc ⁇ 1–4GlcNAc ⁇ 1–Asn or the formula ⁇ Sia 2-6 Gal ⁇ 1-4 G lcNAc ⁇ 1-2 Man ⁇ 1-6 Azido-GlcNAc ⁇ 1-4 Man ⁇
- the glycoproteins comprising predominantly FA2BG2S2(6)-azide N-glycans may be used for conjugating to a payload as disclosed herein.
- the predominant N-glycans are a mixture of bisected A2BG2S2(6)-azide, bisected A2BG2[3]S1(6)-azide, and bisected A2BG2[6]S1(6)-azide N- glycans wherein the bisected A2BG2[3]S1(6)-azide N-glycan is represented by the formula Sia ⁇ 2-6Gal ⁇ 1-4GlcNAc ⁇ 1-2Man ⁇ 1-3(Gal ⁇ 1-4GlcNAc ⁇ 1-2Man ⁇ 1-6)(GlcNAz ⁇ 1-4)Man ⁇ 1- 4GlcNAc ⁇ 1–4GlcNAc ⁇ 1–Asn or the formula 25584 Gal Man ⁇ 1-6 Azido-GlcNAc ⁇ 1-4 Man ⁇ 1-4 GlcNAc ⁇ 1-4 G lcNAc
- glycoproteins comprising these predominant glycoforms may be used for conjugating to a payload as disclosed herein.
- glycoproteins comprising A2BG2-azide N-glycans are reacted with an ⁇ 2-3 sialyltransferase (SiaT) in the presence of CMP-sialic acid to produce a composition of N-glycosylated glycoproteins in which the predominant N-glycan is a bisected A2BG2S2(3)-azide N-glycan represented by the formula Sia ⁇ 2-3Gal ⁇ 1-4GlcNAc ⁇ 1-2Man ⁇ 1- 3(Sia ⁇ 2-3Gal ⁇ 1-4GlcNAc ⁇ 1-2Man ⁇ 1-6)(GlcNAz ⁇ 1-4)Man ⁇ 1-4GlcNAc ⁇ 1–4GlcNAc ⁇ 1–Asn or the formula ⁇ Sia 2-3 Gal ⁇ 1-4 G lcNAc ⁇ 1-2 Man ⁇ 1-6 Azido-GlcNAc ⁇ 1-4 Man
- the glycoproteins comprising predominantly FA2BG2S2(3)-azide N-glycans may be used for conjugating to a payload as disclosed herein.
- the predominant N-glycans are a mixture of bisected A2BG2S2(3)-azide, bisected A2BG2[3]S1(3)-azide, and bisected A2BG2[6]S1(3)-azide N- glycans wherein the bisected A2BG2[3]S1(3)-azide N-glycan is represented by the formula Sia ⁇ 2-3Gal ⁇ 1-4GlcNAc ⁇ 1-2Man ⁇ 1-3(Gal ⁇ 1-4GlcNAc ⁇ 1-2Man ⁇ 1-6)(GlcNAz ⁇ 1-4)Man ⁇ 1- 4GlcNAc ⁇ 1–4GlcNAc ⁇ 1–Asn or the formula ⁇ 1-4 GlcNAc ⁇ 1-2 Man ⁇ 1-6 Azido-GlcNAc ⁇ 1-4 Man Asn S ia ; where
- glycoproteins comprising these predominant glycoforms may be used for conjugating to a payload as disclosed herein.
- the glycoprotein is an antibody, Fab, or scFv comprising at least one N-glycosylation site.
- the glycoprotein is a fusion protein comprising the Fc domain of an antibody fused to a heterologous protein or heterologous glycoprotein.
- the heterologous glycoprotein is a Fab or scFv comprising at least one N-glycosylation site.
- Antibodies comprise an N-glycosylation site beginning with the Asn at position 297 (Eu numbering) of the constant domain of the heavy chain and may comprise one or more naturally occurring N-glycosylation sites located in the V H and V L domains. Since antibodies are tetramers comprising two heterodimers, each heterodimer comprising one light chain and one heavy chain, the maximum DAR achievable for an ADC comprising solely the N-glycosylation sites at position 297 is two.
- the present invention further provides antibodies comprising one or more amino acid substitutions in the variable or constant domain of the antibody that generate one or more non-native N-glycosylation sites comprising the amino acid sequence Asn-X-Thr/Ser, wherein X is any amino acid except Pro, and wherein the N-glycan conjugated to each non-native N-glycosylation site comprises a bisected N-glycan in which the bisecting sugar of the bisected N-glycan is an azido-GlcNAc residue.
- the azide group of the azido-GlcNAc residue of the bisecting N-glycan is further conjugated in a triazole linkage to an alkyne group of a payload.
- Antibodies may be engineered to comprise one to ten amino acid substitutions (or pairs of amino acid substitutions) in the heavy chain constant domain, which generate one to ten non-native N-glycosylation sites, the amino acid substitutions being selected from the group consisting of S134N, G161T, G161S, N203T, N203S, V363T, V363S, Q438N, S176N, A118N, S132N, K133N, A162N, T195N, K210T, Y391T, F423T, F423S,Y436T, Y436S, L193N, K392T, K392S, F423T, S176N/G178T, S176N/G178S, Q419N/
- an ADC in which the N-glycosylation site is at position 297 will have a DAR of up to 2.
- ADCs may be constructed that may comprise a DAR of up to 4, 6, 8, 10, 12, 14, 15, 18, 20, or 22.
- the engineered antibody or fragment thereof may comprise a human IgG1, IgG2, or IgG4 constant domain.
- the engineered antibody comprises a human IgG1 constant domain.
- the engineered antibody comprises a human IgG4 constant domain.
- the engineered antibody comprises at least one or two amino acid substitutions (or a pair of substitutions) in the heavy chain constant domain selected from S134N, G161T and S134N/G161T. In another embodiment, the engineered antibody comprises at least amino acid substitutions in the heavy chain constant domain selected from G161T/S134T and G161S/S134T. In a particular embodiment, the antibody comprises an S134N amino acid substitution, which when combined with the native N297 N-glycosylation site results in an ADC that may comprise a DAR of up to 4.
- the antibody comprises a G161T amino acid substitution, which when combined with the native N297 N- glycosylation site results in an ADC that may comprise a DAR of up to 4.
- the antibody comprises an S134N amino acid substitution and a G1261T amino acid substitution, which when combined with the native N297 N-glycosylation site results in an ADC that may comprise a DAR of up to 6.
- the antibody possess one to two amino acid substitutions in the heavy chain variable framework domain which generate one to two non-native N- glycosylation sites, the amino acid substitutions being selected from the group consisting of Q105N and S113N, the position numbering is according to Kabat numbering.
- An antibody with a Q105N amino acid substitution when combined with the native N297 N-glycosylation site results 25584 in an ADC that may comprise a DAR of up to 4.
- An antibody with a S113N amino acid substitution when combined with the native N297 N-glycosylation site results in an ADC that may comprise a DAR of up to 4.
- An antibody with a Q105N amino acid substitution and an S113N amino acid substitution when combined with the native N297 N-glycosylation site results in an ADC that may comprise a DAR of up to 4.
- Glycoproteins other than antibodies may be modified to comprise one or more non-native N-glycosylation sites comprising the amino acid sequence Asn-Xaa-Thr/Ser, wherein X is any amino acid except Pro, and wherein the N-glycan conjugated to each non-native N- glycosylation site comprises a bisected N-glycan in which the bisecting sugar of the bisected N- glycan is an azido-GlcNAc residue.
- the azide group of the azido- GlcNAc residue of the bisecting N-glycan is further conjugated in a triazole linkage to an alkyne group of a payload.
- the antibodies of the current disclosure are conjugated to a therapeutic effector moiety comprising a therapeutic agent, e.g., a drug moiety (or prodrug thereof) or radiolabeled compound.
- a therapeutic agent e.g., a drug moiety (or prodrug thereof) or radiolabeled compound.
- the therapeutic agent is a cytotoxin.
- Exemplary drug moieties include anti-inflammatory agents, anti-cancer agents, anti-infective agents (e.g., anti-fungal, antibacterial, anti-parasitic, anti-viral, etc.), and anesthetic therapeutic agents.
- the drug moiety is an anti-cancer agent.
- anti-cancer agents include, but are not limited to, cytostatics, enzyme inhibitors, gene regulators, cytotoxic nucleosides, tubulin binding agents, tubulin disrupters, tubulin inhibitors, topoisomerase inhibitors, proteasome inhibitors, hormones and hormone antagonists, anti-angiogenesis agents, and the like. Any such molecule may be conjugated to an antibody or other glycoprotein according to the present invention.
- cytostatic anti-cancer agents include alkylating agents such as the anthracycline family of drugs (e.g., adriamycin, carminomycin, cyclosporin-A, chloroquine, methopterin, mithramycin, porfiromycin, streptonigrin, porfiromycin, anthracenediones, and aziridines).
- alkylating agents such as the anthracycline family of drugs (e.g., adriamycin, carminomycin, cyclosporin-A, chloroquine, methopterin, mithramycin, porfiromycin, streptonigrin, porfiromycin, anthracenediones, and aziridines).
- cytostatic anti-cancer agents include DNA synthesis inhibitors (e.g., methotrexate and dichloromethotrexate, 3-amino-1,2,4-benzotriazine 1,4-dioxide, aminopterin, cytosine ⁇ -D-arabinofuranoside, 5-fluoro-5′-deoxyuridine, 5-fluorouracil, ganciclovir, 25584 hydroxyurea, actinomycin-D, and mitomycin C), DNA-intercalators or cross-linkers (e.g., bleomycin, carboplatin, carmustine, chlorambucil, cyclophosphamide, cis-diammineplatinum(II) dichloride (cisplatin), melphalan, mitoxantrone, and oxaliplatin), and DNA-RNA transcription regulators (e.g., actinomycin D, daunorubicin, doxorubicin, homoharringtonine, and
- quinonoid derivatives e.g., quinolones, genistein, bactacyclin
- busulfan ifosfamide, mechlorethamine
- triaziquone diaziquone
- carbazilquinone indoloquinone EO9
- diaziridinyl-benzoquinone methyl DZQ
- cytotoxic nucleoside anti-cancer agents include, but are not limited to: adenosine arabinoside, cytarabine, cytosine arabinoside, 5-fluorouracil, fludarabine, floxuridine, ftorafur, and 6-mercaptopurine.
- Exemplary anti-cancer tubulin binding agents include, but are not limited to: taxoids (e.g., paclitaxel, docetaxel, taxane), nocodazole, rhizoxin, dolastatins (e.g., Dolastatin-10, -11, or -15), colchicine and colchicinoids (e.g., ZD6126), combretastatins (e.g., Combretastatin A-4, AVE-6032), and vinca alkaloids (e.g., vinblastine, vincristine, vindesine, and vinorelbine (navelbine)).
- taxoids e.g., paclitaxel, docetaxel, taxane
- nocodazole rhizoxin
- dolastatins e.g., Dolastatin-10, -11, or -15
- colchicine and colchicinoids e.g., ZD6126
- anti-cancer hormones and hormone antagonists include, but are not limited to: corticosteroids (e.g., prednisone), progestins (e.g., hydroxyprogesterone or medroprogesterone), estrogens, (e.g., diethylstilbestrol), antiestrogens (e.g., tamoxifen), androgens (e.g., testosterone), aromatase inhibitors (e.g., aminogluthetimide), 17-(allylamino)- 17-demethoxygeldanamycin, 4-amino-1,8-naphthalimide, apigenin, brefeldin A, cimetidine, dichloromethylene-diphosphonic acid, leuprolide (leuprorelin), luteinizing hormone-releasing hormone, pifithrin-a, rapamycin, sex hormone-binding globulin, and thapsigargin.
- corticosteroids e.g.
- anti-cancer, anti-angiogenesis compounds include, but are not limited to: Angiostatin K1-3, DL- a-difluoromethyl-ornithine, endostatin, fumagillin, genistein, minocycline, staurosporine, and ( ⁇ )-thalidomide.
- anti-cancer enzyme inhibitors include, but are not limited to: S(+)- camptothecin, curcumin, ( ⁇ )-deguelin, 5,6-diCHlorobenz-imidazole 1- ⁇ -D-ribofuranoside, etoposide, formestane, fostriecin, hispidin, 2-imino-1-imidazolidineacetic acid (cyclocreatine), mevinolin, trichostatin A, tyrphostin AG 34, and tyrphostin AG 879.
- anti-cancer gene regulators include, but are not limited to: 5-aza-2′- deoxycytidine, 5-azacytidine, cholecalciferol (vitamin D3), 4-hydroxytamoxifen, melatonin, mifepristone, raloxifene, trans-retinal (vitamin A aldehydes), retinoic acid, vitamin A acid, 9-cis- retinoic acid, 13-cis-retinoic acid, retinol (vitamin A), tamoxifen, and troglitazone.
- vitamin D3 cholecalciferol
- raloxifene trans-retinal
- retinoic acid vitamin A acid
- 9-cis- retinoic acid vitamin A acid
- 13-cis-retinoic acid retinol (vitamin A)
- tamoxifen and troglitazone.
- Other classes of anti-cancer agents include, but are not limited to: the pteridine
- Particularly useful members of those classes include, for example, methopterin, podophyllotoxin, or podophyllotoxin derivatives such as etoposide or etoposide phosphate, leurosidine, vindesine, leurosine and the like.
- Still other anti-cancer agents that are compatible with the teachings herein include auristatins (e.g., auristatin E and monomethylauristan E), geldanamycin, calicheamicin, gramicidin D, maytansanoids (e.g., maytansine), neocarzinostatin, topotecan, taxanes, cytochalasin B, ethidium bromide, emetine, tenoposide, colchicin, dihydroxy anthracindione, mitoxantrone, procaine, tetracaine, lidocaine, propranolol, puromycin, and analogs or homologs thereof.
- auristatins e.g., auristatin E and monomethylauristan E
- geldanamycin e.g., auristatin E and monomethylauristan E
- calicheamicin e.g., g., gramicidin D
- anti-cancer agents that are compatible with the teachings herein include tomaymycin derivatives, maytansine derivatives, cryptophycine derivatives, anthracycline derivatives, bisphosphonate derivatives, leptomycin derivatives, streptonigrin derivatives, auristatine derivatives, and duocarmycin derivatives.
- Another class of compatible anti-cancer agents that may be used as drug moieties are radiosensitizing drugs that may be effectively directed to tumor or immunoreactive cells. Such drug moieties enhance the sensitivity to ionizing radiation, thereby increasing the efficacy of radiotherapy.
- an antibody modified with a radiosensitizing drug moiety and internalized by the tumor cell would deliver the radiosensitizer nearer the nucleus where radiosensitization would be maximal.
- Antibodies which lose the radiosensitizer moiety would be cleared quickly from the blood, localizing the remaining radiosensitization agent in the target tumor and providing minimal uptake in normal tissues.
- adjunct radiotherapy could be administered by external beam radiation directed specifically to the tumor, radioactivity directly implanted in the tumor, or systemic radioimmunotherapy with the same modified antibody.
- the therapeutic agent comprises radionuclides or radiolabels with high-energy ionizing radiation that are capable of causing multiple strand breaks in nuclear DNA, leading to cell death.
- high-energy radionuclides include: 90 Y, 125 I, 131 I, 123 I, 111 In, 105 Rh, 153 Sm, 67 Cu, 67 Ga, 166 Ho, 177 Lu, 186 Re and 188 Re. These isotopes typically produce high energy ⁇ - or ⁇ -particles which have a short path length.
- Such radionuclides kill cells to which they are in close proximity, for example neoplastic cells to which the conjugate has attached or has entered.
- high-energy isotopes may be generated by thermal irradiation 25584 of an otherwise stable isotope, for example as in boron neutron-capture therapy (Guan et al., Homogeneous immunoconjugates for boron neutron-capture therapy: Design, synthesis, and preliminary characterization. Proc. Natl. Acad. Sci. USA 95: 13206-10, (1998)).
- the therapeutic agent is selected from MMAE, MMAF, and PEGS-Dol10.
- the therapeutic agent is DXd, DM4, SN-38, camptothecin, or PNU.
- Exemplary cytotoxic agents may be selected from the group consisting of taxanes, anthracyclines, camptothecins, epothilones, mytomycins, combretastatins, vinca alkaloids, maytansinoids, enediynes, duocarmycins, tubulysins, amatoxins, bleomycins, dolastatins and auristatins, pyrrolobenzodiazepine dimers, indolinobenzodiazepine dimers, and radioisotopes.
- anti-inflammatory agents include glucocorticoid receptor agonists, which in further embodiments include cortisol, cortisone acetate, beclometasone, prednisone, prednisolone, methylprednisolone, betamethasone, trimcinolone, budesonide, dexamethasone, fluticasone, or mometasone.
- the effector moiety contains more than one therapeutic agent. These multiple therapeutic agents can be the same or different.
- the antibodies of the current disclosure are conjugated to a payload wherein the payload is a diagnostic effector moiety comprising a diagnostic agent.
- the diagnostic agent is a detectable small molecule label e.g., biotin, fluorophores, chromophores, spin resonance probes, or radiolabels.
- fluorophores include fluorescent dyes (e.g., fluorescein, rhodamine, and the like) and other luminescent molecules (e.g., luminal).
- a fluorophore may be environmentally-sensitive such that its fluorescence changes if it is located close to one or more residues in the modified binding polypeptide that undergo structural changes upon binding a substrate (e.g., dansyl probes).
- exemplary radiolabels include small molecules containing atoms with one or more low sensitivity nuclei and the like).
- the radionuclide can be, e.g., a gamma, photon, or positron-emitting radionuclide with a half-life suitable to permit activity or detection after the elapsed time between administration and localization to the imaging site.
- the diagnostic agent is a polypeptide.
- Exemplary diagnostic polypeptides include enzymes with fluorogenic or chromogenic activity, e.g., the ability to cleave 25584 a substrate which forms a fluorophore or chromophore as a product (i.e., reporter proteins such as luciferase).
- diagnostic proteins may have intrinsic fluorogenic or chromogenic activity (e.g., green, red, and yellow fluorescent bioluminescent aequorin proteins from bioluminescent marine organisms) or they may comprise a protein containing one or more low-energy radioactive nuclei and the like).
- antibodies of the current disclosure may be directly labeled (such as through iodination) or may be labeled indirectly through the use of a chelating agent.
- the phrases “indirect labeling” and “indirect labeling approach” both mean that a chelating agent is covalently attached to a binding polypeptide and at least one radionuclide is associated with the chelating agent.
- Such chelating agents are typically referred to as bifunctional chelating agents as they bind both the polypeptide and the radioisotope.
- Exemplary chelating agents comprise 1- isothiocycmatobenzyl-3-methyldiothelene triaminepentaacetic acid (“MX-DTPA”) and cyclohexyl diethylenetriamine pentaacetic acid (“CHX-DTPA”) derivatives.
- Other chelating agents comprise P-DOTA and EDTA derivatives.
- Exemplary radionuclides for indirect labeling include 111 In and 90 Y. Most imaging studies utilize 5 mCi 111 In-labeled antibody, because this dose is both safe and has increased imaging efficiency compared with lower doses, with optimal imaging occurring at three to six days after antibody administration.
- the diagnostic effector moiety is a FRET (Fluorescence Resonance Energy Transfer) probe.
- FRET Fluorescence Resonance Energy Transfer
- a FRET probe may include a cleavable linker (enzyme sensitive or pH linker) connecting the donor and acceptor moieties of the FRET probe, wherein cleavage results in enhanced fluorescence (including near Infrared) (see, e.g., A. Cobos-Correa et. al. Membrane -bound FRET probe visualizes MMP 12 activity in pulmonary inflammation, Nature Chemical Biology, 5(9), 628-63 (2009); S. Gehrig et. al. Spatially Resolved Monitoring of Neutrophil Elastase Activity with Ratiometric Fluorescent Reporters Angew. Chem. Int. Ed., 51, 6258-6261 (2012)).
- cleavable linker enzyme sensitive or pH linker
- effector moieties may be functionalized to contain one or more additional groups in addition to the effector moiety itself.
- the effector moiety may contain cleavable linkers which release the payload from the antibody under particular conditions.
- the effector moiety may include a linker that is cleavable by cellular enzymes and/or is pH sensitive. Additionally or alternatively, the effector moiety may contain a disulfide bond that cleaved by intracellular glutathione upon uptake into the cell.
- the effector moiety may include hydrophilic and biocompatible moieties such as poly(glycine), poly(oxazoline), and/or PEG moieties.
- Linkers In general, any linker or linker technology known in the art or will be known in the art for use in ADCs may be used to create or construct an ADC of the present disclosure provide the linker comprises an alkyne group capable of forming a triazole with the azido group of the bisecting 6-azido-GlcNAc or GlcNAz residue of the bisected N-glycan.
- the linker is a cleavable linker and in other embodiments, the linker is a non- cleavable linker.
- the linker comprises a distal end and a proximal end, wherein the proximal end comprises an alkyne functional group capable of forming a triazole linkage with the azido group of the bisecting 6-azido-GlcNAc or GlcNAz residue of the bisected N-glycan and the distal end is directly or indirectly covalently linked to a payload.
- the linker comprises a distal end and a proximal end, wherein the proximal end comprises a strained cyclooctyne, and the distal end is directly or indirectly covalently linked to a therapeutic agent.
- the strained cyclooctyne comprises dibenzocyclooctyne (DBCO) amine.
- a representative linker payload comprising a DBCO functional group is represented by wherein Pay is a payload and L is a linker or bond.
- L may be represented by in which each is independently a linker element or a bond.
- the representative linker conjugated to a payload and the azido group of a bisecting GlcNAz residue of a bisected N-glycan of an antibody is represented by 25584 wherein Pay is a payload and L is a linker or bond.
- L may be represented by in which each is independently a linker element or a bond, and the wavy line identifies the bond between the amine group of GlcNAz and the C2 carbon of the glucose comprising the GlcNAz wherein the GlcNAz is the bisecting sugar of a bisected N- glycan linked to the antibody.
- the representative linker conjugated to a payload and the azido group of a bisecting 6-azido-GlcNAc residue of a bisected N-glycan of an antibody is represented by wherein Pay is a payload and L is a linker or bond.
- L may be represented by L 1 and L 2 in which each is independently a linker element or a bond, and the wavy line identifies the bond between the C5 and C6 carbons of the glucose comprising 6-azido- GlcNAc wherein the 6-azido-GlcNAc is the bisecting sugar of a bisected N-glycan linked to the antibody.
- Exemplary linker elements that may be used in the context of the present disclosure include, a sequence of one or more amino acids, for example, dipeptide Val-Cit (valine-citrulline), Val-Ala (valine-alanine), dipeptide site in protease-cleavable linker, Ala-Phe (alanine-phenylalanine), Gly-Gly-Phe-Gly (glycine-glycine-phenylalanine-glycine), dipeptide 25584 site in protease-cleavable linker, PABC (p-aminobenzylcarbamate), and variants and combinations thereof.
- dipeptide Val-Cit valine-citrulline
- Val-Ala valine-alanine
- Ala-Phe alanine-phenylalanine
- Gly-Gly-Phe-Gly glycine-glycine-phenylalanine-glycine
- PABC p-aminobenzylc
- linkers and linker-payloads that can be used in the context of the present disclosure include but are not limited to those disclosed in the following patent publications: WO2021055865; WO2021067861; WO2019195665; WO2019236954; WO2021207701; WO2020132655; WO2018201087; WO2018031690; WO2018112253; WO2017096311; WO2015123679; WO2015095755; WO2015057699; US9504756; US10550190; US10869929; WO2018025168; US20210138077; RE45272E; WO2016102679; WO2009099741; WO2010009124; WO2016040835; WO2016094455; WO2016127081; WO2017062271; WO2018234636; WO2018235024; WO2018237335; and WO2019122447, the contents of each patent publication with respect to linkers and linker-pay
- the linkers are stable in physiological conditions.
- the linkers are cleavable, for instance, able to release at least the payload portion in the presence of an enzyme or at a particular pH range or value.
- a linker comprises an enzyme-cleavable moiety.
- Illustrative enzyme-cleavable moieties include, but are not limited to, peptide bonds, ester linkages, hydrazones, and disulfide linkages.
- the linker comprises a cathepsin-cleavable linker.
- the linker comprises a non-cleavable moiety.
- the linker comprises one or more amino acids.
- Suitable amino acids include natural, non-natural, standard, non-standard, proteinogenic, non- proteinogenic, and L- or D-a-amino acids.
- the linker comprises alanine, valine, glycine, leucine, isoleucine, methionine, tryptophan, phenylalanine, proline, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartic acid, glutamic acid, lysine, arginine, histidine, or citrulline, a derivative thereof, or combination thereof.
- one or more side chains of the amino acids is linked to a side chain group, described below.
- the linker comprises valine and citrulline. In some embodiments, the linker 25584 comprises lysine, valine, and citrulline. In some embodiments, the linker comprises lysine, valine, and alanine. In some embodiments, the linker comprises valine and alanine. In some embodiments, the linker comprises a self-immolative group.
- the self- immolative group can be any such group known to those of skill. In particular embodiments, the self-immolative group is p-aminobenzyl (PAB), or a derivative thereof such as p- aminobenzyloxycarbonyl (PABC).
- the glycoprotein of the present invention comprises the following structure: G P-[B-T-L-Pay] n wherein GP is a glycoprotein; B is a bisected N-glycan wherein the bisecting sugar residue is azido-GlcNAc (either 6-azido-GlcNAc or GlcNAz) having an azide functional group; L is a linker element comprising an alkyne functional group or a bond; Pay is a payload, which comprises an alkyne functional group when L is a bond; T is a triazole linkage formed between the linkage of the azide functional group and the alkyne functional group; and, n is an integer from 1-20.
- the glycoprotein is a Fab or scFv comprising at least one N-glycosylation site.
- the glycoprotein is a fusion protein comprising the Fc domain of an antibody fused to a heterologous protein or heterologous glycoprotein.
- the heterologous glycoprotein is a Fab or scFv comprising at least one N-glycosylation site.
- L is a self-immolative linker.
- L has the formula L 1 -L 2 , wherein each of L 1 and L 2 is independently a linker element or a bond.
- the L comprises a distal end comprising an alkyne containing group linked to the azide of the 6-azido-GlcNAc or GlcNAz of bisected N-glycan B in triazole linkage T and a proximal end linked to Pay.
- the alkyne group is a strained cyclooctyne.
- the strained cyclooctyne is DBCO.
- the bisected N-glycan B comprises a structure selected from those shown in Fig.16A, 16B, or 16C, e.g., selected from A2B-azide; FA2B-azide; A2B[3]G1-azide; FA2B[3]G1-azide; A2B[6]G1-azide; FA2B[6]G1-azide; A2BG2-azide; FA2BG2-azide; A2BG2-azide; FA2BG2-azide; A2B[3]G1S1(6 or 3)-azide; FA2B[3]G1S1(6 or 3)-azide; A2B[6]G1S1(6 or 3)- azide; FA2B[6]G1S1(6 or 3)-azide; A2BG2S2(6 or 3)-azide; FA2BG2S2(6 or 3)-azide; A1B[
- the triazole linkage has the structure wherein the wavy line identifies the bond between the amine group of the GlcNAz residue and the C2 carbon of the glucose residue comprising the GlcNAz residue and the double wavy lines identify bonds between the alkyne functional group of L or Pay when L is a bond or the structure wherein the wavy line identifies the bond between the C5 and C6 carbons of the glucose residue comprising the 6-azido-GlcNAc residue and the double wavy lines identify bonds between the alkyne functional group of L or Pay when L is a bond.
- the present invention further provides compositions comprising a plurality of glycoproteins and a pharmaceutically acceptable carrier, wherein each glycoprotein independently comprises the structure G P-[B-T-L-Pay] n wherein GP is a glycoprotein; B is a bisected N-glycan wherein the bisecting sugar residue is 6- azido-GlcNAc or GlcNAz having an azide functional group; L is a linker element comprising an alkyne functional group or a bond; Pay is a payload, which comprises an alkyne functional group when L is a bond; T is a triazole linkage formed between the linkage of the azide functional group and the alkyne functional group; and, n is an integer from 1-20.
- the glycoprotein is a Fab or scFv comprising at least one N-glycosylation site.
- the glycoprotein is a fusion protein comprising the Fc domain of an antibody fused to a heterologous protein or heterologous glycoprotein.
- the heterologous glycoprotein is a Fab or scFv comprising at least one N-glycosylation site.
- L is a self-immolative linker.
- L has the formula L 1 -L 2 , wherein each of L 1 is independently a linker element or a bond.
- the L comprises a distal end comprising an alkyne containing group linked to the azide of the 6-azido-GlcNAc or GlcNAz of bisected N-glycan B in triazole linkage T and a proximal end linked to Pay.
- the alkyne group is a strained cyclooctyne.
- the strained cyclooctyne is DBCO.
- the triazole linkage has the structure wherein the wavy line identifies the bond between the amine group of the GlcNAz residue and the C2 carbon of the glucose residue comprising the GlcNAz residue and the double wavy lines identify bonds between the alkyne functional group of L or Pay when L is a bond; or, the structure wherein the wavy line identifies the bond between the C5 and C6 carbons of the glucose residue comprising the 6-azido-GlcNAc residue and the double wavy lines identify bonds between the alkyne functional group of L or Pay when L is a bond.
- the predominant bisected N-glycan B in the composition comprises a structure selected from A2B-azide; FA2B-azide; A2B[3]G1-azide; FA2[3]BG1-azide; A2B[6]G1-azide; FA2B[6]G1-azide; A2BG2-azide; FA2BG2-azide; A2B[3]G1S1(6 or 3)-azide; FA2B[3]G1S1(6 or 3)-azide; A2B[6]G1S1(6 or 3)-azide; FA2B[6]G1S1(6 or 3)-azide; A2BG2S2(6 or 3)-azide; FA2BG2S2(6 or 3)-azide; FA2BG2S2(6 or 3)-azide; A1B[3]-azide; FA1B[3]-azide; FA1
- the predominant bisected N-glycan B in the composition comprises the mannose of the ⁇ 1,3 arm linked at the non-reducing end to 25584 the reducing end of a GlcNAc residue.
- the predominant bisected N-glycan B in the composition comprises the mannose of the ⁇ 1,3 arm linked at the non-reducing end to the reducing end of a GlcNAc residue and the mannose of the ⁇ 1,6 arm is linked at the non-reducing end to the reducing end of a GlcNAc residue.
- the predominant N-glycan B in the composition comprises the structure A2B-azide or FA2B-azide, wherein the azide refers to the azide of 6-azido-GlcNAc or GlcNAz, which forms a triazole linkage T with the alkyne functional group.
- the predominant N-glycans in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structure A2B-azide or FA2B-azide, wherein the azide refers to the azide of 6-azido-GlcNAc or GlcNAz, which forms a triazole linkage T with the alkyne functional group.
- the predominant N-glycan B in the composition comprises the structures A2B-azide and FA2B-azide, wherein the azide refers to the azide of 6-azido-GlcNAc or GlcNAz, which forms a triazole linkage T with the alkyne functional group.
- the predominant N-glycans in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structures A2B-azide and FA2B-azide, wherein the azide refers to the azide of 6-azido-GlcNAc or GlcNAz, which forms a triazole linkage T with the alkyne functional group.
- the predominant N-glycan B in the composition comprises the structure A2B[3]G1-azide or FA2B[3]G1-azide, wherein the azide refers to the azide of 6-azido-GlcNAc or GlcNAz, which forms a triazole linkage T with the alkyne functional group.
- the predominant N- glycans in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structure A2B[3]G1-azide or FA2B[3]G1-azide, wherein the azide refers to the azide of 6-azido- GlcNAc or GlcNAz, which forms a triazole linkage T with the alkyne functional group.
- the predominant N-glycan B in the composition comprises the structures A2B[3]G1-azide and FA2B[3]G1-azide, wherein the azide refers to the azide of 6-azido-GlcNAc or GlcNAz, which forms a triazole linkage T with the alkyne functional group.
- the predominant N- glycans in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 25584 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structures A2B[3]G1-azide and FA2B[3]G1-azide, wherein the azide refers to the azide of 6- azido-GlcNAc or GlcNAz, which forms a triazole linkage T with the alkyne functional group.
- the predominant N-glycan B in the composition comprises the structure A2B[6]G1-azide or FA2B[6]G1-azide, wherein the azide is part of the triazole linkage T.
- the predominant N- glycans in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structure A2B[6]G1-azide or FA2B[6]G1-azide, wherein the azide refers to the azide of 6-azido- GlcNAc or GlcNAz, which forms a triazole linkage T with the alkyne functional group.
- the predominant N-glycan B in the composition comprises the structures A2B[6]G1-azide and FA2B[6]G1-azide, wherein the azide refers to the azide of 6-azido-GlcNAc or GlcNAz, which forms a triazole linkage T with the alkyne functional group.
- the predominant N- glycans in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structures A2B[6]G1-azide and FA2B[6]G1-azide, wherein the azide refers to the azide of 6- azido-GlcNAc or GlcNAz, which forms a triazole linkage T with the alkyne functional group.
- the predominant N-glycan B in the composition comprises the structure A2BG2-azide or FA2BG2-azide, wherein the azide refers to the azide of 6-azido-GlcNAc or GlcNAz, which forms a triazole linkage T with the alkyne functional group.
- the predominant N-glycans in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structure A2BG2S2-azide or FA2BG2S2-azide, wherein the azide refers to the azide of 6-azido-GlcNAc or GlcNAz, which forms a triazole linkage T with the alkyne functional group.
- the predominant N-glycan B in the composition comprises the structures A2BG2-azide and FA2BG2-azide, wherein the azide refers to the azide of 6-azido-GlcNAc or GlcNAz, which forms a triazole linkage T with the alkyne functional group.
- the predominant N-glycans in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structures A2BG2- 25584 azide and FA2BG2-azide, wherein the azide refers to the azide of 6-azido-GlcNAc or GlcNAz, which forms a triazole linkage T with the alkyne functional group.
- the predominant N-glycan B in the composition comprises the structure A2B[3]G1S1(6 or 3)-azide or FA2B[3]G1S1(6 or 3)-azide, wherein the azide refers to the azide of 6-azido-GlcNAc or GlcNAz, which forms a triazole linkage T with the alkyne functional group.
- the predominant N-glycans in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structure A2B[3]G1S1(6 or 3)-azide or FA2B[3]G1S1(6 or 3)-azide, wherein the azide refers to the azide of 6-azido-GlcNAc or GlcNAz, which forms a triazole linkage T with the alkyne functional group.
- the predominant N-glycan B in the composition comprises the structures A2B[3]G1S1(6 or 3)-azide and FA2B[3]G1S1(6 or 3)- azide, wherein the azide refers to the azide of 6-azido-GlcNAc or GlcNAz, which forms a triazole linkage T with the alkyne functional group.
- the predominant N-glycans in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structures A2B[3]G1S1(6 or 3)-azide and FA2B[3]G1S1(6 or 3)- azide, wherein the azide refers to the azide of 6-azido-GlcNAc or GlcNAz, which forms a triazole linkage T with the alkyne functional group.
- the predominant N-glycan B in the composition comprises the structure A2B[6]G1S1(6 or 3)-azide or FA2B[6]G1S1(6 or 3)-azide, wherein the azide refers to the azide of 6-azido-GlcNAc or GlcNAz, which forms a triazole linkage T with the alkyne functional group.
- the predominant N-glycans in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structure A2B[6]G1S1(6 or 3)-azide or FA2B[6]G21S1(6 or 3)-azide, wherein the azide refers to the azide of 6-azido-GlcNAc or GlcNAz, which forms a triazole linkage T with the alkyne functional group.
- the predominant N-glycan B in the composition comprises the structures A2B[6]G1S1(6 or 3)-azide and FA2B[6]G1S1(6 or 3)- azide, wherein the azide refers to the azide of 6-azido-GlcNAc or GlcNAz, which forms a triazole linkage T with the alkyne functional group.
- the predominant N-glycans in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structures A2B[6]G1S1(6 or 3)-azide and FA2B[6]G1S1(6 or 3)- azide, wherein the azide refers to the azide of 6-azido-GlcNAc or GlcNAz, which forms a triazole linkage T with the alkyne functional group.
- the predominant N-glycan B in the composition comprises the structures A2BG2S2(6 or 3)-azide or FA2BG2S2(6 or 3)-azide, wherein the azide refers to the azide of 6-azido-GlcNAc or GlcNAz, which forms a triazole linkage T with the alkyne functional group.
- the predominant N-glycans in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structures A2BG2S2(6 or 3)-azide or FA2BG2S2(6 or 3)-azide, wherein the azide refers to the azide of 6-azido-GlcNAc or GlcNAz, which forms a triazole linkage T with the alkyne functional group.
- the predominant N-glycan B in the composition comprises the structures A2BG2S2(6 or 3)-azide and FA2BG2S2(6 or 3)-azide, wherein the azide refers to the azide of 6-azido-GlcNAc or GlcNAz, which forms a triazole linkage T with the alkyne functional group.
- the predominant N-glycans in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structures A2BG2S2(6 or 3)-azide and FA2BG2S2(6 or 3)-azide, wherein the azide refers to the azide of 6-azido-GlcNAc or GlcNAz, which forms a triazole linkage T with the alkyne functional group.
- the ADC of the present invention comprises the following structure: A b-[B-T-L-Pay] n wherein Ab is an antibody; B is a bisected N-glycan wherein the bisecting sugar residue is 6- azido-GlcNAc or GlcNAz having an azide functional group; L is a linker element comprising an alkyne functional group or a bond; Pay is a payload, which comprises an alkyne functional group when L is a bond; T is a triazole linkage formed between the linkage of the azide functional group and the alkyne functional group; and, n is an integer from 1-20.
- L is a self-immolative linker.
- L has the formula L 1 -L 2 , wherein each of L 1 and L 2 is independently a linker 25584 element or a bond.
- the L comprises a distal end comprising an alkyne containing group linked to the azide of the 6-azido-GlcNAc or GlcNAz of bisected N-glycan B in triazole linkage T and a proximal end linked to Pay.
- the alkyne group is a strained cyclooctyne.
- the strained cyclooctyne is DBCO.
- bisected N-glycan B comprises a structure selected from those shown in Fig.16A, 16B, or 16C, e.g., selected from A2B-azide; FA2B-azide; A2B[3]G1-azide; FA2B[3]G1-azide; A2B[6]G1-azide; FA2B[6]G1-azide; A2BG2-azide; FA2BG2-azide; A2BG2-azide; FA2BG2-azide; A2B[3]G1S1(6 or 3)-azide; FA2B[3]G1S1(6 or 3)-azide; A2B[6]G1S1(6 or 3)-azide; FA2B[6]G1S1(6 or 3)-azide; FA2B[6]G1S1(6 or 3)-azide; A2BG2S2(6 or 3)-azide;
- the triazole linkage has the structure wherein the wavy line identifies the bond between the amine group of the GlcNAz residue and the C2 carbon of the glucose residue comprising the GlcNAz residue and the double wavy lines identify bonds between the alkyne functional group of L or Pay when L is a bond; or, the structure wherein the wavy line identifies the bond between the C5 and C6 carbons of the glucose residue comprising the 6-azido-GlcNAc residue and the double wavy lines identify bonds between the alkyne functional group of L or Pay when L is a bond.
- the present invention further provides compositions comprising a plurality of ADCs and a pharmaceutically acceptable carrier, wherein each ADC independently comprises the structure 25584 A b-[B-T-L-Pay] n wherein Ab is an antibody; B is a bisected N-glycan wherein the bisecting sugar residue is 6- azido-GlcNAc or GlcNAz having an azide functional group; L is a linker element comprising an alkyne functional group or a bond; Pay is a payload, which comprises an alkyne functional group when L is a bond; T is a triazole linkage formed between the linkage of the azide functional group and the alkyne functional group; and, n is an integer from 1-20.
- L is a self-immolative linker.
- L has the formula L 1 -L 2 , wherein each of L 1 and L 2 is independently a linker element or a bond.
- the L comprises a distal end comprising an alkyne containing group linked to the azide of the 6-azido- GlcNAc or GlcNAz of bisected N-glycan B in triazole linkage T and a proximal end linked to Pay.
- the alkyne group is a strained cyclooctyne.
- the strained cyclooctyne is DBCO.
- the triazole linkage has the structure wherein the wavy line identifies the bond between the amine group of the GlcNAz residue and the C2 carbon of the glucose residue comprising the GlcNAz residue and the double wavy lines identify bonds between the alkyne functional group of L or Pay when L is a bond; or, the structure wherein the wavy line identifies the bond between the C5 and C6 carbons of the glucose residue comprising the 6-azido-GlcNAc residue and the double wavy lines identify bonds between the alkyne functional group of L or Pay when L is a bond.
- the predominant bisected N-glycan B in the composition comprises a structure selected from A2B-azide; FA2B-azide; A2B[3]G1-azide; FA2[3]BG1-azide; A2B[6]G1-azide; FA2B[6]G1-azide; A2BG2-azide; FA2BG2-azide; A2B[3]G1S1(6 or 3)-azide; FA2B[3]G1S1(6 or 3)-azide; A2B[6]G1S1(6 or 3)-azide; 25584 FA2B[6]G1S1(6 or 3)-azide; A2BG2S2(6 or 3)-azide; FA2BG2S2(6 or 3)-azide; A1B[3]G1-azide; FA1B[3]G1-azide; A1B[3]G1-azi
- the predominant bisected N-glycan B in the composition comprises the mannose of the ⁇ 1,3 arm linked at the non-reducing end to the reducing end of a GlcNAc residue.
- the predominant bisected N-glycan B in the composition comprises the mannose of the ⁇ 1,3 arm linked at the non-reducing end to the reducing end of a GlcNAc residue and the mannose of the ⁇ 1,6 arm is linked at the non-reducing end to the reducing end of a GlcNAc residue.
- the predominant N-glycan B in the composition comprises the structure A2B-azide or FA2B-azide.
- the predominant N-glycans in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structure A2B-azide or FA2B-azide, wherein the azide refers to the azide of 6- azido-GlcNAc or GlcNAz, which forms a triazole linkage T with the alkyne functional group.
- the predominant N-glycan B in the composition comprises the structures A2B-azide and FA2B-azide, wherein the azide refers to the azide of 6-azido-GlcNAc or GlcNAz, which forms a triazole linkage T with the alkyne functional group.
- the predominant N-glycans in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structures A2B-azide and FA2B-azide, wherein the azide refers to the azide of 6-azido-GlcNAc or GlcNAz, which forms a triazole linkage T with the alkyne functional group.
- the predominant N-glycan B in the composition comprises the structure A2B[3]G1-azide or FA2B[3]G1-azide, wherein the azide refers to the azide of 6-azido-GlcNAc or GlcNAz, which forms a triazole linkage T with the alkyne functional group.
- the predominant N- glycans in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structure A2B[3]G1-azide or FA2B[3]G1-azide, wherein the azide refers to the azide of 6-azido- GlcNAc or GlcNAz, which forms a triazole linkage T with the alkyne functional group.
- the predominant N-glycan B in the composition comprises the structures A2B[3]G1-azide and FA2B[3]G1-azide, wherein the azide refers to the azide of 6-azido-GlcNAc or GlcNAz, which forms a triazole linkage T with the alkyne functional group.
- the predominant N- glycans in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structures A2B[3]G1-azide and FA2B[3]G1-azide, wherein the azide refers to the azide of 6- azido-GlcNAc or GlcNAz, which forms a triazole linkage T with the alkyne functional group.
- the predominant N-glycan B in the composition comprises the structure A2B[6]G1-azide or FA2B[6]G1-azide.
- the azide refers to the azide of 6-azido-GlcNAc or GlcNAz, which forms a triazole linkage T with the alkyne functional group.
- the predominant N- glycans in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structure A2B[6]G1-azide or FA2B[6]G1-azide, wherein the azide refers to the azide of 6-azido- GlcNAc or GlcNAz, which forms a triazole linkage T with the alkyne functional group.
- the predominant N-glycan B in the composition comprises the structures A2B[6]G1-azide and FA2B[6]G1-azide, wherein the azide refers to the azide of 6-azido-GlcNAc or GlcNAz, which forms a triazole linkage T with the alkyne functional group.
- the predominant N- glycans in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structures A2B[6]G1-azide and FA2B[6]G1-azide, wherein the azide refers to the azide of 6- azido-GlcNAc or GlcNAz, which forms a triazole linkage T with the alkyne functional group.
- the predominant N-glycan B in the composition comprises the structure A2BG2-azide or FA2BG2-azide, wherein the azide refers to the azide of 6-azido-GlcNAc or GlcNAz, which forms a triazole linkage T with the alkyne functional group.
- the predominant N-glycans in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structure A2BG2- azide or FA2BG2-azide, wherein the azide refers to the azide of 6-azido-GlcNAc or GlcNAz, which forms a triazole linkage T with the alkyne functional group.
- the predominant N-glycan B in the composition comprises the structures A2BG2-azide and FA2BG2-azide, wherein the azide refers to the azide of 6-azido-GlcNAc or GlcNAz, which forms a triazole linkage T with the alkyne functional group.
- the predominant N-glycans in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structures A2BG2- azide and FA2BG2-azide, wherein the azide refers to the azide of 6-azido-GlcNAc or GlcNAz, which forms a triazole linkage T with the alkyne functional group.
- the predominant N-glycan B in the composition comprises the structure A2B[3]G1S1(6)-azide or FA2B[3]G1S1(6)-azide, wherein the azide refers to the azide of 6-azido-GlcNAc or GlcNAz, which forms a triazole linkage T with the alkyne functional group.
- the predominant N-glycans in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structure A2B[3]G1S1(6)-azide or FA2B[3]G1S1(6)-azide, wherein the azide refers to the azide of 6-azido-GlcNAc or GlcNAz, which forms a triazole linkage T with the alkyne functional group.
- the predominant N-glycan B in the composition comprises the structures A2B[3]G1S1(6)-azide and FA2B[3]G1S1(6)-azide, wherein the azide refers to the azide of 6-azido-GlcNAc or GlcNAz, which forms a triazole linkage T with the alkyne functional group.
- the predominant N-glycans in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structures A2B[3]G1S1(6)-azide and FA2B[3]G1S1(6)-azide, wherein the azide refers to the azide of 6-azido-GlcNAc or GlcNAz, which forms a triazole linkage T with the alkyne functional group.
- the predominant N-glycan B in the composition comprises the structure A2B[6]G1S1(6)-azide or FA2B[6]G1S1(6)-azide, wherein the azide refers to the azide of 6-azido-GlcNAc or GlcNAz, which forms a triazole linkage T with the alkyne functional group.
- the predominant N-glycans in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structure A2B[6]G1S1(6)-azide or FA2B[6]G21S1(6)-azide, wherein the azide refers to the azide 25584 of 6-azido-GlcNAc or GlcNAz, which forms a triazole linkage T with the alkyne functional group.
- the predominant N-glycan B in the composition comprises the structures A2B[6]G1S1(6)-azide and FA2B[6]G1S1(6)-azide, wherein the azide refers to the azide of 6-azido-GlcNAc or GlcNAz, which forms a triazole linkage T with the alkyne functional group.
- the predominant N-glycans in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structures A2B[6]G1S1(6)-azide and FA2B[6]G1S1(6)-azide, wherein the azide refers to the azide of 6-azido-GlcNAc or GlcNAz, which forms a triazole linkage T with the alkyne functional group.
- the predominant N-glycan B in the composition comprises the structures A2BG2S2(6)-azide or FA2BG2S2(6)-azide, wherein the azide refers to the azide of 6-azido-GlcNAc or GlcNAz, wherein the azide refers to the azide of 6-azido-GlcNAc or GlcNAz, which forms a triazole linkage T with the alkyne functional group.
- the predominant N-glycans in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structures A2BG2S2(6)-azide or FA2BG2S2(6)-azide, wherein the azide refers to the azide of 6-azido-GlcNAc or GlcNAz, which forms a triazole linkage T with the alkyne functional group.
- the predominant N-glycan B in the composition comprises the structures A2BG2S2(6)-azide and FA2BG2S2(6)-azide, wherein the azide refers to the azide of 6-azido-GlcNAc or GlcNAz, which forms a triazole linkage T with the alkyne functional group.
- the predominant N- glycans in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structures A2BG2S2(6)-azide and FA2BG2S2(6)-azide, wherein the azide refers to the azide of 6-azido-GlcNAc or GlcNAz, which forms a triazole linkage T with the alkyne functional group.
- the predominant N-glycan B in the composition comprises the structure A2B[3]G1S1(3)-azide or FA2B[3]G1S1(3)-azide, wherein the azide refers to the azide of 6-azido-GlcNAc or GlcNAz, which forms a triazole linkage T with the alkyne functional group.
- the predominant N-glycans in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 25584 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structure A2B[3]G1S1(3)-azide or FA2B[3]G1S1(3)-azide, wherein the azide refers to the azide of 6-azido-GlcNAc or GlcNAz, which forms a triazole linkage T with the alkyne functional group.
- the predominant N-glycan B in the composition comprises the structures A2B[3]G1S1(3)-azide and FA2B[3]G1S1(3)-azide, wherein the azide refers to the azide of 6-azido-GlcNAc or GlcNAz, which forms a triazole linkage T with the alkyne functional group.
- the predominant N-glycans in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structures A2B[3]G1S1(3)-azide and FA2B[3]G1S1(3)-azide, wherein the azide refers to the azide of 6-azido-GlcNAc or GlcNAz, which forms a triazole linkage T with the alkyne functional group.
- the predominant N-glycan B in the composition comprises the structure A2B[6]G1S1(3)-azide or FA2B[6]G1S1(3)-azide, wherein the azide refers to the azide of 6-azido-GlcNAc or GlcNAz, which forms a triazole linkage T with the alkyne functional group.
- the predominant N-glycans in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structure A2B[6]G1S1(3)-azide or FA2B[6]G21S1(3)-azide, wherein the azide refers to the azide of 6-azido-GlcNAc or GlcNAz, which forms a triazole linkage T with the alkyne functional group.
- the predominant N-glycan B in the composition comprises the structures A2B[6]G1S1(3)-azide and FA2B[6]G1S1(3)-azide, wherein the azide refers to the azide of 6-azido-GlcNAc or GlcNAz, which forms a triazole linkage T with the alkyne functional group.
- the predominant N-glycans in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structures A2B[6]G1S1(3)-azide and FA2B[6]G1S1(3)-azide, wherein the azide refers to the azide of 6-azido-GlcNAc or GlcNAz, which forms a triazole linkage T with the alkyne functional group.
- the predominant N-glycan B in the composition comprises the structures A2BG2S2(3)-azide or FA2BG2S2(3)-azide, wherein the 25584 wherein the azide refers to the azide of 6-azido-GlcNAc or GlcNAz, which forms a triazole linkage T with the alkyne functional group.
- the predominant N-glycans in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structures A2BG2S2(3)-azide or FA2BG2S2(3)-azide, wherein the azide refers to the azide of 6-azido-GlcNAc or GlcNAz, which forms a triazole linkage T with the alkyne functional group.
- the predominant N-glycan B in the composition comprises the structures A2BG2S2(3)-azide and FA2BG2S2(3)-azide, wherein the azide refers to the azide of 6-azido-GlcNAc or GlcNAz, which forms a triazole linkage T with the alkyne functional group.
- the predominant N- glycans in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structures A2BG2S2(3)-azide and FA2BG2S2(3)-azide, wherein the azide refers to the azide of 6-azido-GlcNAc or GlcNAz, which forms a triazole linkage T with the alkyne functional group.
- the present invention further provides compositions comprising a plurality of ADCs and a pharmaceutically acceptable carrier, wherein each ADC independently comprises an antibody conjugated to a bisected N-glycan comprising a structure selected from A2B-triazole-L-payload; FA2B-triazole-L-payload; A2B[3]G1-triazole-L-payload; FA2[3]BG1-triazole-L-payload; A2B[6]G1-triazole-L-payload; FA2B[6]G1-triazole-L-payload; A2BG2-triazole-L-payload; FA2BG2-triazole-L-payload; A2B[3]G1S1(6 or 3)-triazole-L- payload; FA2B[3]G1S1(6 or 3)-triazole-L-payload; FA2B[3]G1S1(6 or 3)-triazole-L-payload; A2B
- the predominant bisected N-glycan in the composition comprises the structure A2B-triazole-L-payload or FA2B-triazole-L-payload.
- the predominant N-glycans in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structure A2B-triazole-L-payload or FA2B-triazole-L-payload.
- the predominant bisected N-glycan in the composition comprises the structures A2B-triazole-L-payload and FA2B-triazole-L- payload.
- the predominant bisected N-glycans in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structures A2B- triazole-L-payload and FA2B-triazole-L-payload.
- the predominant bisected N-glycan in the composition comprises the structure A2B[3]G1-triazole-L-payload or FA2B[3]G1-triazole- L-payload.
- the predominant bisected N-glycans in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structure A2B[3]G1-triazole-L-payload or FA2B[3]G1-triazole-L-payload.
- the predominant bisected N-glycan in the composition comprises the structures A2B[3]G1-triazole-L-payload and FA2B[3]G1- triazole-L-payload.
- the predominant bisected N- glycans in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structures A2B[3]G1-triazole-L-payload and FA2B[3]G1-triazole-L-payload.
- the predominant bisected N-glycan in the composition comprises the structure A2B[6]G1-triazole-L-payload or FA2B[6]G1-triazole- L-payload.
- the predominant bisected N-glycans in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structure A2B[6]G1-triazole-L-payload or FA2B[6]G1-triazole-L-payload.
- the predominant bisected N-glycan in the composition comprises the structures A2B[6]G1-triazole-L-payload and FA2B[6]G1- triazole-L-payload.
- the predominant bisected N- glycans in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structures A2B[6]G1-triazole-L-payload and FA2B[6]G1-triazole-L-payload.
- the predominant bisected N-glycan in the composition comprises the structure A2BG2-triazole-L-payload or FA2BG2-triazole-L- payload.
- the predominant bisected N-glycans in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structure A2BG2- triazole-L-payload or FA2BG2-triazole-L-payload.
- the predominant bisected N-glycan in the composition comprises the structures A2BG2-triazole-L-payload and FA2BG2-triazole-L- payload.
- the predominant bisected N-glycans in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structures A2BG2- triazole-L-payload and FA2BG2-triazole-L-payload.
- the predominant bisected N-glycan in the composition comprises the structure A2B[3]G1S1(6)-triazole-L-payload or FA2B[3]G1S1(6)-triazole-L-payload.
- the predominant bisected N-glycans in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structure A2B[3]G1S1(6)-triazole-L-payload or FA2B[3]G1S1(6)-triazole-L- payload.
- the predominant bisected N-glycan in the composition comprises the structures A2B[3]G1S1(6)-triazole-L-payload and FA2B[3]G1S1(6)-triazole-L-payload.
- the predominant bisected N-glycans in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structures A2B[3]G1S1(6)-triazole-L-payload and FA2B[3]G1S1(6)-triazole- L-payload.
- the predominant bisected N-glycan in the composition comprises the structure A2B[6]G1S1(6)-triazole-L-payload or FA2B[6]G1S1(6)-triazole-L-payload.
- the predominant bisected N-glycans in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structure A2B[6]G1S1(6)-triazole-L-payload or FA2B[6]G21S1(6)-triazole-L- payload.
- the predominant bisected N-glycan in the composition comprises the structures A2B[6]G1S1(6)-triazole-L-payload and FA2B[6]G1S1(6)-triazole-L-payload.
- the predominant bisected N-glycasn in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structures A2B[6]G1S1(6)-triazole-L-payload and FA2B[6]G1S1(6)-triazole- L-payload.
- the predominant bisected N-glycan in the composition comprises the structures A2BG2S2(6)-triazole-L-payload or FA2BG2S2(6)- triazole-L-payload.
- the predominant bisected N- glycans in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structures A2BG2S2(6)-triazole-L-payload or FA2BG2S2(6)-triazole-L-payload.
- the predominant bisected N-glycan in the composition comprises the structures A2BG2S2(6)-triazole-L-payload and FA2BG2S2(6)- triazole-L-payload.
- the predominant bisected N- glycans in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structures A2BG2S2(6)-triazole-L-payload and FA2BG2S2(6)-triazole-L-payload.
- the predominant bisected N-glycan in the composition comprises the structure A2B[3]G1S1(3)-triazole-L-payload or FA2B[3]G1S1(3)-triazole-L-payload.
- the predominant bisected N-glycans in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structure A2B[3]G1S1(3)-triazole-L-payload or FA2B[3]G1S1(3)-triazole-L- payload.
- the predominant bisected N-glycan in the composition comprises the structures A2B[3]G1S1(3)-triazole-L-payload and FA2B[3]G1S1(3)-triazole-L-payload.
- the predominant bisected N-glycans in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structures A2B[3]G1S1(3)-triazole-L-payload and FA2B[3]G1S1(3)-triazole- L-payload.
- the predominant bisected N-glycan in the composition comprises the structure A2B[6]G1S1(3)-triazole-L-payload or FA2B[6]G1S1(3)-triazole-L-payload.
- the 25584 predominant bisected N-glycans in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structure A2B[6]G1S1(3)-triazole-L-payload or FA2B[6]G21S1(3)-triazole-L- payload.
- the predominant bisected N-glycan in the composition comprises the structures A2B[6]G1S1(3)-triazole-L-payload and FA2B[6]G1S1(3)-triazole-L-payload.
- the predominant bisected N-glycasn in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structures A2B[6]G1S1(3)-triazole-L-payload and FA2B[6]G1S1(3)-triazole- L-payload.
- the predominant bisected N-glycan in the composition comprises the structures A2BG2S2(3)-triazole-L-payload or FA2BG2S2(3)- triazole-L-payload.
- the predominant bisected N- glycans in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structures A2BG2S2(3)-triazole-L-payload or FA2BG2S2(3)-triazole-L-payload.
- the predominant bisected N-glycan in the composition comprises the structures A2BG2S2(3)-triazole-L-payload and FA2BG2S2(3)- triazole-L-payload.
- the predominant bisected N- glycans in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structures A2BG2S2(3)-triazole-L-payload and FA2BG2S2(3)-triazole-L-payload.
- Fig.18 and 20 Representative structures of bisected N-glycans comprising a bisecting 6-azido- GlcNAc or GlcNAz residue conjugated to a payload via a triazole linkage are shown in Fig.18 and 20. Synthesis of glycoproteins comprising bisected N-glycans wherein the bisecting sugar is GlcNAz Mammalian and human complex N-glycans comprise GlcNAc, mannose, galactose, and sialic acid residues.
- Complex N-glycans comprise a paucimannose core represented by the formula Man 3 GlcNAc 2 forming a Y-shaped molecule wherein the terminal mannose residues are on the distal end of the chitobiose core and the GlcNAc residue at the reducing end of the chitobiose core is linked to asparagine (Asn) in a ⁇ 1-N linkage.
- the terminal 25584 mannose residues are linked by ⁇ 1-6 and ⁇ 1-3 linkages to a central mannose residue to provide an ⁇ 1-6-linked mannose arm and an ⁇ 1-3-linked mannose arm.
- the central mannose is in turn linked to the chitobiose core by a ⁇ 1-4 linkage.
- Terminal GlcNAc residues when present, are linked to the terminal mannose residue on the ⁇ 1-3-linked mannose arm in a ⁇ 1-2 linkage by GnT-I to produce hybrid N-glycans, and then to the terminal mannose residue on the a1-6 linked arm by GnT-II to produce bi-antennary N-glycans.
- GlcNAc residue when present, may be linked to the terminal mannose residue on the ⁇ 1-3-linked mannose arm of bi-antennary N-glycans in a ⁇ 1-4 linkage by GnT-IV or the terminal mannose residue on the ⁇ 1-6-linked mannose arm of bi-antennary N-glycans in a ⁇ 1-6 linkage by GnT-V to produce tri-antennary N- glycans.
- a GlcNAc residue when present, may be linked to the arm of the tri- antennary N-glycan that is linked to only one GlcNAc residue with the appropriate GnT to produce multi-antennary N-glycans in which each arm comprises two GlcNAc residues, the ⁇ 1-3- linked mannose arm comprising GlcNAc residues linked in a ⁇ 1-2 linkage and a ⁇ 1-4 linkage and the ⁇ 1-6-linked mannose arm comprising GlcNAc residues linked in a ⁇ 1-2 linkage and a ⁇ 1-6 linkage.
- the central mannose of bi-antennary N-glycans may be linked to a GlcNAc residue by a ⁇ 1-4 linkage by GnTIII to produce bisected N-glycans.
- Terminal galactose residues when present, are linked to the terminal GlcNAc residues of bi-antennary, tri-antennary, or multi-antennary N-glycans in a ⁇ 1-4 linkage by GalT or to the ⁇ 1-6-linked mannose arm and an ⁇ 1-3-linked mannose arm GlcNAc residues of bisected N-glycans in a ⁇ 1-4 linkage by GalT.
- Terminal sialic acid residues when present, are linked to one or more of the terminal galactose residues of any of the bi-antennary, tri-antennary, multi-antennary, or bisected N-glycans comprising terminal galactose residues in either an ⁇ 2-3 or ⁇ 2-6 linkage by ⁇ 2,3-siaT or ⁇ 2,6- siaT, respectively, to produce ⁇ 2,3- or ⁇ 2.6-sialylated N-glycans.
- the sialic acid is N-Acetylneuraminic acid (Neu5Ac or NANA), a predominant sialic acid found in human cells and many mammalian cells.
- the N-glycosylated glycoproteins obtained from cell culture comprising mammalian or human cells or yeast cells genetically engineered to produce complex N-glycans are sequentially reacted with one or more glycosidases selected from group consisting of neuraminidase, galactosidase, and N- acetylglucosaminidase, to remove one or more terminal sugar residues on the N-glycan to produce a core structure.
- the glycoproteins are reacted with one or more neuraminidases to remove the sialic acid residues from those N-glycans that comprise terminal sialic acid residues to provide a population of N-glycans comprising terminal galactose 25584 residues.
- the glycoproteins may then be reacted with one or more galactosidases that remove the galactose residues from those N-glycans that comprise terminal galactose residues to provide a population of N-glycans comprising terminal GlcNAc residues.
- the glycoproteins may then be reacted with one or more N-acetylglucosaminidases that remove the GlcNAc residues from those N-glycans that comprise terminal galactose residues to provide a population of paucimannose N-glycans (M3), each N-glycan comprising a central mannose residue linked to a chitobiose core in a ⁇ 1-4 linkage and two terminal mannose residues, one linked to the central mannose in an ⁇ 1,3 linkage and the other linked to the central mannose in an ⁇ 1,6 linkage.
- M3 paucimannose N-glycans
- the glycoproteins may be further reacted with a fucosidase to remove fucose residues from those the N-glycans comprising a fucose linked to the GlcNAc residue at the reducing end of the chitobiose core in an ⁇ 1,6 linkage.
- the population of N-glycans may be reacted with a glycosyltransferase capable of adding a specific sugar to the terminal sugar residues of a particular population of N-glycans.
- Successive reactions each utilizing a specific glycosyltransferase, may be used to add sugars to the termini of the N- glycans in a stepwise manner to produce a population of N-glycans having particular glycoforms.
- the particular glycosyltransferase that may be used in a particular reaction will depend on the N- glycan substrate to be reacted upon by the glycosyltransferase as each glycosyltransferase is specific for a particular substrate.
- a population of glycoproteins is reacted with a neuraminidase, a galactosidase, and one or more N-acetylglucosaminidases to produce a population of glycoproteins comprising fucosylated and non-fucosylated M3 N- glycans.
- the fucosylated and non-fucosylated M3 N-glycans are reacted with an GnT-I in the presence of UDP-GlcNAc to produce a population of glycoproteins comprising predominantly A1[3] N-glycans and FA1[3] N-glycans in which the ⁇ 1,3-linked mannose residue is linked to a GlcNAc residue by a ⁇ 1-2 linkage.
- the population of glycoproteins may then be reacted with GnT-III in the presence of UDP-GlcNAz or UDP-6-azido-GlcNAc to produce a population of glycoproteins comprising predominantly A1B[3]-azide N-glycans and/or FA1B[3]-azide N- glycans.
- the population of glycoproteins comprising predominantly A1B[3]-azide N- glycans and FA1B[3]-azide N-glycans may then be reacted with a GalT in the presence of UDP- galactose to produce a population of glycoproteins comprising predominantly A1B[3]G1-azide 25584 N-glycans and/or FA1B[3]G1-azide N-glycans in which galactose is linked to the GlcNAc residue on the ⁇ 1,3 arm in a ⁇ 1-4 linkage.
- the population of glycoproteins comprising predominantly A1B[3]G1-azide and FA1B[3]G1-azide N-glycans may then be reacted with an ⁇ 2,6- or ⁇ 2,3-siaT in the presence of CMP-sialic acid to produce a population of glycoproteins comprising predominantly A1B[3]G1S1(6 or 3)-azide N-glycans and/or FA1B[3]G1S1(6 or 3)-azide N-glycans in which sialic acid is linked to the galactose residue in an ⁇ 2-6 or ⁇ 2-3 linkage, respectively.
- any one of the above glycoprotein populations may be reacted with a payload comprising an alkyne functional group under metal-free click chemistry conditions to produce a glycoprotein conjugates in which the azide functional group of the 6- azido-GlcNAc or GlcNAz is linked to the alkyne functional group of the payload in a triazole linkage.
- Exemplary glycoprotein conjugates may comprise predominantly A1B[3]-triazole- payload N-glycans; FA1B[3]-triazole-payload N-glycans; A1B[3]G1-triazole-payload N-glycans; FA1B[3]G1-triazole-payload N-glycans; A1B[3]G1S1(6 or 3)-triazole-payload N-glycans; and/or FA1B[3]G1S1(6 or 3)-triazole-payload N-glycans.
- the glycoprotein population comprises predominantly a mixture of two or three of the aforementioned exemplary glycoprotein conjugates.
- one or more of the above glycoprotein populations may be reacted with a fucosidase to produce a substantially afucosylated population of glycoproteins in which the N-glycans lack fucose or reacted with a fucosyltransferase in the presence of GDP-fucose to produce a substantially fucosylated population of glycoproteins in which the N-glycans comprise fucose.
- the fucosyltransferase is an ⁇ 1- 6-fucosyltransferase, which transfers a fucose residue from GDP-fucose to the GlcNAc residue on the reducing end of the chitobiose core of the N-glycan in an ⁇ 1-6 linkage.
- a population of glycoproteins is reacted with a neuraminidase, and a galactosidase to produce a population of glycoproteins comprising predominantly fucosylated and non-fucosylated A2 N-glycans (A2 and/or FA2, respectively).
- the population of glycoproteins may then be reacted with GnT-III in the presence of UDP-6-azido-GlcNAc or UDP-GlcNAz to produce a population of glycoproteins comprising predominantly A2B-azide and/or FA2B-azide N-glycans.
- the population of glycoproteins comprising predominantly A1B-azide N-glycans and/or FA1B-azide N-glycans may then be reacted with a GalT in the presence of UDP-galactose to produce a population of glycoproteins comprising predominantly A2B[3]G1-azide; 25584 FA2B[3]G1-azide, A2B[6]G1-azide N-glycans; FA2B[6]G1-azide N-glycans; A2BG2-azide N- glycans; and/or FA2BG2-azide N-glycans in which galactose is linked to the GlcNAc residue on the ⁇ 1,3 arm in a ⁇ 1-4 linkage and/or ⁇ 1,6 arm in a ⁇ 1-4 linkage.
- the population of glycoproteins comprising predominantly A2B[3]G1-azide, FA2B[3]G1-azide N-glycans, A2B[6]G1-azide N-glycans, FA2B[6]G1-azide N-glycans, A2BG2-azide N-glycans, and/or FA2BG2-azide N-glycans may then be reacted with an ⁇ 2,6- or ⁇ 2,3-siaT in the presence of CMP-sialic acid to produce a population of glycoproteins comprising predominantly A2B[3]G1S1(6 or 3)-azide N-glycans; FA2B[3]G1S1(6 or 3)-azide N- glycans; A2B[6]G1S1(6 or 3)-azide N-glycans; FA2B[6]G1S1(6 or 3)-azide
- any one of the above glycoprotein populations may be reacted with a payload comprising an alkyne functional group under metal-free click chemistry conditions to produce a glycoprotein conjugates in which the azide functional group of the 6- azido-GlcNAc or GlcNAz is linked to the alkyne functional group of the payload in a triazole linkage.
- Exemplary glycoprotein conjugates may comprise predominantly A2B[3]G1-triazole- payload N-glycans; FA2B[3]G1-triazole-payload N-glycans, A2B[6]G1-triazole-payload N- glycans; FA2B[6]G1-triazole-payload N-glycans; A2BG2-triazole-payload N-glycans; and FA2BG2-triazole-payload N-glycans; A2B[3]G1-triazole-payload N-glycans; FA2B[3]G1- triazole-payload N-glycans; A2B[6]G1-triazole-payload N-glycans; FA2B[6]G1-triazole-payload N-glycans; A2BG2-triazole-payload N-glycans; FA2BG2-triazole-payload N-glycans
- the glycoprotein population comprises predominantly a mixture of two or three of the aforementioned exemplary glycoprotein conjugates.
- one or more of the above exemplary glycoprotein populations may be reacted with a fucosidase to produce a substantially afucosylated population of glycoproteins in which the N-glycans lack fucose or reacted with a fucosyltransferase in the presence of GDP-fucose to produce a substantially fucosylated population of glycoproteins in which the N-glycans comprise fucose.
- the fucosyltransferase is an ⁇ 1- 25584 6-fucosyltransferase, which transfers a fucose residue from GDP-fucose to the GlcNAc residue on the reducing end of the chitobiose core of the N-glycan in an ⁇ 1-6 linkage.
- the glycoprotein is an antibody, a Fab, or scFv comprising at least one N-glycosylation site.
- the glycoprotein is a fusion protein comprising the Fc domain of an antibody fused to a heterologous protein or heterologous glycoprotein.
- the heterologous glycoprotein is a Fab or scFv comprising at least one N-glycosylation site.
- a population of antibodies is reacted with a neuraminidase, a galactosidase, and one or more N-acetylglucosaminidases to produce a population of antibodies comprising fucosylated and non-fucosylated M3 N-glycans.
- the fucosylated and non-fucosylated M3 N-glycans are reacted with an GnT-I in the presence of UDP-GlcNAc to produce a population of antibodies comprising predominantly A1[3] N-glycans and FA1[3] N-glycans in which the ⁇ 1,3-linked mannose residue is linked to a GlcNAc residue by a ⁇ 1-2 linkage.
- the population of antibodies may then be reacted with GnT-III in the presence of UDP-6-azido-GlcNAc or UDP-GlcNAz to produce a population of antibodies comprising predominantly A1B[3]-azide N-glycans and/or FA1B[3]-azide N-glycans.
- the population of antibodies comprising predominantly A1B[3]-azide N-glycans and FA1B[3]-azide N-glycans may then be reacted with a GalT in the presence of UDP-galactose to produce a population of antibodies comprising predominantly A1B[3]G1-azide N-glycans and/or FA1B[3]G1-azide N-glycans in which galactose is linked to the GlcNAc residue on the ⁇ 1,3 arm in a ⁇ 1-4 linkage.
- the population of antibodies comprising predominantly A1B[3]G1-azide and FA1B[3]G1-azide N-glycans may then be reacted with an ⁇ 2,6- or ⁇ 2,3-siaT in the presence of CMP-sialic acid to produce a population of antibodies comprising predominantly A1B[3]G1S1(6 or 3)-azide N-glycans and/or FA1B[3]G1S1(6 or 3)-azide N-glycans in which sialic acid is linked to the galactose residue in an ⁇ 2-6 or ⁇ 2-3 linkage, respectively.
- any one of the above antibody populations may be reacted with a payload comprising an alkyne functional group under metal-free click chemistry conditions to produce an antibody conjugates in which the azide functional group of the 6-azido- GlcNAc or GlcNAz is linked to the alkyne functional group of the payload in a triazole linkage.
- Exemplary antibody conjugates may comprise predominantly A1B[3]-triazole-payload N- glycans; FA1B[3]-triazole-payload N-glycans; A1B[3]G1-triazole-payload N-glycans; FA1B[3]G1-triazole-payload N-glycans; A1B[3]G1S1(6 or 3)-triazole-payload N-glycans; and/or 25584 FA1B[3]G1S1(6 or 3)-triazole-payload N-glycans.
- the antibody population comprises predominantly a mixture of two or three of the aforementioned exemplary antibody conjugates.
- one or more of the above antibody populations may be reacted with a fucosidase to produce a substantially afucosylated population of antibodies in which the N-glycans lack fucose or reacted with a fucosyltransferase in the presence of GDP- fucose to produce a substantially fucosylated population of antibodies in which the N-glycans comprise fucose.
- the fucosyltransferase is an ⁇ 1-6-fucosyltransferase, which transfers a fucose residue from GDP-fucose to the GlcNAc residue on the reducing end of the chitobiose core of the N-glycan in an ⁇ 1-6 linkage.
- a population of antibodies is reacted with a neuraminidase, and a galactosidase to produce a population of antibodies comprising predominantly fucosylated and non-fucosylated A2 N-glycans (A2 and/or FA2, respectively).
- the population of antibodies may then be reacted with GnT-III in the presence of UDP-6-azido-GlcNAc or UDP-GlcNAz to produce a population of antibodies comprising predominantly A2B-azide and/or FA2B-azide N-glycans.
- the population of antibodies comprising predominantly A1B-azide N-glycans and/or FA1B-azide N-glycans may then be reacted with a GalT in the presence of UDP-galactose to produce a population of antibodies comprising predominantly A2B[3]G1-azide; FA2B[3]G1- azide, A2B[6]G1-azide N-glycans; FA2B[6]G1-azide N-glycans; A2BG2-azide N-glycans; and/or FA2BG2-azide N-glycans in which galactose is linked to the GlcNAc residue on the ⁇ 1,3 arm in a ⁇ 1-4 linkage and/or ⁇ 1,6 arm in a ⁇ 1-4 linkage.
- the population of antibodies comprising predominantly A2B[3]G1-azide, FA2B[3]G1-azide N-glycans, A2B[6]G1-azide N-glycans, FA2B[6]G1-azide N-glycans, A2BG2-azide N-glycans, and/or FA2BG2-azide N-glycans may then be reacted with an ⁇ 2,6- or ⁇ 2,3-siaT in the presence of CMP-sialic acid to produce a population of antibodies comprising predominantly A2B[3]G1S1(6 or 3)-azide N-glycans; FA2B[3]G1S1(6 or 3)-azide N-glycans; A2B[6]G1S1(6 or 3)-azide N-glycans; FA2B[6]G1S1(6 or 3)-azide N-glycan
- any one of the above antibody populations may be reacted with a payload comprising an alkyne functional group under metal-free click chemistry conditions to produce an antibody conjugates in which the azide functional group of the 6-azido- 25584 GlcNAc or GlcNAz is linked to the alkyne functional group of the payload in a triazole linkage.
- Exemplary antibody conjugates may comprise predominantly A2B[3]G1-triazole-payload N- glycans; FA2B[3]G1-triazole-payload N-glycans, A2B[6]G1-triazole-payload N-glycans; FA2B[6]G1-triazole-payload N-glycans; A2BG2-triazole-payload N-glycans; and FA2BG2- triazole-payload N-glycans; A2B[3]G1-triazole-payload N-glycans; FA2B[3]G1-triazole-payload N-glycans; A2B[6]G1-triazole-payload N-glycans; FA2B[6]G1-triazole-payload N-glycans; A2BG2-triazole-payload N-glycans; FA2BG2-triazole-payload N-glycans;
- the antibody population comprises predominantly a mixture of two or three of the aforementioned exemplary antibody conjugates.
- one or more of the above exemplary antibody populations may be reacted with a fucosidase to produce a substantially afucosylated population of antibodies in which the N-glycans lack fucose or reacted with a fucosyltransferase in the presence of GDP-fucose to produce a substantially fucosylated population of antibodies in which the N-glycans comprise fucose.
- the fucosyltransferase is an ⁇ 1-6- fucosyltransferase, which transfers a fucose residue from GDP-fucose to the GlcNAc residue on the reducing end of the chitobiose core of the N-glycan in an ⁇ 1-6 linkage.
- Remodeling of glycoprotein N-glycans may be found in patent publication WO2022221163, which is incorporated herein by reference in its entirety. The following examples are intended to promote a further understanding of the present invention.
- GENERAL METHODS AND MATERIALS Anti-HER2 Human IgG1 Trastuzumab biosimilar (SIM0005), anti-HER2 mouse IgG2a (BE0277), isotype human IgG1 (BP0297), and isotype mouse IgG2a (BE00085) were purchased from BioXCell.
- ⁇ 2-3/6/8 Neuraminidase (P0720) and ⁇ 1-4 Galactosidase (P0745) were purchased from New England Biolabs (NEB).
- Mouse 25584 anti-human IgG Fc gamma-FITC (209-095-098) for cell binding assay and AffiniPure rat Anti- Mouse IgG (415-065-166) for serum stability assays were purchased from Jackson ImmunoResearch.
- Tris-HCl T-5941
- sodium acetate S2889 sodium chloride
- M4880 magnesium chloride
- manganese chloride solution M1787
- sodium chloride solution S5150
- CMP-NANA C8271
- UDP-Gal U4500
- UDP-GlcNAc U4375
- NH 2 NH 2 •AcOH 259748
- Bis(2-cyanoethyl)-N,N-diisopropyl phosporamidite 766305
- m-CPBA 273031)
- Tetrazole 88185
- DEAE-Sepharose DFF100
- Triethylammonium bicarbonate buffer T7408
- 1,4- dithiothreitol D9779
- 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3- oxid hexafluorophosphate HATU
- Ac3-6AzGlcNAc (1258) was purchased from Click Chemistry Tools. Heat- inactivated fetal bovine serum (FBS) (16140-071), Dulbecco's phosphate-buffered saline (DPBS) (14190-144) and McCoy’s 5A (16600-082) buffer were purchased from Gibco. Dibenzocyclooctyne (DBCO)-PEG8-acid (BP-24017) and DBCO-PEG4-Val-Cit-PAB-MMAE (BP-25659)), and NHS-PEG4-Val-Cit-PAB-MMAE (BP-25503) were purchased from Broadpharm.
- FBS fetal bovine serum
- DPBS Dulbecco's phosphate-buffered saline
- McCoy’s 5A (16600-082) buffer were purchased from Gibco.
- UDP-azidoacetylglucosamine (UDP-GlcNAz or UDP-6-azido-GlcNAc) (ES104) was purchased from R&D Systems.
- MWCO filters 10K molecular weight cutoff (MWCO) filters (UFC503096) were purchased from Millipore Sigma. Octet sensors (18-5101) and Incucyte FabFluor probes (4722) were purchased from Sartorius. MabSelect SuRe TM protein A resin (17543801) was obtained from Cytiva. Male rat plasma (Sprague Dowley rat plasma K2EDTA, RATPLEDTA2-M) was purchased from BioIVT. Reagents for CellTiter-Glo ® luminescent cell viability assay were purchased from Progema (G7570).
- LC-QToF-MS Liquid Chromatography
- Agilent MassHunter software was used for the analysis, including data acquisition, chromatogram/mass analysis, mass deconvolution, and drug-antibody ratio (DAR) calculation.
- Hydrophobic interactions chromatography (HIC) and size-exclusion chromatography (SEC) studies were performed on Agilent 1290 Infinity II LC systems (with ChemStation C.01.10).
- Protein/antibody concentration was measured using NanoDrop TM OneC (Thermo Scientific). BCA (bicinchoninic acid) assay signal was read on Synergy TM Neo2 (BioTek) plate reader. Melting temperature (Tm) and aggregation temperature (Tagg) were performed on Uncle (all-in-one biologics stability screening platform) from Unchained Labs (Pleasanton, CA).
- UDP-6-azido-GlcNAc was synthesized as described in literature with minor modifications (Morrison et al., Carbohydrate Research, 495: 108071 (2020); Zhao et al., Nature Protocols, 5: 636-646 (2010); Mayer et al., Bioorg Med Chem Lett, 21: 1199-2012011).
- Compound S1 200 mg, 0.53 mmol
- NH 2 NH 2 •CH 3 CO 2 H 59.3 mg, 0.644 mmol
- DMF dimethyl formamide
- UDP-GlcNAc derivatives chemically diversified at the C2-acylamide moiety were synthesized via active ester chemistry by reacting corresponding N-Hydroxysuccinimide (NHS) esters with UDP-Glucosamine (UDP-GlcNH 2 ).
- NHS N-Hydroxysuccinimide
- UDP-GlcNH 2 UDP-Glucosamine
- Oasis SPE Solid Phase Extraction
- ⁇ Plate from Waters was washed with water (1 column volume) and conditioned with water-acetonitrile solution (10:90 v/v, 1 column volume).
- the glycan sample prepared above in 90% acetonitrile solution was then charged to the ⁇ Plate, followed by washing with washing buffer (formic acid/water/acetonitrile 1:9:90 v/v/v, 2 column volume).
- the N-glycans were eluted using 90 ⁇ L elution buffer (200 mM ammonium acetate in 5% acetonitrile).
- the reaction then was diluted with 2X (v/v) 25 mM phosphate buffered saline (PBS) pH 7.5 and the antibody was purified using protein A resin (Cytiva).
- PBS phosphate buffered saline
- the glycoengineered antibody FA2 was mixed with 5 weight percent (wt%) GnT-III in a 1.5 mL microtube, followed by buffer transfer into the GnT-III buffer (50 mM Tris pH 7 with 50 mM NaCl and 10 mM MnCl 2 ) using 10 K MWCO tubes.
- MMAE Monomethylauristatin E
- DBCO dibenzocyclooctyne
- the payloads were dissolved in dimethylsulfoxide (DMSO) to make a 100 mg/mL stock solution.
- DMSO dimethylsulfoxide
- the conjugation reactions were carried out by mixing the glycoengineered antibody prepared above with 30 equivalent payloads in 25 mM Tris 7.4 buffer with 100 mM NaCl. The reaction volume was adjusted to give a final antibody concentration between 4-5 mg/mL. Additional DMSO was added to the reaction to a final amount of 10% (v/v) DMSO to improve the payload solubility.
- the reaction was incubated at room temperature with shaking.
- the LC-QToF-MS was used to monitor the reaction until the reaction was complete. A longer incubation time is required for the reactions with antibodies having galactosylated and sialylated N-glycans.
- the samples were diluted with 2X (v/v) 25 mM Tris-HCl pH 7.5 buffer charged to a protein A (Cytiva) column. After washing with 5 column volume of the Tris-HCl buffer, the MMAE-ADCs were eluted from the column, buffer-exchanged into 50 mM sodium acetate buffer (pH 5.5), and stored at 4°C before use. BCA assays were used to determine the concentration of ADCs.
- HIC Hydrophobic Interactions Chromatography
- SEC-UPLC Size-Exclusion Chromatography
- Ni-NTA Octet ® sensors were hydrated in Octet buffer (25 mM Tris-HCl pH 7.4, 50 mM NaCl, 0.02% Tween 20) for 30 minutes before the experiments. To begin the measurement, the sensors were loaded with 0.5 ⁇ g/mL His-tagged Fc ⁇ Rs for 240 seconds, followed by baseline equilibration for 2 minutes. Association of recombinant human ACE2 was performed with the antibody or ADCs from 12.5 to 1000 nM for 600 seconds. Dissociation was measured for 600 seconds. The equilibrium 25584 dissociation constant (KD) values were calculated using a 1:1 global fit model in the Octet data analysis software.
- KD dissociation constant
- the assays were carried out at 30°C and the Octet buffer was used as the solvent in all the steps.
- Nickel- Nitriloacetic acid (Ni-NTA) sensors were loaded with 0.5 ⁇ g/mL His-tagged Fc ⁇ R-IIa or Fc ⁇ R- IIIa for 240 seconds, followed by incubation with 5 ⁇ g/mL Fc ⁇ R-IIa or 40 ⁇ g/mL Fc ⁇ R-IIIa for 240 seconds.
- the binding response was monitored in real-time.
- Western Blotting for studying HER2 binding Standard SDS-PAGE and Western detection protocols were used except the human anti-HER2-MMAE ADC was used as the primary antibody in the experiment.
- HER2 was added to a NuPage TM 4-12% Bis-Tris gel (Invitrogen NP0323BOX), followed by electrophoresis at 200V for 50 minutes. Protein transfer from the gel to a Polyvinylidene fluoride (PVDF) membrane was carried out using iBlotTM 2 Gel Transfer Device (ThermoFisher) at 20 V for 7 minutes. Following the transfer, the membrane was blocked using 5% bovine serum albumen (BSA) for 2 hours at room temperature, then washed 3X with ris-buffered saline with 0.1% Tween ® 20 (TBST), and incubated with the 10 ⁇ g/mL ADC at 4°C overnight.
- BSA bovine serum albumen
- the ADC was detected using a goat anti-human IgG antibody (1 ⁇ g/mL, LI-COR, 926-32232). The blot was then imaged using LI-COR, Odyssey ® CLx. ADC synthesis using lysine conjugation NHS-PEG4-Val-Cit-PAB-MMAE from Broadpharm (BP-25503) was used for the antibody conjugation through lysine residues. The payload was dissolved in DMSO to a final stock concentration of 25 mg/mL. The conjugation reactions were carried out by mixing the native anti-HER2 human IgG1 Trastuzumab biosimilar with 5 equivalent payloads in 1X PBS buffer.
- the reactions were adjusted to give a final antibody concentration of 4 mg/mL and 10% DMSO.
- the reaction was incubated at room temperature with shaking.
- the reactions were monitored by the LC-QToF-MS every 30 minutes until the reaction reached a DAR of 2, immediately followed by protein A purification.
- the concentration of the resulting ADCs was determined by bicinchoninic acid assays (BCAs).
- BCAs bicinchoninic acid assays
- Trastuzumab biosimilar and an isotype IgG1 antibody with site mutations at serine 375 (S375C; Eu numbering scheme) and the MMAE derivative with a Val-Cit-PAB-maleimide linker were used.
- the reaction was carried out by mixing the antibodies with 5 equivalent of the payload (25 mg/mL, DMSO stock solution) in 1 X PBS.
- the reaction volume was adjusted to a final antibody concentration of 4 mg/mL and 10% DMSO.
- the reaction was incubated at room temperature with shaking until the DAR reached 2 (tracking by LC-MS).
- the concentration of the resulting ADCs was determined by BCA.
- SKBR3 cells (ATCC HTB-30) expressing HER2 (epidermal growth factor receptor 2) were seeded to clear bottom 96-well plates to a density of 9,000 cells per well (50 ⁇ L). The cells were allowed to adhere to the well bottom for 24 hours. Test antibodies and antibody conjugates were mixed with FabFluor (0.5 mg/mL) in a 1:3 ratio and the volume was adjusted using fresh culture media (McCoy's 5A with 10% fetal bovine serum) to give a final concentration of 4 ⁇ g/mL. After an incubation of 30 minutes at 37°C, the mixture was added to the cell plates (50 ⁇ L each well).
- test antibodies/conjugates internalization was monitored every 30 minutes by the fluorescence readout using Incucyte Internalization Assay (Sartorius). This assay was done in triplicate.
- Cell binding assay SKBR3 cells from culture plates were harvested and suspended in ice-cold PBS. The cells were washed with PBS (ice-cold) once using a centrifuge and resuspended in 0.5 mL stain buffer (Dulbecco's phosphate-buffered saline (PBS), pH 7.4, 2% heat-inactivated fetal bovine serum (FBS), 0.09% sodium azide).
- stain buffer Dulbecco's phosphate-buffered saline (PBS), pH 7.4, 2% heat-inactivated fetal bovine serum (FBS), 0.09% sodium azide).
- test antibodies or antibody conjugates were added to the cell solution (10 ⁇ g/mL), followed by incubation at 4°C for 30 minutes. After another washing step using ice-cold PBS, the secondary mAb (mouse anti-human IgG Fc gamma-FITC) was added to the cell solution (stain buffer) and incubated for 30 minutes (4°C). The cells were then washed with PBS, resuspended to the stain buffer, and subjected to a Guava ® flow cytometry system (Millipore Sigma). About 1x10 6 cells were used per staining condition.
- POROSTM R2 reverse-phase columns (2.1 x 30 mm, 10 ⁇ m) from Applied Biosystems were used for the UPLC system.
- the samples were frozen immediately at -80°C after ADCs were added. Samples from all the time points were frozen, thawed, and processed together in one experiment.
- mAb monoclonal antibody
- HER2 human epidermal growth factor receptor 2
- LC-MS Liquid chromatograph-mass spectrometer
- EXAMPLE 2 Characterization of the bisecting glycan-bridged linker cleavage and stability
- the proposed mechanism of action for anti-cancer ADCs includes 1) binding to the targeted antigens on the cancer cell surface, 2) internalization of the ADCs, and 3) the release of the cytotoxic payload to kill the cancer cells (Peters, & Brown, Biosci. Rep.35, e00225, doi:10.1042/BSR20150089 (2015); Chalouni. & Doll, J. Exper. & Clinical Cancer Res.37, 20 (2018)).
- the linker that connects the antibody framework and the drug payload plays a critical role in the payload release mechanism (Su et al., Acta Pharmaceutica Sinica B 11, 3889-3907 (2021)). They are designed to be stable in the bloodstream but can be efficiently cleaved at the tumor site.
- Val-Cit-PABC Valine-Citrulline-p-aminobenzylcarbamate
- ADC ADC development as it has outstanding stability in plasma but remains labile to 25584 lysosomal enzymes, such as Cathepsin B.
- Glycan-bridged conjugation presents another possibility to design enzyme-mediated payload release through the activity of glycosidases.
- the endoglycosidase from Streptococcus pyogenes also known as Endo S
- shaves off IgG glycans by cleaving the ⁇ 1-4 linkage between the GlcNAc residues in the chitobiose core Freeze & Kranz, Curr. Protoc. Mol. Biol.17.13A.1, doi:10.1002/0471142727.mb1713as89 (2010); Collin & Olsén, EMBO J.20, 3046-3055 (2001)).
- Trastuzumab is a well- studied mAb for breast and stomach cancer drug development.40 Similar to the mouse IgG2a substrate, the native glycan profile of the Trastuzumab biosimilar comprises bi-antennary N- glycans with terminal galactose or GlcNAc (Fig.5A). However, it also has a small amount ( ⁇ 10%) of afucosylated glycoforms that were not found in the mouse IgG. We removed terminal 25584 galactose and confirmed the addition of an azido-GlcNAc residue to the A2 and FA2 glycoforms using LC-MS as well as the downstream MMAE conjugation (Fig.5B, Fig.11).
- Fig.6E cell viability studies demonstrate target-specific toxicity of the hIgG- MMAE was comparable to ADCs synthesized by using lysine conjugation or engineered cysteine conjugation (positive controls).
- Fig.6F shows that HER2-expressing cell killing activity between hIgG-MMAE conjugated to FA2B-azide or FA2BG2-azide were comparable.
- Mouse IgG2a is reported to have cross-binding affinities to certain types of human Fc ⁇ Rs, including Fc ⁇ R-I, Fc ⁇ R-IIa, and Fc ⁇ R-IIIa V158 (Temming et al., Mol. Immunol 127, 79- 86 (2020)).
- MMAE ADCs prepared in this study preserve binding abilities to the antigen target and Fc ⁇ Rs while a slight decrease in Fc ⁇ Rs binding affinity was observed ( ⁇ 10-fold KD change). Since payload molecules could have distinct chemical and physical properties, the effect of payload conjugation should be evaluated when different payloads are used, especially for weaker IgG-protein interactions, e.g., Fc ⁇ R-IIIa.
- IgG glycans are involved in Fc ⁇ R interactions and thus play regulatory roles in effector cell function, such as antibody-dependent cellular cytotoxicity (ADCC) (Thomann et al., PLOS ONE 10, e0134949, doi:10.1371/journal.pone.0134949 (2015); Li et al., Proc. National Acad. Sci. (USA) 114, 3485-3490 (2017); Gudelj et al., Cell. Immunol. 333, 65-79 (2016); Cambay et al., Curr. Res. Immunol.1, 23-37 (2020)).
- ADCC antibody-dependent cellular cytotoxicity
- IgG the lifetime and physical properties of IgG can be affected by the glycan structures.
- sialylation of IgG glycans was reported to increase IgG longevity by either facilitating the evasion from serum circulation mediated by asialoglycoprotein receptors, or by enhancing IgG interaction with neonatal Fc gamma receptors (FcRn) (Ashwell & Harford Annu. Rev. Biochem.51, 531-554, doi:10.1146/annurev.bi.51.070182.002531 (1982); Bas et al., J. Immunol.202, 1582 (2019); Morell et al., J. Biol. Chem.246, 1461-1467 (1971)).
- IgG galactosylation is known to promote C1q binding and downstream complement activity (van Osch et al., J. Immunol., ji2100399, doi:10.4049/jimmunol.2100399 (2021); Dekkers et al., Front. Immunol.8, doi:10.3389/fimmu.2017.00877 (2017); Peschke et al., Front. Immunol.8, 646 (2017)).
- IgG glycans therefore, serve as versatile handles to fine-tune the immune response and pharmacokinetic properties of antibodies, and potentially as for ADCs.
- Payload conjugation through the bisecting GlcNAc residues preserves the opportunity of engineering the bi-antennary arms of the N-glycan.
- This can be achieved by introducing glycosyltransferases to IgG with the azido-glycoforms (e.g., FA2B-Azide) to rebuild the terminal galactose or sialic acid residues (Fig.7A).
- the human IgG1 Trastuzumab biosimilar as an example. Treating the substrate with human ⁇ 1-4 galactosyltransferase (Homo sapiens) following the GnT-III reaction gave the di-galactosylated glycoform (FA2BG2-Azide).
- UDP-GlcNAc glycopeptide beta 4-N- acetylglucosaminyltransferase III, an enzyme in hen oviduct which adds GlcNAc in beta 1-4 linkage to the beta-linked mannose of the trimannosyl core of N-glycosyl oligosaccharides.
- Dolastatin 10 a powerful cytostatic peptide derived from a marine animal: Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain. Biochemical Pharmacology 39, 1941-1949 (1990). 33. Hsu, Y.-P. et al. Successive remodeling of IgG glycans using a solid-phase enzymatic platform. Communications Biology 5, 328 (2022). 34. Thomann, M. et al. In Vitro Glycoengineering of IgG1 and Its Effect on Fc Receptor Binding and ADCC Activity. PLOS ONE 10, e0134949, doi:10.1371/journal.pone.0134949 (2015). 35. Peters, C. & Brown, S.
- Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Biosci Rep 35, e00225, doi:10.1042/BSR20150089 (2015). 25584 36. Chalouni, C. & Doll, S. Fate of Antibody-Drug Conjugates in Cancer Cells. Journal of Experimental & Clinical Cancer Research 37, 20 (2018). 37. Su, Z. et al. Antibody–drug conjugates: Recent advances in linker chemistry. Acta Pharmaceutica Sinica B 11, 3889-3907 (2021). 38. Freeze, H. H. & Kranz, C. Endoglycosidase and glycoamidase release of N-linked glycans.
- a glycoprotein comprising a protein conjugated to at least one bisected N- glycan in which the nonreducing end of the ⁇ 1,4 linked mannose residue of the trimannosyl core (M3) of the bisected N-glycan is linked to the reducing end of an azido-N-acetyl glucosamine residue in a ⁇ 1,4 linkage, wherein M3 is represented by the formula comprising Man ⁇ 1-3(Man ⁇ 1-6)Man ⁇ 1- 4GlcNAc ⁇ 1–4GlcNAc ⁇ 1–Asn; wherein the azido-N-acetyl glucosamine is selected from the group consisting of 6-azido-GlcNAc comprising the formula: 25584 wherein the nonreducing end of at least one of the ⁇ 1,6-linked or ⁇ 1,3-linked mannose residues is linked to the reducing end
- Embodiment 2 The glycoprotein of embodiment 1, wherein the nonreducing end of the GlcNAc residue is linked to the reducing end of a galactose residue by a ⁇ 1,4 linkage.
- Embodiment 3 The glycoprotein of embodiment 2, wherein the nonreducing end of the galactose residue is linked to the reducing end of a sialic acid residue by an ⁇ 2,6 linkage.
- Embodiment 4. The glycoprotein of embodiment 3, wherein the nonreducing end of the galactose residue is linked to the reducing end of a sialic acid residue by an ⁇ 2,3 linkage.
- glycoprotein of embodiment 1 wherein the nonreducing end of the ⁇ 1,6-linked mannose residue is linked to the reducing end of a first GlcNAc residue by a ⁇ 1,2 linkage and the nonreducing end of the ⁇ 1,3-linked mannose residue is linked to the reducing end of a second GlcNAc residue by a ⁇ 1,2 linkage.
- Embodiment 6
- glycoprotein of embodiment 5 wherein (i) the nonreducing end of the first GlcNAc residue is linked to the reducing end of a galactose residue by a ⁇ 1,4 linkage; (ii) the nonreducing end of the second GlcNAc residue is linked to the reducing end of a galactose 25584 residue by a ⁇ 1,4 linkage; or (iii) the nonreducing end of the first GlcNAc residue is linked to the reducing end of a first galactose residue by a ⁇ 1,4 linkage and the nonreducing end of the second GlcNAc residue is linked to the reducing end of a second galactose residue by a ⁇ 1,4 linkage.
- Embodiment 7 Embodiment 7.
- glycoprotein of embodiment 6 wherein the nonreducing end of the galactose residue of (i) or (ii) or the nonreducing end of the first and second galactose residues of (iii) each linked to the reducing end of a sialic acid residue by an ⁇ 2,3 linkage.
- Embodiment 8 The glycoprotein of embodiment 6, wherein the nonreducing end of the galactose residue of (i) or (ii) or the nonreducing end of the first and second galactose residues of (iii) each linked to the reducing end of a sialic acid residue by an ⁇ 2,6 linkage.
- Embodiment 10. The glycoprotein of embodiment 9, wherein the payload is a therapeutic agent, a diagnostic agent, radionuclide, or protecting group.
- Embodiment 11. The glycoprotein of embodiment 10, wherein the therapeutic agent is a cytotoxic agent, an anti-inflammatory agent, a peptide, an immune agonist, or a nucleic acid molecule or nucleic acid analog.
- Embodiment 12 The glycoprotein of embodiment 11, wherein the anti-inflammatory agent is a glucocorticoid receptor agonist.
- glycoprotein of embodiment 12, wherein the anti-inflammatory agent is Cortisol, cortisone acetate, beclometasone, prednisone, prednisolone, methylprednisolone, betamethasone, trimcinolone, budesonide, dexamethasone, fluticasone, or mometasone.
- the anti-inflammatory agent is Cortisol, cortisone acetate, beclometasone, prednisone, prednisolone, methylprednisolone, betamethasone, trimcinolone, budesonide, dexamethasone, fluticasone, or mometasone.
- Embodiment 14 is Cortisol, cortisone acetate, beclometasone, prednisone, prednisolone, methylprednisolone, betamethasone, trimcinolone, budesonide, dexamethasone, fluticasone
- the cytotoxic agent is selected from the group consisting of taxanes, anthracyclines, camptothecins, epothilones, mytomycins, combretastatins, vinca alkaloids, maytansinoids, enediynes, duocarmycins, 25584 tubulysins, amatoxins, bleomycins, dolastatins and
- Embodiment 17 An antibody conjugated to at least one bisected N-glycan in which the nonreducing end of the ⁇ 1,4 linked mannose residue of the trimannosyl core (M3) of the bisected N-glycan is linked to the reducing end of an azido-N-acetyl glucosamine residue in a ⁇ 1,4 linkage, wherein M3 is represented by the formula comprising Man ⁇ 1-3(Man ⁇ 1-6)Man ⁇ 1- 4GlcNAc ⁇ 1–4GlcNAc ⁇ 1–Asn; wherein the azido-N-acetyl glucosamine is selected from the group consisting of 6-azido-GlcNAc comprising the formula: wherein the nonreducing end of at least one of the ⁇ 1,6-linked or ⁇ 1,3-linked mannose residues is linked to the reducing end of an N-acetyl glucosamine (G
- Embodiment 18 The antibody of embodiment 17, wherein the nonreducing end of the GlcNAc residue is linked to the reducing end of a galactose residue by a ⁇ 1,4 linkage.
- Embodiment 19 The antibody of embodiment 18, wherein the nonreducing end of the galactose residue is linked to the reducing end of a sialic acid residue by an ⁇ 2,6 linkage.
- Embodiment 20 The antibody of embodiment 18, wherein the nonreducing end of the galactose residue is linked to the reducing end of a sialic acid residue by an ⁇ 2,3 linkage.
- Embodiment 21 Embodiment 21.
- Embodiment 17 wherein the azido group of the azido-N- acetyl glucosamine is conjugated to a payload comprising an alkyne functional group in a triazole linkage.
- Embodiment 26 The antibody of embodiment 25, wherein the payload is a therapeutic agent, a diagnostic agent, radionuclide, or protecting group.
- Embodiment 27 The antibody of embodiment 26, wherein the therapeutic agent is a cytotoxic agent, an anti-inflammatory agent, a peptide, an immune agonist, or a nucleic acid molecule or nucleic acid analog.
- Embodiment 28 The antibody of embodiment 27, wherein the anti-inflammatory agent is a glucocorticoid receptor agonist.
- Embodiment 29 The antibody of embodiment 17, wherein the azido group of the azido-N- acetyl glucosamine is conjugated to a payload comprising an alkyne functional group in a triazole linkage.
- the antibody of embodiment 28, wherein the anti-inflammatory agent is Cortisol, cortisone acetate, beclometasone, prednisone, prednisolone, methylprednisolone, betamethasone, trimcinolone, budesonide, dexamethasone, fluticasone, or mometasone.
- the anti-inflammatory agent is Cortisol, cortisone acetate, beclometasone, prednisone, prednisolone, methylprednisolone, betamethasone, trimcinolone, budesonide, dexamethasone, fluticasone, or mometasone.
- Embodiment 30 wherein the anti-inflammatory agent is Cortisol, cortisone acetate, beclometasone, prednisone, prednisolone, methylprednisolone, betamethasone, trimcinolone, budesonide, dexamet
- the cytotoxic agent is selected from the group consisting of taxanes, anthracyclines, camptothecins, epothilones, mytomycins, combretastatins, vinca alkaloids, maytansinoids, enediynes, duocarmycins, tubulysins, amatoxins, bleomycins, dolastatins and auristatins, pyrrolobenzodiazepine dimers, indolinobenzodiazepine dimers, and radioisotopes.
- the cytotoxic agent is selected from the group consisting of taxanes, anthracyclines, camptothecins, epothilones, mytomycins, combretastatins, vinca alkaloids, maytansinoids, enediynes, duocarmycins, tubulysins, amatoxins, bleomycins, dolastatins and auristatins, pyrrolobenzodia
- An antibody conjugate comprising the structure: A b-[B-T-L-Pay] n 25584 wherein Ab is an antibody; B is a bisected N-glycan wherein the bisecting sugar residue is azido- GlcNAc or GlcNAz having an azide functional group; L is a linker element comprising an alkyne functional group or a bond; Pay is a payload, which comprises an alkyne functional group when L is a bond; T is a triazole linkage formed between the linkage of the azide functional group and the alkyne functional group; and, n is an integer from 1-20.
- Embodiment 34 The antibody of embodiment 33, wherein L is a self-immolative linker.
- Embodiment 35 The antibody of embodiment 33, wherein L has the formula L 1 -L 2 , wherein each of L 1 and L 2 is independently a linker element or a bond.
- Embodiment 36 The antibody of embodiment 33, wherein L comprises a distal end comprising an alkyne containing group linked to the azide of the azido-GlcNAc or GlcNAz of bisected N-glycan B in triazole linkage T and a proximal end linked to Pay.
- Embodiment 37 The antibody of embodiment 36, wherein the alkyne group is a strained cyclooctyne.
- Embodiment 38 The antibody of embodiment 33, wherein L has the formula L 1 -L 2 , wherein each of L 1 and L 2 is independently a linker element or a bond.
- Embodiment 36 The antibody of embodiment 33, wherein L comprises a distal end comprising an alkyne containing group linked to the azide of the azido
- the antibody of embodiment 37, wherein the strained cyclooctyne is DBCO.
- Embodiment 39. The antibody of embodiment 33, wherein the bisected N-glycan B comprises a structure selected from the group consisting of A2B-azide; FA2B-azide; A2B[3]G1- azide; FA2[3]BG1-azide; A2B[6]G1-azide; FA2B[6]G1-azide; A2BG2-azide; FA2BG2-azide; A2BG2-azide; A2B[3]G1S1(6)-azide; FA2B[3]G1S1(6)-azide; A2B[6]G1S1(6)-azide; FA2B[6]G1S1(6)-azide; A2BG2S2(6)-azide; FA2BG2S2(6)-azide; A2B[3]G1S1(3)-azi
- Embodiment 40 The antibody of embodiment 33, wherein the bisecting sugar residue is GlcNAz and the triazole linkage has the structure: wherein the wavy line identifies the bond between the amine group of the GlcNAz residue and the C2 carbon of the glucose residue comprising the GlcNAz residue and the double wavy lines identify bonds between the alkyne functional group of L or Pay when L is a bond; or, the bisecting sugar residue is 6-azido-GlcNAc and the triazole linkage has the structure: wherein the wavy line identifies the bond between the C5 and C6 carbons of the glucose residue comprising the 6-azido-GlcNAc residue and the double wavy lines identify bonds between the alkyne functional group of L or Pay when L is a bond.
- Embodiment 41 A composition comprising a plurality of antibody-drug conjugates (ADCs) and a pharmaceutically acceptable carrier, wherein each ADC independently comprises the structure A b-[B-T-L-Pay] n wherein Ab is an antibody; B is a bisected N-glycan wherein the bisecting sugar residue is azido- GlcNAc or GlcNAz residue having an azide functional group; L is a linker element comprising an alkyne group or a bond; Pay is a payload, which comprises an alkyne group when L is a bond; T is a triazole linkage formed between the linkage of the azide group and the alkyne group; and, n is an integer from 1-20.
- ADCs antibody-drug conjugates
- Embodiment 42 The composition of embodiment 41, wherein L is a self-immolative linker. 25584 Embodiment 43.
- the composition of embodiment 41, wherein L has the formula L 1 -L 2 , wherein each of L 1 and is independently a linker element or a bond.
- Embodiment 44. The composition of embodiment 41, wherein L comprises a distal end comprising an alkyne containing group linked to the azide of the azido-GlcNAc or GlcNAz of bisected N-glycan B in triazole linkage T and a proximal end linked to Pay.
- Embodiment 45 The composition of embodiment 44, wherein the alkyne group is a strained cyclooctyne.
- Embodiment 46 The composition of embodiment 45, wherein the strained cyclooctyne is DBCO.
- Embodiment 47 The composition of embodiment 41, wherein the bisected N-glycan B comprises a structure selected from the group consisting of A2B-azide; FA2B-azide; A2B[3]G1- azide; FA2[3]BG1-azide; A2B[6]G1-azide; FA2B[6]G1-azide; A2BG2-azide; FA2BG2-azide; A2B[3]G1S1(6)-azide; FA2B[3]G1S1(6)-azide; A2B[6]G1S1(6)-azide; FA2B[6]G1S1(6)-azide; FA2B[6]G1S1(6)-azide; A2BG2S2(6)-azide; FA2BG2S2(6)-azide; A2B
- Embodiment 48 The composition of embodiment 41, wherein the bisecting sugar residue is GlcNAz and the triazole linkage has the structure: 25584 wherein the wavy line identifies the bond between the amine group of the GlcNAz residue and the C2 carbon of the glucose residue comprising the GlcNAz residue and the double wavy lines identify bonds between the alkyne group of L or Pay when L is a bond; or, the bisecting sugar residue is 6-azido-GlcNAc and the triazole linkage has the structure: wherein the wavy line identifies the bond between the C5 and C6 carbons of the glucose residue comprising the 6-azido-GlcNAc residue and the double wavy lines identify bonds between the alkyne group of L or Pay when L is a bond.
- Embodiment 49 The composition of embodiment 41, wherein the predominant N-glycans in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structure A2B-azide or FA2B-azide or both A2B-azide and FA2B-azide, wherein the azide is part of the triazole linkage T.
- Embodiment 50 Embodiment 50.
- composition of embodiment 41 wherein the predominant N-glycans in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structure A2B[3]G1-azide or FA2B[3]G1-azide or both A2B[3]G1-azide and FA2B[3]G1-azide, wherein the azide is part of the triazole linkage T.
- Embodiment 51 Embodiment 51.
- composition of embodiment 41 wherein the predominant N-glycans in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structure A2B[6]G1-azide or FA2B[6]G1-azide or both A2B[6]G1-azide and FA2B[6]G1-azide, wherein the azide is part of the triazole linkage T.
- Embodiment 52 Embodiment 52.
- composition of embodiment 41 wherein the predominant N-glycans in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structure 25584 A2BG2S2-azide or FA2BG2S2-azide or both A2BG2-azide and FA2BG2-azide, wherein the azide is part of the triazole linkage T.
- Embodiment 53 Embodiment 53.
- composition of embodiment 401 wherein the composition, the predominant N-glycans in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structure A2B[3]G1S1(6 or 3)-azide or FA2B[3]G1S1(6 or 3)-azide or both A2B[3]G1S1(6 or 3)-azide and FA2B[3]G1S1(6 or 3)-azide, wherein the azide is part of the triazole linkage T.
- Embodiment 54 Embodiment 54.
- composition of embodiment 41 wherein the predominant N-glycans in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structure A2B[6]G1S1(6 or 3)-azide or FA2B[6]G21S1(6 or 3)-azide or both A2B[6]G1S1(6 or 3)-azide and FA2B[6]G1S1(6 or 3)-azide, wherein the azide is part of the triazole linkage T.
- Embodiment 55 Embodiment 55.
- composition of embodiment 41 wherein the predominant N-glycans in the composition comprise greater than 50 mole%, 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structures A2BG2S2(6 or 3)-azide or FA2BG2S2(6 or 3)-azide or both A2BG2S2(6 or 3)-azide and FA2BG2S2(6 or 3)-azide, wherein the azide is part of the triazole linkage T.
- Embodiment 56 Embodiment 56.
- Embodiment 57 An antibody comprising one or more N-glycans selected from the group consisting of A2B-azide; FA2B-azide; A2B[3]G1-azide; FA2[3]BG1-azide; A2B[6]G1-azide; 25584 FA2B[6]G1-azide; A2BG2-azide; FA2BG2-azide; A2B[3]G1S1(6)-azide; FA2B[3]G1S1(6)- azide; A2B[6]G1S1(6)-azide; FA2B[6]G1S1(6)-azide; A2BG2S2(6)-azide; FA2BG2S2(6)-azide; A2B[3]G1S1(3)-azide; FA2B[3]G1S1(3)-azide; A2B[6]G1S1(3)-azide; FA2B[6]G
- Embodiment 58 An antibody comprising one or more N-glycans selected from the group consisting of A2B-azide; FA2B-azide; A2B[3]G1-azide; FA2[3]BG1-azide; A2B[6]G1-azide; FA2B[6]G1-azide; A2BG2-azide; FA2BG2-azide; A2B[3]G1S1(6)-azide; FA2B[3]G1S1(6)- azide; A2B[6]G1S1(6)-azide; FA2B[6]G1S1(6)-azide; A2BG2S2(6)-azide; FA2BG2S2(6)-azide; A2B[3]G1S1(3)-azide; FA2B[3]G1S1(3)-azide; A2B[6]G1S1(3)-azide; FA2B[6]G1S1
- Embodiment 59 An antibody-drug conjugate (ADC) comprising an antibody of embodiment 57 or 58 conjugated to a payload comprising an alkyne group.
- Embodiment 60 The ADC of embodiment 59, wherein the payload is a cytotoxic agent, an anti-inflammatory agent, a radionuclide, or diagnostic agent.
- Embodiment 61 Embodiment 61.
- composition of embodiment 41 wherein the predominant N-glycans in the composition comprise greater than 50 mole% of the structure A2B[3]G1-azide or FA2B[3]G1-azide or both A2B[3]G1-azide and FA2B[3]G1-azide, wherein the azide is part of the triazole linkage T.
- Embodiment 62 Embodiment 62.
- composition of embodiment 41 wherein the predominant N-glycans in the composition comprise greater than 50 mole% of the structure A2B[6]G1-azide or FA2B[6]G1-azide or both A2B[6]G1-azide and FA2B[6]G1-azide, wherein the azide is part of the triazole linkage T.
- the predominant N-glycans in the composition comprise greater than 50 mole% of the structure A2BG2S2-azide or FA2BG2S2-azide or both A2BG2-azide and FA2BG2-azide, wherein the azide is part of the triazole linkage T.
- Embodiment 64 The composition of embodiment 41, wherein the composition, the predominant N-glycans in the composition comprise greater than 50 mole% of the structure A2B[3]G1S1(6 or 3)-azide or FA2B[3]G1S1(6 or 3)-azide or both A2B[3]G1S1(6 or 3)-azide and FA2B[3]G1S1(6 or 3)-azide, wherein the azide is part of the triazole linkage T.
- Embodiment 65 Embodiment 65.
- composition of embodiment 41 wherein the predominant N-glycans in the composition comprise greater than 50 mole% of the structure A2B[6]G1S1(6 or 3)-azide or FA2B[6]G21S1(6 or 3)-azide or both A2B[6]G1S1(6 or 3)-azide and FA2B[6]G1S1(6 or 3)- azide, wherein the azide is part of the triazole linkage T.
- Embodiment 66 Embodiment 66.
- composition of embodiment 41 wherein the predominant N-glycans in the composition comprise greater than 50 mole% of the structures A2BG2S2(6 or 3)-azide or FA2BG2S2(6 or 3)-azide or both A2BG2S2(6 or 3)-azide and FA2BG2S2(6 or 3)-azide, wherein the azide is part of the triazole linkage T.
- Embodiment 67 Embodiment 67.
- composition of embodiment 41 wherein the predominant N-glycans in the composition comprise greater than 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structure A2B[3]G1- azide or FA2B[3]G1-azide or both A2B[3]G1-azide and FA2B[3]G1-azide, wherein the azide is part of the triazole linkage T.
- Embodiment 68 Embodiment 68.
- composition of embodiment 41 wherein the predominant N-glycans in the composition comprise greater than 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structure A2B[6]G1- azide or FA2B[6]G1-azide or both A2B[6]G1-azide and FA2B[6]G1-azide, wherein the azide is part of the triazole linkage T. 25584 Embodiment 69.
- composition of embodiment 41 wherein the predominant N-glycans in the composition comprise greater than 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structure A2BG2S2- azide or FA2BG2S2-azide or both A2BG2-azide and FA2BG2-azide, wherein the azide is part of the triazole linkage T.
- Embodiment 70 Embodiment 70.
- composition of embodiment 41 wherein the composition, the predominant N-glycans in the composition comprise greater than 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structure A2B[3]G1S1(6 or 3)-azide or FA2B[3]G1S1(6 or 3)-azide or both A2B[3]G1S1(6 or 3)-azide and FA2B[3]G1S1(6 or 3)-azide, wherein the azide is part of the triazole linkage T.
- Embodiment 71 Embodiment 71.
- composition of embodiment 41 wherein the predominant N-glycans in the composition comprise greater than 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structure A2B[6]G1S1(6 or 3)-azide or FA2B[6]G21S1(6 or 3)-azide or both A2B[6]G1S1(6 or 3)-azide and FA2B[6]G1S1(6 or 3)-azide, wherein the azide is part of the triazole linkage T.
- Embodiment 72 Embodiment 72.
- composition of embodiment 41 wherein the predominant N-glycans in the composition comprise greater than 60 mole%, 70 mole%, 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structures A2BG2S2(6 or 3)-azide or FA2BG2S2(6 or 3)-azide or both A2BG2S2(6 or 3)-azide and FA2BG2S2(6 or 3)-azide, wherein the azide is part of the triazole linkage T.
- Embodiment 73 Embodiment 73.
- composition of embodiment 41 wherein the predominant N-glycans in the composition comprise greater than 70 mole% of the structure A2B[3]G1-azide or FA2B[3]G1-azide or both A2B[3]G1-azide and FA2B[3]G1-azide, wherein the azide is part of the triazole linkage T.
- Embodiment 74 Embodiment 74.
- composition of embodiment 41 wherein the predominant N-glycans in the composition comprise greater than 70 mole% of the structure A2B[6]G1-azide or FA2B[6]G1-azide or both A2B[6]G1-azide and FA2B[6]G1-azide, wherein the azide is part of the triazole linkage T.
- the predominant N-glycans in the composition comprise greater than 70 mole% of the structure A2BG2S2-azide or FA2BG2S2-azide or both A2BG2-azide and FA2BG2-azide, wherein the azide is part of the triazole linkage T.
- Embodiment 76 The composition of embodiment 41, wherein the composition, the predominant N-glycans in the composition comprise greater than 70 mole% of the structure A2B[3]G1S1(6 or 3)-azide or FA2B[3]G1S1(6 or 3)-azide or both A2B[3]G1S1(6 or 3)-azide and FA2B[3]G1S1(6 or 3)-azide, wherein the azide is part of the triazole linkage T.
- Embodiment 77 Embodiment 77.
- composition of embodiment 41 wherein the predominant N-glycans in the composition comprise greater than 70 mole% of the structure A2B[6]G1S1(6 or 3)-azide or FA2B[6]G21S1(6 or 3)-azide or both A2B[6]G1S1(6 or 3)-azide and FA2B[6]G1S1(6 or 3)- azide, wherein the azide is part of the triazole linkage T.
- Embodiment 78 Embodiment 78.
- composition of embodiment 41 wherein the predominant N-glycans in the composition comprise greater than 70 mole% of the structures A2BG2S2(6 or 3)-azide or FA2BG2S2(6 or 3)-azide or both A2BG2S2(6 or 3)-azide and FA2BG2S2(6 or 3)-azide, wherein the azide is part of the triazole linkage T.
- Embodiment 79 Embodiment 79.
- composition of embodiment 41 wherein the predominant N-glycans in the composition comprise greater than 80 mole%, 90 mole%, 95 mole%, 96 mole%, 97 mole%, 98 mole%, 99 mole%, or 100 mole% of the structure A2B[3]G1-azide or FA2B[3]G1- azide or both A2B[3]G1-azide and FA2B[3]G1-azide, wherein the azide is part of the triazole linkage T.
- Embodiment 80 Embodiment 80.
- composition of embodiment 41 wherein the predominant N-glycans in the composition comprise greater than 80 mole%of the structure A2B[6]G1-azide or FA2B[6]G1-azide or both A2B[6]G1-azide and FA2B[6]G1-azide, wherein the azide is part of the triazole linkage T.
- the predominant N-glycans in the composition comprise greater than 80 mole% of the structure A2BG2S2-azide or FA2BG2S2-azide or both A2BG2-azide and FA2BG2-azide, wherein the azide is part of the triazole linkage T.
- Embodiment 82 The composition of embodiment 41, wherein the composition, the predominant N-glycans in the composition comprise greater than 80 mole% of the structure A2B[3]G1S1(6 or 3)-azide or FA2B[3]G1S1(6 or 3)-azide or both A2B[3]G1S1(6 or 3)-azide and FA2B[3]G1S1(6 or 3)-azide, wherein the azide is part of the triazole linkage T.
- Embodiment 83 Embodiment 83.
- composition of embodiment 41 wherein the predominant N-glycans in the composition comprise greater than 80 mole% of the structure A2B[6]G1S1(6 or 3)-azide or FA2B[6]G21S1(6 or 3)-azide or both A2B[6]G1S1(6 or 3)-azide and FA2B[6]G1S1(6 or 3)- azide, wherein the azide is part of the triazole linkage T.
- Embodiment 84 Embodiment 84.
- composition of embodiment 41 wherein the predominant N-glycans in the composition comprise greater than 80 mole% of the structures A2BG2S2(6 or 3)-azide or FA2BG2S2(6 or 3)-azide or both A2BG2S2(6 or 3)-azide and FA2BG2S2(6 or 3)-azide, wherein the azide is part of the triazole linkage T.
- Embodiment 85 Embodiment 85.
- composition of embodiment 41 wherein the predominant N-glycans in the composition comprise greater than 90 mole% of the structure A2B[3]G1-azide or FA2B[3]G1-azide or both A2B[3]G1-azide and FA2B[3]G1-azide, wherein the azide is part of the triazole linkage T.
- Embodiment 86 Embodiment 86.
- composition of embodiment 41 wherein the predominant N-glycans in the composition comprise greater than 90 mole% of the structure A2B[6]G1-azide or FA2B[6]G1-azide or both A2B[6]G1-azide and FA2B[6]G1-azide, wherein the azide is part of the triazole linkage T.
- Embodiment 87 The composition of embodiment 41, wherein the predominant N-glycans in the composition comprise greater than 90 mole% of the structure A2BG2S2-azide or 25584 FA2BG2S2-azide or both A2BG2-azide and FA2BG2-azide, wherein the azide is part of the triazole linkage T.
- Embodiment 88 The composition of embodiment 41, wherein the composition, the predominant N-glycans in the composition comprise greater than 90 mole% of the structure A2B[3]G1S1(6 or 3)-azide or FA2B[3]G1S1(6 or 3)-azide or both A2B[3]G1S1(6 or 3)-azide and FA2B[3]G1S1(6 or 3)-azide, wherein the azide is part of the triazole linkage T.
- Embodiment 89 Embodiment 89.
- composition of embodiment 41 wherein the predominant N-glycans in the composition comprise greater than 90 mole% of the structure A2B[6]G1S1(6 or 3)-azide or FA2B[6]G21S1(6 or 3)-azide or both A2B[6]G1S1(6 or 3)-azide and FA2B[6]G1S1(6 or 3)- azide, wherein the azide is part of the triazole linkage T.
- Embodiment 90 Embodiment 90.
- composition of embodiment 41 wherein the predominant N-glycans in the composition comprise greater than 90 mole% of the structures A2BG2S2(6 or 3)-azide or FA2BG2S2(6 or 3)-azide or both A2BG2S2(6 or 3)-azide and FA2BG2S2(6 or 3)-azide, wherein the azide is part of the triazole linkage T.
- Embodiment 91 Embodiment 91.
- composition of embodiment 41 wherein the predominant N-glycans in the composition comprise greater than 95 mole% of the structure A2B[3]G1-azide or FA2B[3]G1-azide or both A2B[3]G1-azide and FA2B[3]G1-azide, wherein the azide is part of the triazole linkage T.
- Embodiment 92 Embodiment 92.
- composition of embodiment 41 wherein the predominant N-glycans in the composition comprise greater than 95 mole% of the structure A2B[6]G1-azide or FA2B[6]G1-azide or both A2B[6]G1-azide and FA2B[6]G1-azide, wherein the azide is part of the triazole linkage T.
- Embodiment 93 The composition of embodiment 41, wherein the predominant N-glycans in the composition comprise greater than 95 mole% of the structure A2BG2S2-azide or FA2BG2S2-azide or both A2BG2-azide and FA2BG2-azide, wherein the azide is part of the triazole linkage T.
- Embodiment 94 The composition of embodiment 41, wherein the composition, the predominant N-glycans in the composition comprise greater than 95 mole% of the structure A2B[3]G1S1(6 or 3)-azide or FA2B[3]G1S1(6 or 3)-azide or both A2B[3]G1S1(6 or 3)-azide and FA2B[3]G1S1(6 or 3)-azide, wherein the azide is part of the triazole linkage T.
- Embodiment 95 Embodiment 95.
- composition of embodiment 41 wherein the predominant N-glycans in the composition comprise greater than 95 mole% of the structure A2B[6]G1S1(6 or 3)-azide or FA2B[6]G21S1(6 or 3)-azide or both A2B[6]G1S1(6 or 3)-azide and FA2B[6]G1S1(6 or 3)- azide, wherein the azide is part of the triazole linkage T.
- Embodiment 96 Embodiment 96.
- composition of embodiment 41 wherein the predominant N-glycans in the composition comprise greater than 95 mole% of the structures A2BG2S2(6 or 3)-azide or FA2BG2S2(6 or 3)-azide or both A2BG2S2(6 or 3)-azide and FA2BG2S2(6 or 3)-azide, wherein the azide is part of the triazole linkage T.
- Embodiment 97 Embodiment 97.
- composition of embodiment 41 wherein the predominant N-glycans in the composition comprise greater than 96 mole% of the structure A2B[3]G1-azide or FA2B[3]G1-azide or both A2B[3]G1-azide and FA2B[3]G1-azide, wherein the azide is part of the triazole linkage T.
- Embodiment 98 Embodiment 98.
- composition of embodiment 41 wherein the predominant N-glycans in the composition comprise greater than 96 mole% of the structure A2B[6]G1-azide or FA2B[6]G1-azide or both A2B[6]G1-azide and FA2B[6]G1-azide, wherein the azide is part of the triazole linkage T.
- Embodiment 99 The composition of embodiment 41, wherein the predominant N-glycans in the composition comprise greater than 96 mole% of the structure A2BG2S2-azide or FA2BG2S2-azide or both A2BG2-azide and FA2BG2-azide, wherein the azide is part of the triazole linkage T.
- Embodiment 100 The composition of embodiment 41, wherein the composition, the predominant N-glycans in the composition comprise greater than 96 mole% of the structure 25584 A2B[3]G1S1(6 or 3)-azide or FA2B[3]G1S1(6 or 3)-azide or both A2B[3]G1S1(6 or 3)-azide and FA2B[3]G1S1(6 or 3)-azide, wherein the azide is part of the triazole linkage T.
- Embodiment 101 Embodiment 101.
- composition of embodiment 41 wherein the predominant N-glycans in the composition comprise greater than 96 mole% of the structure A2B[6]G1S1(6 or 3)-azide or FA2B[6]G21S1(6 or 3)-azide or both A2B[6]G1S1(6 or 3)-azide and FA2B[6]G1S1(6 or 3)- azide, wherein the azide is part of the triazole linkage T.
- Embodiment 102 Embodiment 102.
- composition of embodiment 41 wherein the predominant N-glycans in the composition comprise greater than 96 mole% of the structures A2BG2S2(6 or 3)-azide or FA2BG2S2(6 or 3)-azide or both A2BG2S2(6 or 3)-azide and FA2BG2S2(6 or 3)-azide, wherein the azide is part of the triazole linkage T.
- Embodiment 103 Embodiment 103.
- composition of embodiment 41 wherein the predominant N-glycans in the composition comprise greater than 97 mole% of the structure A2B[3]G1-azide or FA2B[3]G1-azide or both A2B[3]G1-azide and FA2B[3]G1-azide, wherein the azide is part of the triazole linkage T.
- Embodiment 104 Embodiment 104.
- composition of embodiment 41 wherein the predominant N-glycans in the composition comprise greater than 97 mole% of the structure A2B[6]G1-azide or FA2B[6]G1-azide or both A2B[6]G1-azide and FA2B[6]G1-azide, wherein the azide is part of the triazole linkage T.
- Embodiment 105 The composition of embodiment 41, wherein the predominant N-glycans in the composition comprise greater than 97 mole% of the structure A2BG2S2-azide or FA2BG2S2-azide or both A2BG2-azide and FA2BG2-azide, wherein the azide is part of the triazole linkage T.
- Embodiment 106 The composition of embodiment 41, wherein the composition, the predominant N-glycans in the composition comprise greater than 97 mole% of the structure A2B[3]G1S1(6 or 3)-azide or FA2B[3]G1S1(6 or 3)-azide or both A2B[3]G1S1(6 or 3)-azide and FA2B[3]G1S1(6 or 3)-azide, wherein the azide is part of the triazole linkage T. 25584 Embodiment 107.
- composition of embodiment 41 wherein the predominant N-glycans in the composition comprise greater than 97 mole% of the structure A2B[6]G1S1(6 or 3)-azide or FA2B[6]G21S1(6 or 3)-azide or both A2B[6]G1S1(6 or 3)-azide and FA2B[6]G1S1(6 or 3)- azide, wherein the azide is part of the triazole linkage T.
- Embodiment 108 Embodiment 108.
- composition of embodiment 41 wherein the predominant N-glycans in the composition comprise greater than 97 mole% of the structures A2BG2S2(6 or 3)-azide or FA2BG2S2(6 or 3)-azide or both A2BG2S2(6 or 3)-azide and FA2BG2S2(6 or 3)-azide, wherein the azide is part of the triazole linkage T.
- Embodiment 109 Embodiment 109.
- composition of embodiment 41 wherein the predominant N-glycans in the composition comprise greater than 98 mole% of the structure A2B[3]G1-azide or FA2B[3]G1-azide or both A2B[3]G1-azide and FA2B[3]G1-azide, wherein the azide is part of the triazole linkage T.
- Embodiment 110 wherein the predominant N-glycans in the composition comprise greater than 98 mole% of the structure A2B[3]G1-azide or FA2B[3]G1-azide or both A2B[3]G1-azide and FA2B[3]G1-azide, wherein the azide is part of the triazole linkage T.
- composition of embodiment 41 wherein the predominant N-glycans in the composition comprise greater than 98 mole% of the structure A2B[6]G1-azide or FA2B[6]G1-azide or both A2B[6]G1-azide and FA2B[6]G1-azide, wherein the azide is part of the triazole linkage T.
- Embodiment 111 The composition of embodiment 41, wherein the predominant N-glycans in the composition comprise greater than 98 mole% of the structure A2BG2S2-azide or FA2BG2S2-azide or both A2BG2-azide and FA2BG2-azide, wherein the azide is part of the triazole linkage T.
- Embodiment 112 The composition of embodiment 41, wherein the composition, the predominant N-glycans in the composition comprise greater than 98 mole% of the structure A2B[3]G1S1(6 or 3)-azide or FA2B[3]G1S1(6 or 3)-azide or both A2B[3]G1S1(6 or 3)-azide and FA2B[3]G1S1(6 or 3)-azide, wherein the azide is part of the triazole linkage T.
- Embodiment 113 Embodiment 113.
- composition of embodiment 41 wherein the predominant N-glycans in the composition comprise greater than 98 mole% of the structure A2B[6]G1S1(6 or 3)-azide or 25584 FA2B[6]G21S1(6 or 3)-azide or both A2B[6]G1S1(6 or 3)-azide and FA2B[6]G1S1(6 or 3)- azide, wherein the azide is part of the triazole linkage T.
- Embodiment 114 Embodiment 114.
- composition of embodiment 41 wherein the predominant N-glycans in the composition comprise greater than 98 mole% of the structures A2BG2S2(6 or 3)-azide or FA2BG2S2(6 or 3)-azide or both A2BG2S2(6 or 3)-azide and FA2BG2S2(6 or 3)-azide, wherein the azide is part of the triazole linkage T.
- Embodiment 115 Embodiment 115.
- composition of embodiment 41 wherein the predominant N-glycans in the composition comprise greater than 99 mole% of the structure A2B[3]G1-azide or FA2B[3]G1-azide or both A2B[3]G1-azide and FA2B[3]G1-azide, wherein the azide is part of the triazole linkage T.
- Embodiment 116 Embodiment 116.
- composition of embodiment 41 wherein the predominant N-glycans in the composition comprise greater than 99 mole% of the structure A2B[6]G1-azide or FA2B[6]G1-azide or both A2B[6]G1-azide and FA2B[6]G1-azide, wherein the azide is part of the triazole linkage T.
- Embodiment 117 The composition of embodiment 41, wherein the predominant N-glycans in the composition comprise greater than 99 mole% of the structure A2BG2S2-azide or FA2BG2S2-azide or both A2BG2-azide and FA2BG2-azide, wherein the azide is part of the triazole linkage T.
- Embodiment 118 The composition of embodiment 41, wherein the composition, the predominant N-glycans in the composition comprise greater than 99 mole% of the structure A2B[3]G1S1(6 or 3)-azide or FA2B[3]G1S1(6 or 3)-azide or both A2B[3]G1S1(6 or 3)-azide and FA2B[3]G1S1(6 or 3)-azide, wherein the azide is part of the triazole linkage T.
- Embodiment 119 Embodiment 119.
- composition of embodiment 41 wherein the predominant N-glycans in the composition comprise greater than 99 mole% of the structure A2B[6]G1S1(6 or 3)-azide or FA2B[6]G21S1(6 or 3)-azide or both A2B[6]G1S1(6 or 3)-azide and FA2B[6]G1S1(6 or 3)- azide, wherein the azide is part of the triazole linkage T. 25584 Embodiment 120.
- composition of embodiment 41 wherein the predominant N-glycans in the composition comprise greater than 99 mole% of the structures A2BG2S2(6 or 3)-azide or FA2BG2S2(6 or 3)-azide or both A2BG2S2(6 or 3)-azide and FA2BG2S2(6 or 3)-azide, wherein the azide is part of the triazole linkage T.
- Embodiment 121 Embodiment 121.
- composition of embodiment 41 wherein the predominant N-glycans in the composition comprise greater than 100 mole% of the structure A2B[3]G1-azide or FA2B[3]G1-azide or both A2B[3]G1-azide and FA2B[3]G1-azide, wherein the azide is part of the triazole linkage T.
- Embodiment 122 Embodiment 122.
- composition of embodiment 41 wherein the predominant N-glycans in the composition comprise greater than 100mole% of the structure A2B[6]G1-azide or FA2B[6]G1-azide or both A2B[6]G1-azide and FA2B[6]G1-azide, wherein the azide is part of the triazole linkage T.
- Embodiment 123 The composition of embodiment 41, wherein the predominant N-glycans in the composition comprise greater than 100 mole% of the structure A2BG2S2-azide or FA2BG2S2-azide or both A2BG2-azide and FA2BG2-azide, wherein the azide is part of the triazole linkage T.
- Embodiment 124 The composition of embodiment 41, wherein the composition, the predominant N-glycans in the composition comprise greater than 100 mole% of the structure A2B[3]G1S1(6 or 3)-azide or FA2B[3]G1S1(6 or 3)-azide or both A2B[3]G1S1(6 or 3)-azide and FA2B[3]G1S1(6 or 3)-azide, wherein the azide is part of the triazole linkage T.
- Embodiment 125 Embodiment 125.
- composition of embodiment 41 wherein the predominant N-glycans in the composition comprise greater than 100 mole% of the structure A2B[6]G1S1(6 or 3)-azide or FA2B[6]G21S1(6 or 3)-azide or both A2B[6]G1S1(6 or 3)-azide and FA2B[6]G1S1(6 or 3)- azide, wherein the azide is part of the triazole linkage T.
- Embodiment 126 Embodiment 126.
- composition of embodiment 41 wherein the predominant N-glycans in the composition comprise greater than 100 mole% of the structures A2BG2S2(6 or 3)-azide or 25584 FA2BG2S2(6 or 3)-azide or both A2BG2S2(6 or 3)-azide and FA2BG2S2(6 or 3)-azide, wherein the azide is part of the triazole linkage T. While the present invention is described herein with reference to illustrated embodiments, it should be understood that the invention is not limited hereto. Those having ordinary skill in the art and access to the teachings herein will recognize additional modifications and embodiments within the scope thereof. Therefore, the present invention is limited only by the specification and the claims attached herein.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
L'invention concerne une stratégie de conjugaison pontée par glycane bisécant qui permet une conjugaison spécifique de site de glycoprotéines sans avoir besoin d'une synthèse chimique d'oligosaccharide et d'ingénierie d'acides aminés. L'application de ce procédé est démontrée par conjugaison d'anticorps humains et de souris avec une cytotoxine. Cette stratégie préserve la fonction effectrice Fc des anticorps et confère la capacité à remodeler les glycanes pour affiner l'immunogénicité et les propriétés pharmacocinétiques de conjugués anticorps-médicaments par glycoingénierie.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263423282P | 2022-11-07 | 2022-11-07 | |
US63/423,282 | 2022-11-07 | ||
US202363509684P | 2023-06-22 | 2023-06-22 | |
US63/509,684 | 2023-06-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024102603A1 true WO2024102603A1 (fr) | 2024-05-16 |
Family
ID=91033543
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2023/078425 WO2024102603A1 (fr) | 2022-11-07 | 2023-11-02 | Conjugaison pontée par glycane bisécant pour la production de conjugués de glycoprotéines |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024102603A1 (fr) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160257764A1 (en) * | 2013-10-14 | 2016-09-08 | Synaffix B.V. | Glycoengineered antibody, antibody-conjugate and methods for their preparation |
US20180133340A1 (en) * | 2016-11-14 | 2018-05-17 | CHO Pharma Inc. | Antibody-drug conjugates |
WO2018218004A1 (fr) * | 2017-05-24 | 2018-11-29 | The Board Of Regents Of The University Of Texas System | Lieurs pour conjugués anticorps-médicament |
US20190091332A1 (en) * | 2014-08-19 | 2019-03-28 | Merck Sharp & Dohme Corp. | Anti-lag3 antibodies and antigen-binding fragments |
US20210087298A1 (en) * | 2017-11-09 | 2021-03-25 | National Research Council Of Canada | Antibody glycoconjugates and methods of production and use |
US20220160882A1 (en) * | 2014-10-01 | 2022-05-26 | Medimmune, Llc | Method of conjugating a polypeptide |
-
2023
- 2023-11-02 WO PCT/US2023/078425 patent/WO2024102603A1/fr unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160257764A1 (en) * | 2013-10-14 | 2016-09-08 | Synaffix B.V. | Glycoengineered antibody, antibody-conjugate and methods for their preparation |
US20190091332A1 (en) * | 2014-08-19 | 2019-03-28 | Merck Sharp & Dohme Corp. | Anti-lag3 antibodies and antigen-binding fragments |
US20220160882A1 (en) * | 2014-10-01 | 2022-05-26 | Medimmune, Llc | Method of conjugating a polypeptide |
US20180133340A1 (en) * | 2016-11-14 | 2018-05-17 | CHO Pharma Inc. | Antibody-drug conjugates |
WO2018218004A1 (fr) * | 2017-05-24 | 2018-11-29 | The Board Of Regents Of The University Of Texas System | Lieurs pour conjugués anticorps-médicament |
US20210087298A1 (en) * | 2017-11-09 | 2021-03-25 | National Research Council Of Canada | Antibody glycoconjugates and methods of production and use |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11130816B2 (en) | Site-specific antibody-drug conjugation through glycoengineering | |
US20210147524A1 (en) | Fc containing polypeptides with altered glycosylation and reduced effector function | |
EP3204425B1 (fr) | Conjugués médicament-anticorps modifiés par glycane | |
EP3366705B1 (fr) | Polypeptides comprenants le domaine fc ayant une glycosylation modifiee et une fonction effecteur reduite | |
EP3129067B1 (fr) | Modification de la glyco-ingéniérie de fractions de ciblage spécifique à un site | |
US20200055923A1 (en) | Antibody Preparation | |
WO2024102603A1 (fr) | Conjugaison pontée par glycane bisécant pour la production de conjugués de glycoprotéines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23889522 Country of ref document: EP Kind code of ref document: A1 |